user_input,reference_contexts,reference,synthesizer_name,answer,source_content,source_document_info
"Whats the neuro status of the pashent with systmic murmer at RUSB, especaily ther alertness and cranial nerve intactness?","['0070a23b-dc9f-483f-a66d-a8d84a4b995b\n\nCARDIOVASCULAR: Regular rate and rhythm with late ___ systolic\nmurmur at RUSB, no rubs or gallops\nLUNGS: clear to auscultation bilaterally without rhonchi,\nwheezes, or crackles\nGI: soft, nontender, without rebounding or guarding, \nnondistended\nwith normal active bowel sounds, no hepatomegaly\nEXTREMITIES: no clubbing, cyanosis, or edema\nGU: no foley\nSKIN: no rashes, petechia, lesions, or echymoses; warm to\npalpation\nNEURO: Alert and interactive to person, ___ (daughters\nstated that this is a hospital before pt named it), ___, but\nthinks that it is ___, cranial nerves II-XII intact, strength \nis\n___ in RUE, RLE, LLE, ___ in LUE elbow flexion/extension and\nhand grip. Gait is WNL, negative Romberg, negative pronator\ndrift.\nPSYCH: normal mood and affect\nDISCHARGE EXAM\nVS: 97.9 PO 151 / 65 64 18 99 RA \nGEN: Alert and interactive, comfortable, no acute distress\nHEENT: PERRL, anicteric, conjunctiva pink, oropharynx without\nlesion or exudate, moist mucus membranes, ears without lesions \nor', '688ac351-3658-4804-8bb2-2bd5b3e5aaac\n\nEXTREMITIES: 2+ pitting edema bilaterally in lower extremities.\nPulses 2+ bilaterally. \nNEURO: Alert & oriented x3. Non-focal neuro exam.\nDISCHARGE PHYSICAL EXAMINATION:  \n===============================\n24 HR Data (last updated ___ @ 809)\n    Temp: 98.1 (Tm 99.0), BP: 168/75 (142-168/69-79), HR: 88\n(87-95), RR: 18 (___), O2 sat: 97% (94-97)  \n___ Total Intake: 720ml PO Amt: 720ml \n___ Total Output: 1100ml Urine Amt: 1100ml \nFluid balance: -380\n___ Total Intake: 180ml PO Amt: 180ml \n___ Total Output: 900ml Urine Amt: 900ml \nFluid balance: -720\nGENERAL: Sitting up comfortably at edge of bed, in NAD\nHEENT: NC/AT\nNECK: Supple. unable to appreciate JVD at 90 degrees\nCARDIAC: RRR, no rubs/gallops\nLUNGS: Faint bibasilar crackles on auscultation\nABDOMEN: Soft, NTND\nEXTREMITIES: 2+ pitting edema bilaterally to knees in ___. Pulses\n2+ bilaterally. WARM']","The patient is Alert and interactive to person, with some memory or recognition issues (as indicated by the patient initially not naming the hospital correctly but later doing so). The patient thinks it is a different time/frame than actual (exact details not specified). Cranial nerves II-XII are intact. Strength is noted as being 5/5 in Right Upper Extremity (RUE), Right Lower Extremity (RLE), Left Lower Extremity (LLE), and 4/5 in Left Upper Extremity (LUE) for elbow flexion/extension and hand grip. Gait is Within Normal Limits (WNL), with a negative Romberg and negative pronator drift.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, I'll do my best to answer the question. However, please note that the question contains specific clinical details (""systemic murmer at RUSB"", ""cranial nerve intactness"") that are not mentioned in the provided documents, except for some general information. Here's how I approach the answer based on the available data:

**Question Breakdown:**
1. **Patient's Neuro Status**
2. **Specifics about Alertness**
3. **Cranial Nerve Intactness**
4. **Context of Systemic Murmur at RUSB** (not mentioned in the documents)

**Answer Based on Provided Documents:**

1. **Patient's Neuro Status:**
   - **Mental Status:** Clear and coherent (Document 3, under ""DISCHARGE CONDITION"")
   - **Level of Consciousness:** Alert and interactive (Document 3, under ""DISCHARGE CONDITION"")
   - **No specific information on cranial nerve intactness or systemic murmur at RUSB is available in the provided documents.**

2. **Alertness:**
   - As mentioned, the patient is described as ""Alert and interactive"" (Document 3).

3. **Cranial Nerve Intactness:**
   - **No information available in the provided documents.**

4. **Context of Systemic Murmur at RUSB:**
   - **No mention of this condition in the provided documents.** Document 5 discusses some cardiac findings (e.g., Diastolic Dysfunction, Right Ventricular findings, Valvular findings), but it does not specify a ""systemic murmur at RUSB"".

**Metadata Consistency for Patient ID:**
- The **Patient/Subject ID: 13180007** is consistently mentioned across all documents (Document 1 through Document 5), along with the same **Note ID (13180007-DS-19)** and **Admission ID (20774429)**, indicating these documents pertain to the same patient's admission.

**Exact ID Values as Requested:**
- **Patient/Subject ID:** 13180007
- **Note ID:** 13180007-DS-19
- **Admission ID:** 20774429

**Summary:**
Given the information available, we can confirm the patient's mental status and level of consciousness at discharge but cannot provide details on cranial nerve intactness or the specific condition of a systemic murmur at RUSB, as these are not mentioned in the documents.","['**Key Findings:**\n\n* Slightly improved Hemoglobin (Hgb) level from admission (7.4 to 7.6)\n* Elevated Creatinine (Cr) level at discharge (2.9), indicating persistent renal impairment\n* Abnormal glucose', '* **Discharge Status:**\n\t+ Symptoms associated with volume overload had subsided, but patient was still slightly volume up on exam.\n\t+ 1+ edema to ankles bilaterally.\n\t+ JVP of 12cm.\n* **Medications a', 'Here is the extracted and summarized information for the subheading ""* DISCHARGE CONDITION"":\n\n**DISCHARGE CONDITION**\n\n* **Mental Status**: Clear and coherent\n* **Level of Consciousness**: Alert and i', '* **Discharge Status**: Still slightly volume up on exam with 1+ edema to ankles, JVP ~12', '+ **Diastolic Dysfunction**: Present (grade indeterminate)\n* **Right Ventricular (RV) Findings**:\n\t+ **Cavity Size**: Normal\n\t+ **Free Wall Motion**: Normal\n* **Valvular and Other Findings**:\n\t+ **Aor']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
What were the initial presentation and immediate interventions for the patient with acute Heart Failure with preserved Ejection Fraction (HFpEF) exacerbation in the Emergency Department (ED)?,"['595bbed3-a542-444b-b48a-e6edf79ac096\n\nHistory of Present Illness:\n___ year old man with numerous cardiac risk factors, prior CVA\npresented with sudden onset worsening of subacute dyspnea found\nto have flash pulmonary edema admitted for acute HFpEF\nexacerbation. \n Per EMS and confirmed with family, patient was found on the\ncouch by his family was minimally responsive. Patient described\nsubacute shortness of breath over the last two weeks (e.g.,\nhaving to sit down multiple times when going to grocery store or\nup steps at home).  He has also had a cough, rhinorrhea but no\nfever, no sputum.  This worsened acutely this morning when he\nwoke-up struggling to breath.  EMS was called, SBP to 176 per ED\ndocumentation, patient was given nitro x2 and started on CPAP. \n In the ED, he was started on bipap diuresed with OV Lasix,\nstarted on home BP medications and then transferred to floor. \n - Initial vitals: HR 109 BP 176/67 RR 26 ___ 90, patient was\ntachypneic, unable to speak in full sentences, crackles L>R, no\nfocal deficits\n - EKG:  not commented upon\n - Labs/studies notable for: Patient was given: NG x2. Lasix IV\n40mg (at 4:30am), Zosyn/Vanc  \n Amlodipine 10mg, Carvedilol 25mg, Lisinopril 2.5mg,\nlevothyroxine, insulin 10U regular,  \n - Vitals on transfer:  ___ 1040 Temp: 98.4 PO BP: 115/45 R', ""a6e734ef-1c30-4cb6-ba6d-41227251d4d0\n\nWhen he came home to ___, he apparently thought that he was\nstill in ___, confused his wife for his daughter. On\n___ morning, he fell again. He was confused about the\nconfiguration of the bathroom (no tub in bathroom in PR), so he\ntripped and fell, called his daughter in tears (he often gets\nemotional since his CVA). She booked an appointment for same \nday,\nat which his FSBG>500, HbA1c (point of care, not in OMR) was\n15.0%. He declined to be transferred to the ED. Daughter ___\nwas on vacation from work, and so was able to check on him\nregularly. During these visits, she again established that he is\nnot taking prescribed medications. On the morning of\npresentation, pt's wife called daughter ___, concerned that \npt\nwas increasingly confused. FSBG was >500, and administered\nTresiba 50u at about 8 am. Pt called ___ about 15 minutes\nlater, at which time she again noted confusion and slurred\nspeech, which has intermittently been present since his CVA.\nDecision was made to bring him to the ED. \nOf note, during his last hospitalization ___, he had an\nepisode of dysarthria with confusion and mild expressive and\nreceptive aphasia for which code stroke was called. MRI/MRA \nbrain\nand EEG were unrevealing, with chronic changes and EEG slowing\nonly. He was continued on ASA and atorvastatin.""]","The patient, a man with numerous cardiac risk factors and a prior CVA, presented to the ED with sudden onset worsening of subacute dyspnea, leading to flash pulmonary edema. Initial vitals in the ED showed HR 109, BP 176/67, RR 26, with the patient being tachypneic. Immediate interventions included administration of nitro x2 by EMS, initiation of CPAP, which was later switched to BiPAP in the ED, diuresis with IV Lasix (40mg), and the continuation of home BP medications (Amlodipine 10mg, Carvedilol 25mg, Lisinopril 2.5mg).",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Patient Identification (from METADATA, as per instruction 1):**
* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, and Document 5)
* **Note ID:** 13180007-DS-19 (consistent across all documents)
* **Admission ID:** 20774429 (consistent across all documents)

**Initial Presentation and Immediate Interventions for HFpEF Exacerbation:**
Extracted from **CONTENT** of the documents, as this information is not provided in the **METADATA**:

* **Initial Presentation:**
	+ **Symptoms:** 1 day of dyspnea and discomfort (Document 4, Document 5)
	+ **Condition:** Admitted for Heart Failure with preserved Ejection Fraction (HFpEF) exacerbation (All Documents, but details in Document 3, Document 4, and Document 5)
* **Immediate Interventions in the Emergency Department (ED) or upon Admission:**
	+ **Treatment:** Diuresed with several doses of IV Lasix 80mg (Document 4)
	+ **Outcome of Immediate Intervention:** Symptoms improved with IV Lasix; patient was then discharged on torsemide 100mg daily for active diuresis (Document 4, summarized in Document 5)

**Additional Context (not directly asked but relevant for understanding the patient's scenario):**
* **Trigger for Exacerbation:** Unclear, possibly medication non-compliance (Document 4, Document 5)
* **Relevant Lab Values for Secondary Diagnosis (Acute Kidney Injury):** Admission - BUN 39, Cr 2.6; Discharge - Cr 2.9 (elevated from baseline 1.8-2.2), BUN not provided at discharge (Document 3)","['**ACUTE PROBLEMS**\n=====================\n\n### 1. **Acute on Chronic HFpEF (Heart Failure with Preserved Ejection Fraction)**', '**ACUTE PROBLEMS**\n=====================\n\n### 1. **Acute on Chronic HFpEF (Heart Failure with Preserved Ejection Fraction)**', '* **Primary Diagnosis:**\n\t+ **Condition:** Acute on chronic diastolic heart failure exacerbation\n\t+ **Implication:** Heart failure with preserved ejection fraction (HFpEF) exacerbation, as noted in Hi', '* **Summary**: \n\t+ Patient with HFpEF (EF 55-60%) admitted for HF exacerbation with dyspnea and discomfort\n\t+ Trigger unclear, possibly medication non-compliance\n\t+ Symptoms improved with IV Lasix; di', '* **Patient Profile**: ___ male with history of HFpEF (EF 55-60%), prior CVA, CKD, DM, hypertension, and carotid artery disease\n* **Presentation**: 1 day of dyspnea and discomfort, admitted for HF exa']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"Whats the relevent med list for DM managment in a pateint with Hx of CAD, ischemic CVA, CKD, and Hypothyroidism, with med speling dont mater?","['8c0badb1-fe3b-4585-8010-1ef4ba8fdd98\n\n================\n# Hx of CAD \n# Hx of ischemic CVA\nStress test in ___ with area of inducible ischemia in LCx \ndistribution. Trop peaked at 0.06 (iso CKD) and then \ndowntrended. No EKG changes seen. Continued home carvedilol, ASA \nand high dose atorvastatin. \n# CKD: Cr at presentation close to baseline. Underlying etiology \nlikely combination of HTN, DM. \n# Hypothyroidism: Continued home levothyroxine 100 mcg daily\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Furosemide 40 mg PO 3X/WEEK (___) \n2. sevelamer CARBONATE 800 mg PO TID W/MEALS \n3. Minoxidil 2.5 mg PO DAILY \n4. Levothyroxine Sodium 100 mcg PO DAILY \n5. CARVedilol 37.5 mg PO BID \n6. amLODIPine 10 mg PO DAILY \n7. Albuterol Inhaler 2 PUFF IH Q6H \n8. Jardiance (empagliflozin) 10 mg oral DAILY \n9. Victoza 3-Pak (liraglutide) 1.2 mg subcutaneous DAILY', '8d31665e-700b-4b64-8af5-51456ad55ff5\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-140 \nK-4.6 Cl-99 HCO3-25 AnGap-16\n___ 06:35AM BLOOD Calcium-8.4 Phos-6.0* Mg-2.1\n \nBrief Hospital Course:\nSUMMARY\n=======\n___ male with history of HFpEF (EF 55-60% in ___,\nprior CVA, CKD, DM, hypertension, and carotid artery disease\nwho presented with 1 day of dyspnea and discomfort, and was\nadmitted for HF exacerbation. The trigger was unclear, possible \nmedication non-compliance. He was diuresed with several doses of \nIV Lasix 80 and by time of discharge symptoms had improved. He \nwas still slightly volume up on exam, with JVP ~12 and 1+ edema \nto ankles.\nTRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally and JVP of 12cm. He is being \ndischarged on torsemide 100 daily for active diuresis, with \nabout 3lb of fluid still left to lose.']","Based on the provided context, for a patient with a history of CAD, ischemic CVA, CKD, Hypothyroidism, and specifically focusing on Diabetes Mellitus (DM) management, the relevant medications from the admission list are:  1. **Jardiance (empagliflozin) 10 mg oral DAILY** - an SGLT2 inhibitor used in the treatment of type 2 diabetes. 2. **Victoza 3-Pak (liraglutide) 1.2 mg subcutaneous DAILY** - a GLP-1 receptor agonist used for type 2 diabetes management. Additionally, medications indirectly beneficial for DM management due to their effects on related conditions include: - **CARVedilol 37.5 mg PO BID** and **amLODIPine 10 mg PO DAILY** for hypertension, a common comorbidity with DM. - **sevelamer CARBONATE 800 mg PO TID W/MEALS** for CKD, which can be influenced by DM management.",custom_multi_hop_query_synthesizer,"Based on the provided documents, I'll address the question step by step, following the given instructions.

**Question Breakdown:**
- Relevant medication list for **DM (Diabetes Mellitus) management**
- In a patient with:
	1. **Hx of CAD (Coronary Artery Disease)**: Implied by ""History of CVA (Cerebrovascular Accident)"" and ""Carotid Artery Disease""
	2. **Ischemic CVA (Cerebrovascular Accident)**
	3. **CKD (Chronic Kidney Disease)**
	4. **Hypothyroidism**

**Metadata Observations (Instruction 1, 2, 3):**
- **Patient/Subject ID**: Consistently **13180007** across all documents.
- **Note ID**, **Admission ID**, **Chart Time**, and **Store Time** are also consistent but not directly relevant to the medication question.

**Medication List Relevant to DM Management (Considering Comorbidities):**
Based on the content of the documents, **no specific diabetes medications are listed**. However, we can infer the patient's diabetes management needs from the provided information:

- **Document 4** mentions **DM** as part of the patient's profile but does not specify medications.
- **Document 5** lists **IDDM (Insulin-Dependent Diabetes Mellitus)** with an **A1c of 11.4%**, indicating poorly controlled diabetes. No specific diabetes medications are mentioned.

**Relevant Medications from Provided Lists (Not Specifically for DM but Important for Overall Management):**
Given the patient's comorbidities, the following medications from the documents are relevant for overall management but not directly for DM:

- **For Hypothyroidism**: Levothyroxine Sodium 100 mcg PO DAILY (Document 1 & 2)
- **For History of CVA (and implied CAD, considering the context of Carotid Artery Disease)**:
	+ Aspirin 81 mg PO DAILY (Document 1 & 2)
	+ Atorvastatin 80 mg PO QPM (Document 1 & 2)
- **For CKD and Hypertension (with implications for DM management due to renal protection)**: No specific medications are listed for CKD or hypertension management in the provided documents.
- **For Acute HFpEF Exacerbation (with implications for DM management due to fluid status and cardiac function)**: 
	+ IV Lasix 80 (treatment outcome, Document 4)
	+ Torsemide 100 daily (discharge medication for active diuresis, Document 4)

**Direct Answer to the Question (Considering the Spelling Instruction is to Ignore Spelling):**
Given the documents do not explicitly list diabetes medications but highlight the patient's poorly controlled IDDM (A1c 11.4%), **there are no specific DM medications to report from the provided documents**. Management of comorbid conditions (e.g., hypertension, CKD, hypothyroidism) is crucial for overall diabetes care, but direct diabetes medications are not mentioned.

**Recommendation for Clinical Practice:**
- Given the patient's A1c of 11.4%, initiating or adjusting diabetes medications (e.g., metformin, if not contraindicated by CKD; insulin, considering IDDM) would be crucial. Consultation with an endocrinologist or a primary care physician for diabetes management is recommended.
- Regular monitoring of renal function (for CKD management and medication adjustment), thyroid function, and cardiac status is advised.","['Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D', 'Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D', '6. **Carotid Artery Disease** (mentioned in Past Medical History, no specific medications listed in discharge medications)\n7. **Secundum ASD (Atrial Septal Defect)** (mentioned in Past Medical History', '* **Patient Profile**: ___ male with history of HFpEF (EF 55-60%), prior CVA, CKD, DM, hypertension, and carotid artery disease\n* **Presentation**: 1 day of dyspnea and discomfort, admitted for HF exa', '* **Acute Problems Addressed**:\n\t1. **Acute on Chronic HFpEF**\n\t2. **Chest Pain** (mild troponin elevation, likely related to CKD)\n\t3. **CKD** (elevated Cr, possibly due to renal congestion)\n\t4. **Hyp']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
Whats the comon complictions of uncontrolld DM2 in patiants with exsisting CVA and HTN?,"['2574c42a-a6ef-418e-ac90-a21855611d18\n\npulmonary edema. No pneumonia, no pneumothorax.  The lateral \nradiograph shows mild flattening of the hemidiaphragms, \npotentially as a consequence of functional obstruction.\n___ CT HEAD -\n1. No evidence of acute intracranial abnormality.\n2. Unchanged appearance of chronic infarcts within the right \nfrontal lobe and left occipital lobe.\n3. Chronic lacunar infarcts within the right basal ganglia.\n4. Re-demonstration of few calcifications within the pons, \nfindings which are unchanged in appearance and likely sequela of \nprior ischemic or inflammatory process.\nMICRO:\n___ 3:38 pm URINE\n                            **FINAL REPORT ___\n   URINE CULTURE (Final ___:    < 10,000 CFU/mL. \n \nBrief Hospital Course:\nMr. ___ is a ___ ___ speaking male with a \nPMH of prior CVA ___, residual emotional lability, \ndysarthria), HFpEF, uncontrolled DM2, HTN, CAD, CKD, \n?hypothyroidism, asthma, mild cognitive impairment who presented', 'e2f22eea-f842-4b4c-8542-dfd4f8a519ce\n\n___ yo M with IDDM, HTN, CVA, asthma who presents to the ED after\nvomiting multiple times last night. He notes he ate taco bell at\n5, then at 6pm ate dinner and vomited all his rice at that time.\nContinued to vomit multiple times and decided to come to the ED.\nNon bilious non bloody. Doesn\'t have vomiting often. Denies any\nproblems with bowel movements. \nHe notes that he has been having problems with his BPs at home.\nNotes compliance and uses a pill box that his wife helps him\nfill. Notes that he tries to eat healthy (although he did have\ntacobell last night around 5pm). He also notes feeling ""off\nbalance"" when his BPs are raised but doesn\'t check them often at\nhome. Has been trying to check blood sugars more recently.\nDoesn\'t have a log here. \nNotes he sometimes has chest pain. Currently without chest pain.\nNotes that he doesn\'t get it with walking unless walking long\ndistance. Can walk up about 20 steps without stopping. \n \nPast Medical History:\n- DM2\n- Diabetic Retinopathy\n- Hypothyroidism\n- CKD Stage IIIa\n- HLD\n- HTN']","Based on the provided context, common complications or associated conditions with uncontrolled DM2 (Diabetes Mellitus Type 2) in patients with existing CVA (Cerebrovascular Accident) and HTN (Hypertension) include:               - **Chronic Infarcts**: As seen in the CT HEAD results, indicating potential previous brain tissue damage due to lack of blood supply.              - **Cognitive Impairment**: Mentioned in the brief hospital course, suggesting a decline in cognitive function.              - **Chronic Lacunar Infarcts**: Within the basal ganglia, indicative of small vessel disease, common in diabetes and hypertension.              - **CKD (Chronic Kidney Disease)**: Stage IIIa noted in the past medical history, a known complication of long-standing diabetes and hypertension.              - **Diabetic Retinopathy**: Listed in the past medical history, a common complication of diabetes affecting the eyes.              - **Emotional Lability and Dysarthria**: Residual effects from the CVA, potentially exacerbated by the metabolic and vascular stress of uncontrolled DM2 and HTN.",custom_multi_hop_query_synthesizer,"Based on the provided documents and the question about common complications of uncontrolled DM2 (Diabetes Mellitus Type 2) in patients with existing CVA (Cerebrovascular Accident) and HTN (Hypertension), I'll analyze the information step by step as per your instructions.

**Step 1: Identify Relevant Patient Information from Metadata**
- **Patient/Subject ID:** 13180007 (consistent across all documents)
- **Note ID, Admission ID, Chart Time, Store Time:** While these are provided, they are not directly relevant to the clinical question asked.

**Step 2: Extract Clinically Relevant Information from Document Content**

- **Uncontrolled DM2 Complications with CVA and HTN:**
  - **Document 1 (CONTENT):**
    - **IDDM (poorly controlled, A1c 11.4%):** Indicates uncontrolled Diabetes Mellitus Type 1 (not Type 2, but we'll consider the broader context of uncontrolled diabetes).
    - **CVA and HTN:** Not directly linked to DM complications here but mentioned as separate acute/problems.
  - **Document 4 (CONTENT):**
    - **History of CVA** and **Hypertension (well-controlled)** mentioned in the context of chronic problems and medications.
  - **Common Complications of Uncontrolled DM2 with CVA and HTN (Inferred from Provided Documents and General Medical Knowledge):**
    - While the documents specifically mention DM1 and not DM2, common complications of uncontrolled diabetes (considering both types) in the context of CVA and HTN might include:
      - **Renal Impairment (CKD):** Document 1 and implied in Document 3 with elevated Creatinine levels.
      - **Cardiovascular Events:** The patient already has a history of CVA, indicating increased risk.
      - **Worsening Hypertension:** Though currently well-controlled, uncontrolled diabetes can exacerbate hypertension.
      - **Anemia:** Mentioned in Document 1 as ""Acute on Chronic Anemia,"" which can be a complication of CKD, often seen in diabetic patients.

**Answer to the Question:**
Given the patient's profile (uncontrolled diabetes, history of CVA, and hypertension), common complications that might be anticipated or are already evident include:

1. **Renal Impairment (CKD)**
2. **Increased Risk of Cardiovascular Events** (beyond the existing CVA)
3. **Worsening Hypertension**
4. **Anemia** (in the context of CKD)

**Note:** The documents specifically mention Type 1 Diabetes (IDDM) rather than Type 2 (DM2). However, the question's context and the complications listed are broadly relevant to uncontrolled diabetes in the presence of CVA and HTN. For precise Type 2 Diabetes complications, additional specific information about the patient's DM2 status would be ideal.","['* **Acute Problems Addressed**:\n\t1. **Acute on Chronic HFpEF**\n\t2. **Chest Pain** (mild troponin elevation, likely related to CKD)\n\t3. **CKD** (elevated Cr, possibly due to renal congestion)\n\t4. **Hyp', '+ Tissue Doppler: Increased LV filling pressure (PCWP > 18 mmHg)\n\t+ Diastolic Dysfunction: Grade Indeterminate\n\t+ Right Ventricular (RV) Characteristics:\n\t\t- Normal RV cavity size\n\t\t- Normal free wall', '**Key Findings:**\n\n* Slightly improved Hemoglobin (Hgb) level from admission (7.4 to 7.6)\n* Elevated Creatinine (Cr) level at discharge (2.9), indicating persistent renal impairment\n* Abnormal glucose', 'Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D', '### 2. **Chest Pain**\n\n* **Presentation:** Chest pain with mild troponin elevation (0.03)\n* **Interpretation:** Difficult due to CKD, levels similar to prior months\n* **Findings:**\n\t+ No evidence of d']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"Whats the perscribd dose of Aspirin for a patiant with NSTEMI and hypertension, and whats its role in ther care plan?","['5afc91e0-6481-46b3-aa3c-473b2c2e6895\n\n#Community acquired pneumonia\nCough, worsened SOB, hypoxemia (although alternate explanation) \nbut no leukocytosis or fevers; influenza negative. Legionella \nand strep were negative. Patient was given a 5-day course of \nceftriaxone and azithromycin. \n#Hypertension\nGoal <130/80. As patient is on several anti-hypertensives with \nstill an elevated blood pressure, he underwent a secondary \nhypertension workup. His last renal ultrasound in ___ was \nwithin normal limits. He was placed on continuous O2 monitoring \novernight, and patient did not desaturate. His aldosterone to \nrenin ratio was 0.13, indicating no primary hyperaldosteronism. \n24 hour urine metanephrines and catecholamines were within \nnormal limits.\n#CAD w/ inducible ischemia\n#NSTEMI\nTroponin peaked at 0.02, thought to be type 2 due to volume \noverload. Continued aspirin, atorvastatin, carvedilol. The \ndecision was made to hold off on coronary angiogram due to \nkidney function and the suspicion that this was type 2.\n#H/o CVA\nPatient had an episode while in hospital with dysarthria,', '784a4f17-941d-40ee-a5aa-7471e6a5f600\n\n70/30 10 Units Lunch \n3.  Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath  \n4.  amLODIPine 10 mg PO DAILY  \n5.  Aspirin 81 mg PO DAILY  \n6.  Atorvastatin 80 mg PO QPM  \n7.  CARVedilol 50 mg PO BID  \n8.  Levothyroxine Sodium 100 mcg PO DAILY  \n9.  Minoxidil 10 mg PO DAILY  \n10.  Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine  \n11.  sevelamer CARBONATE 800 mg PO TID W/MEALS  \n12.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n13.  Vitamin D 1000 UNIT PO DAILY  \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPrimary Diagnosis:\n-Acute on chronic diastolic heart failure exacerbation\nSecondary Diagnosis:']","For a patient with NSTEMI and hypertension, as observed in the provided medical context, the prescribed dose of Aspirin is 81 mg PO DAILY. The role of Aspirin in this care plan is consistent with managing Non-ST Elevation Myocardial Infarction (NSTEMI), where Aspirin is standard for its antiplatelet effects to reduce the risk of further cardiac events. Additionally, its anti-inflammatory properties may indirectly support the management of the patient's overall cardiovascular health, including hypertension, although its primary role in this context is related to the patient's CAD with inducible ischemia and NSTEMI rather than directly lowering blood pressure.",custom_multi_hop_query_synthesizer,"Based on the provided documents and following the instructions, here's the answer to the question:

**Question:** What's the prescribed dose of Aspirin for a patient with NSTEMI and hypertension, and what's its role in their care plan?

**Prescribed Dose of Aspirin:**
- **Dose:** 81 mg
- **Administration:** PO (Orally) DAILY

**Role in Care Plan (as inferred from the documents):**
- For **History of CVA (Cerebrovascular Accident):** Aspirin is continued from home as part of managing the patient's condition, implying its role in preventing further cerebrovascular events.
- **Hypertension:** While not explicitly stated as a condition in the provided content sections, given the presence of hypertension in the question and considering the patient's medication list (e.g., Amlodipine, Carvedilol, which are used to treat hypertension), Aspirin's role might also include contributing to the management of cardiovascular risk associated with hypertension. However, this is an inference since the documents directly mention Aspirin's continuation for CVA history and not explicitly for hypertension or NSTEMI (which is not mentioned at all in the provided documents).

**Metadata Relevance to the Question:**
- The question doesn't directly require metadata values (Patient/Subject ID, Note ID, Admission ID, Chart Time, Store Time) for answering the Aspirin dose or its role. However, for context:
  - **Patient/Subject ID:** 13180007 (consistent across all documents)
  - **Note ID, Admission ID:** Also consistent across documents (13180007-DS-19 and 20774429, respectively), but not directly relevant to the question asked. 

**Note on NSTEMI:**
- NSTEMI (Non-ST Elevation Myocardial Infarction) is mentioned in the question but not found in the provided documents. Therefore, any specific role of Aspirin in the context of NSTEMI for this patient cannot be determined from the given information. Typically, Aspirin is a standard part of acute and long-term management for patients with NSTEMI due to its antiplatelet effects, but this cannot be confirmed from the documents provided.","['* **Medications to Take as Prescribed:**\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (30 Units Breakfast, 10 Units Lunch)\n\t3. Albuterol Inhaler 2 PUFF IH Q8H:PRN\n\t4. Amlodipine 10 mg PO DAILY\n\t5. ', '+ **Follow-up Appointments**: [NOT PROVIDED]\n* **Discharge Medications** (same as listed in the original document):\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (dosage and timing)\n\t3. Albuterol In', '1. **Medications**:\n\t* List of discharge medications (13 items, see below)\n\t* **Note**: Take all medications as prescribed\n\t* **Discharge Medications List**:\n\t\t1. Torsemide 100 mg PO DAILY\n\t\t2. 70/30 ', '1. **Albuterol Inhaler**\n\t* Dose: 2 PUFF IH Q8H\n\t* Indication: PRN shortness of breath\n2. **Amlodipine**\n\t* Dose: 10 mg PO DAILY\n3. **Atorvastatin**\n\t* Dose: 80 mg PO QPM\n4. **Carvedilol**\n\t* Dose: 50', 'Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What specific insulin regimen should a discharged patient, who was hospitalized for worsening shortness of breath and leg swelling, continue to follow as part of their post-discharge care, considering their pre-admission insulin schedule?","['cd30826d-ad9e-4a08-8b63-15e1e3bbfe0c\n\nYou were admitted to the hospital because:\n================================\n-You had worsening shortness of breath, with increased leg \nswelling and weight gain.\nDuring your stay:\n============\n-You had too much volume onboard so you were given IV diuretic \nmedications,. You improved significantly.\nAfter your discharge:\n================\n-Please continue taking all medications as prescribed (see \nbelow).\n-Please stop taking Lisinopril and metoprolol.\n-Please continue taking insulin according to the regimen you \nwere following before this admission.\n-New medications:\n  - Aspirin 81mg once daily\n  - Carvedilol 25mg twice daily\n  - Furosemide 40mg twice daily\n  - Hydralazine 100mg three times daily\n-Please attend any upcoming outpatient appointments you have \n(see below).\nWe wish you the very best!', ""fd49a2e0-9612-4cbf-91c3-bbfc765fb300\n\n[ ] Changed medications: Insulin (lantus 40 qam and 10 qpm w/ \nNovolog ___ w/ SSI with meals; discharged w/ insulin pens), \ncoreg was increased to 37.5 mg BID. Amlodipine was switched from \nqod to everyday.\n[ ] Please monitor BP as an outpatient and consider starting \nimdur.\n[ ] HFpEF - Consider initiation of spironolactone once Cr is \ndowntrending.\n[ ] ?COPD - Consider PFTs to see if patient has COPD. Started on \nadvair as an inpatient.\n[ ] DM: Please monitor his blood glucose as an outpatient as his \nblood glucoses ran elevated as an inpatient. He should follow-up \nwith ___ as an outpatient.\n[ ] Lung cancer screening - Given patient's smoking history, \nconsider outpatient CT Chest.\n[ ] Hyperlipidemia - Per prior cardiology note, patient approved \nfor PCSK9 inhibitor.\n[ ] Iron deficiency anemia: Will need a colonoscopy as an \noutpatient\n[ ] CKD - Anticipate he may need dialysis in the future. K on \ndischarge was 4.8 and Cr on discharge was 3.7.\n[ ] Labs: Please recheck a BMP at his next follow-up appointment \nto monitor K and Cr.\n[ ] Discharge weight: 72.7 kg\n==============""]","The patient should continue taking insulin according to the regimen they were following before this admission, which specifically includes: Insulin (Lantus 40 qam and 10 qpm with Novolog, with Sliding Scale Insulin (SSI) adjustments with meals), now discharged with insulin pens for administration.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, here's the answer to the question about the specific insulin regimen for the discharged patient:

**Answer:**
The specific insulin regimen for the discharged patient (Patient/Subject ID: **13180007**) to continue as part of their post-discharge care is:

* **70/30 Insulin** with the following dosage and timing:
	+ **30 Units** at **Breakfast**
	+ **10 Units** at **Lunch**

**Rationale and References:**

* **Patient/Subject ID Confirmation**: This insulin regimen is for Patient/Subject ID **13180007**, which is consistently mentioned across all documents (Document 1 through Document 5) in the **METADATA** section.
* **Insulin Regimen Details**: The specific dosage and timing of the 70/30 Insulin are found in **Document 5** under **CONTENT** > **1. Medications** > **Discharge Medications List** > **Item 2**.
* **Pre-admission Insulin Schedule**: Unfortunately, the pre-admission insulin schedule is not provided in the given documents to compare or contrast with the post-discharge regimen. The answer is therefore based solely on the post-discharge care instructions as per the documents.

**Metadata Consistency Note**: 
- **Patient/Subject ID**: Consistently **13180007** across all documents.
- **Note ID**, **Admission ID**, **Chart Time**, and **Store Time** are also consistent across all documents, but this information is not directly relevant to answering the question about the insulin regimen.","['+ **Follow-up Appointments**: [NOT PROVIDED]\n* **Discharge Medications** (same as listed in the original document):\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (dosage and timing)\n\t3. Albuterol In', '+ **Follow-up Appointments**: [NOT PROVIDED]\n* **Discharge Medications** (same as listed in the original document):\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (dosage and timing)\n\t3. Albuterol In', '* **Additional Recommendations:**\n\t+ Consider completing the 4-day course of **ferric gluconate** (started during admission; received 2 doses of 250mg IV on **[NOT PROVIDED]**).\n\t+ One additional infu', '+ **Symptoms to Report (Danger Signs)**: Not explicitly listed under Discharge Condition, but implied to be monitored based on hospital course (e.g., worsening edema, shortness of breath, chest pain)', '1. **Medications**:\n\t* List of discharge medications (13 items, see below)\n\t* **Note**: Take all medications as prescribed\n\t* **Discharge Medications List**:\n\t\t1. Torsemide 100 mg PO DAILY\n\t\t2. 70/30 ']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What ar the commen causis of Congestive Heart Failure (CHF) exaserbation in pashents with a history of hypertension and diabetis, and how do sympoms like shortness of breath and lower extremity edema relait to the condishun?","['6ca6759d-052d-4b9a-b47d-014a869a41be\n\nechocardiographic evidence of tamponade.\nIMPRESSION: Mild symmetric biventricular hypetrophy with \npreserved biventricular systolic function. No clinically \nsignificant valvular disease. Small, predominantly anterior \npericardial effusion\nwithout echocardiographic evidence of tamponade.\n \nBrief Hospital Course:\n___ M w/ PMH significant for HTN, HLD, T2DM, and CVA in ___ \nwho presents w/ increased SOB and volume retention, concerning \nfor CHF exacerbation. \nACTIVE ISSUES: \n==============\n#Acute HF exacerbation (preserved EF 65% on stress echo in ___, \nunknown current EF)\n#Hypertension\nPatient presented with worsening shortness of breath, lower \nextremity edema and was hypervolemic on exam w/ diffuse rhonchi \non lung auscultation, as well as elevated BNP, all concerning \nfor CHF exacerbation. Stress echo in ___ showed \npreserved EF. Etiology could be either uncontrolled hypertension \nvs ischemia (especially given history of positive stress echo). \nExacerbation could be due to medication/dietary non-compliance.', 'e0673342-03d7-4e47-9dd2-f1d0eaafa133\n\n___ (PORTABLE AP)\nIMPRESSION: \nIn comparison with the study of earlier in this date, the \nendotracheal tube\nhas been pulled back so that the tip now lies approximately 5 cm \nabove the\ncarina.  Cardiomediastinal silhouette is stable.  The vascular \ncongestion\nsuggested previously is no longer appreciated.\n \nBrief Hospital Course:\n___ year old male w history of diastolic CHF, diabetes type 2 \nrecent admission for CHF exacerbation, re-admitted ___ \nwith hyperglycemia and respiratory distress requiring \nintubation, status post treatment of acute diastolic CHF, \nsubsequently optimizing glucose control, able to be discharged \nhome with ___ for medication assistance.  \nTRANSITIONAL ISSUES:\n====================\n[ ] Will need repeat Cr at his ___ appointment on ___, \n___, to ensure stability.\n[ ] Repeat CMP within 1 week of discharge, to ensure stability \nin electrolytes \n[ ] Patient has now had multiple presentations the hospital with']","Based on the provided context, CHF exacerbation in patients with a history of hypertension and diabetes can be attributed to two main etiologies: **1. Uncontrolled Hypertension** and **2. Ischemia** (especially in patients with a history of positive stress echo). Symptoms such as **worsening shortness of breath (SOB)**, **lower extremity edema**, and being **hypervolemic on exam** along with **diffuse rhonchi on lung auscultation** and **elevated BNP**, are all concerning for CHF exacerbation. Additionally, **medication/dietary non-compliance** can also contribute to the exacerbation of CHF. In patients with diastolic CHF, optimizing glucose control (for those with diabetes) and managing the underlying causes are crucial for stabilization and discharge.",custom_multi_hop_query_synthesizer,"**Response to Current Question**

**Common Causes of Congestive Heart Failure (CHF) Exacerbation in Patients with a History of Hypertension and Diabetes:**

While the provided documents do not explicitly list common causes of CHF exacerbation, based on medical knowledge, the following are frequent triggers in patients with a history of hypertension and diabetes:

1. **Medication Non-compliance**: As hinted at in Document 5 (""possible medication non-compliance"" as a trigger), not adhering to prescribed medications for CHF, hypertension, or diabetes can lead to exacerbation.
2. **Fluid Overload**: Consuming too much fluid or not managing fluid intake properly, especially in patients with a history of hypertension.
3. **Dietary Indiscretion**: High sodium intake can exacerbate fluid retention, worsening CHF symptoms in patients with hypertension.
4. **Infection**: Respiratory or other infections can increase the body's demand for oxygen, worsening heart failure symptoms.
5. **Worsening of Underlying Conditions**: Progression of diabetes (as indicated by the poorly controlled A1c of 11.4% in Document 3) or hypertension can directly impact heart function.
6. **Renal Dysfunction**: As seen in the patient's profile (CKD with elevated Cr levels), kidney issues can complicate heart failure management.

**Relationship Between Symptoms (Shortness of Breath and Lower Extremity Edema) and CHF Exacerbation:**

1. **Shortness of Breath (Dyspnea)**: In CHF, the heart's reduced ability to pump blood efficiently can lead to fluid buildup in the lungs (pulmonary congestion), causing shortness of breath. This symptom is consistent with the patient's presentation in Document 5 (""1 day of dyspnea and discomfort"").

2. **Lower Extremity Edema**: Fluid overload, a common issue in CHF exacerbations, often manifests as swelling in the legs, ankles, and feet due to gravity's effect on the body's fluid distribution. Although not explicitly mentioned in the provided documents, lower extremity edema is a typical symptom associated with the conditions described (e.g., acute on chronic diastolic heart failure exacerbation, CKD).

**Metadata Observations (as per instructions):**

- **Patient/Subject ID**: Consistently listed as **13180007** across all documents (1 through 5).
- **Note ID**: Uniformly identified as **13180007-DS-19** in all documents.
- **Admission ID**: Always **20774429** across the documents.
- **Chart Time & Store Time**: Listed as **N/A** in all provided metadata sections.","['* **Primary Diagnosis:**\n\t+ **Condition:** Acute on chronic diastolic heart failure exacerbation\n\t+ **Implication:** Heart failure with preserved ejection fraction (HFpEF) exacerbation, as noted in Hi', '* **Discharge Location**: Home With Service\n* **Facility**: [REDACTED]\n* **Discharge Diagnosis**:\n\t+ **Primary Diagnosis**: Acute on chronic diastolic heart failure exacerbation\n\t+ **Secondary Diagnos', '* **Acute Problems Addressed**:\n\t1. **Acute on Chronic HFpEF**\n\t2. **Chest Pain** (mild troponin elevation, likely related to CKD)\n\t3. **CKD** (elevated Cr, possibly due to renal congestion)\n\t4. **Hyp', '**ACUTE PROBLEMS**\n=====================\n\n### 1. **Acute on Chronic HFpEF (Heart Failure with Preserved Ejection Fraction)**', '* **Patient Profile**: ___ male with history of HFpEF (EF 55-60%), prior CVA, CKD, DM, hypertension, and carotid artery disease\n* **Presentation**: 1 day of dyspnea and discomfort, admitted for HF exa']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
Whats the perscribed dose of CARVedilol for the patient with Hx of CAD and CKD stage III?,"['4b3d7a96-6534-434e-8295-b8356c5ca64d\n\nbasal/bolus four times daily regimen. However, this is not a \nsustainable regimen for patient on discharge. Discussed \npossibility of switching to 70/30 mix BID, however currently \npatient cannot be guaranteed to eat regular meal after each \ninsulin injection therefore currently not a tenable plan. In the \nfuture, if patient able to be placed in a day program, \npotentially could switch to this but for now will we continued \nhis prior home regimen (EXCEPT for Jardiance, which was \ndiscontinued due to contraindication with chronic kidney \ndisease) on discharge, with very close ___ follow-up and ___ \nservices to help increase compliance. With regards to his more \nsubacute mental status decompensation, would benefit from \nreferral for outpatient neurocognitive evaluation.\n# Hx of CAD: \n# Hx of ischemic CVA:\nStress test in ___ with area of inducible ischemia in LCx \ndistribution, in setting of multiple risk factors. Has been \nmedically optimized by prescribed medications, but as above it \nseems that pt has been taking these medications. TnT 0.04->0.02 \nin setting of CKD stage III-IV. Continued home aspirin, \natorvastatin, and carvedilol. Note that he was once on \nlisinopril (most recently filled in ___ for 2.5mg dose) \nhowever seems that this has since been discontinued.\n# CKD stage III:', 'dc9c33c0-6523-4835-a02f-162ecaa61776\n\n2. amLODIPine 10 mg PO DAILY \n3. Atorvastatin 80 mg PO QPM \n4. Minoxidil 10 mg PO DAILY \n5. CARVedilol 50 mg PO BID \n6. Levothyroxine Sodium 100 mcg PO DAILY \n7. Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine \n8. sevelamer CARBONATE 800 mg PO TID W/MEALS \n9. Vitamin D 1000 UNIT PO DAILY \n10. Torsemide 100 mg PO DAILY \n11. Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY \n12. 70/30 30 Units Breakfast\n70/30 10 Units Lunch\n13. Aspirin 81 mg PO DAILY \n \nDischarge Medications:\n1.  Acetaminophen 650 mg PO Q6H:PRN Pain - Mild/Fever  \n2.  70/30 30 Units Breakfast\n70/30 20 Units Dinner \n3.  Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath  \n4.  amLODIPine 10 mg PO DAILY  \n5.  Aspirin 81 mg PO DAILY  \n6.  Atorvastatin 80 mg PO QPM  \n7.  CARVedilol 50 mg PO BID']","The prescribed dose of CARVedilol for the patient is 50 mg PO BID (twice a day). This is part of the patient's medically optimized regimen for CAD, alongside other medications such as aspirin, atorvastatin, and with careful management due to CKD stage III-IV.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, here's the answer to the question:

**Question:** What's the prescribed dose of Carvedilol for the patient with Hx of CAD and CKD stage III?

**Note:** 
* The patient's medical history (Hx) of CAD (Coronary Artery Disease) is not explicitly mentioned in the provided documents, but we can infer the patient has a history of hypertension and CKD (Chronic Kidney Disease) from the documents.
* CKD stage III is not explicitly mentioned, but the patient is noted to have **Chronic Kidney Disease (CKD)** in Document 1 and **Acute on Chronic Kidney Disease (CKD)** in Document 2, implying a pre-existing CKD condition.

**Answer to the Carvedilol dose question:**

* **Patient/Subject ID:** 13180007 (consistent across all documents)
* **Prescribed Dose of Carvedilol:**
	+ **50 mg PO BID (Twice a Day)**, as mentioned in:
		- Document 1: Under **Hypertension** > Medications
		- Document 2: Under **4. Hypertension** > Management
		- Document 4: Under **Medications to Take as Prescribed**, item 7

**Additional Observations (as per instruction 3):**
- The **Patient/Subject ID (13180007)**, **Note ID (13180007-DS-19)**, and **Admission ID (20774429)** are consistent across all five documents, indicating they all pertain to the same patient encounter.","['1. **Hypertension**\n\t* Medications: \n\t\t+ Amlodipine 10 mg PO DAILY (continued from home)\n\t\t+ Carvedilol 50 mg PO BID (continued from home)\n\t\t+ Minoxidil 10 mg PO DAILY (continued from home)\n2. **Diabe', '### 3. **Acute on Chronic Kidney Disease (CKD)**\n\n* **Presentation:** Elevated Cr (2.6 from baseline 1.8-2.2)\n* **Concerns:** Renal congestion causing renal dysfunction\n* **Status at Discharge:** Cr 2', '8. Levothyroxine Sodium 100 mcg PO DAILY\n\t\t9. Minoxidil 10 mg PO DAILY\n\t\t10. Polyethylene Glycol 17 g PO DAILY:PRN\n\t\t11. Sevelamer Carbonate 800 mg PO TID W/MEALS\n\t\t12. Victoza (Liraglutide) 0.6 mg/0.', '* **Medications to Take as Prescribed:**\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (30 Units Breakfast, 10 Units Lunch)\n\t3. Albuterol Inhaler 2 PUFF IH Q8H:PRN\n\t4. Amlodipine 10 mg PO DAILY\n\t5. ', '**Additional Medication Administration on Admission:**\n\n* **IV Lasix 80mg** (received in the ED, as mentioned in the History of Present Illness section)']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What is the standard dosage of Levothyroxine for a patient with Hypothyroidism in the context of multiple comorbidities (e.g., Hypertension, IDDM, CKD) as observed in clinical care coordination?","['08e7114b-32bf-470b-a3c6-d919c6de4e69\n\n# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n# Acute on chronic anemia:\nHb on admission was 7.4. No evidence of bleeding per history or \nexam. Possibly related to worsening of his renal function vs \ndilutional iso heart failure. His Hb was 7.6 on discharge. He \nreceived 3 doses of ferric gluconate 250 mg IV on ___.\n#IDDM\nPoorly controlled. A1c 14.4 in ___ in ___ at ___. \nRepeat A1C ___ was 11.4%. He was given Lantus 30u night of \nadmission, then transitioned to home insulin ___ with 70/30 \n30u with breakfast and 20u with lunch. He was also on ISS while \ninpatient.\nCHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.', '8c0badb1-fe3b-4585-8010-1ef4ba8fdd98\n\n================\n# Hx of CAD \n# Hx of ischemic CVA\nStress test in ___ with area of inducible ischemia in LCx \ndistribution. Trop peaked at 0.06 (iso CKD) and then \ndowntrended. No EKG changes seen. Continued home carvedilol, ASA \nand high dose atorvastatin. \n# CKD: Cr at presentation close to baseline. Underlying etiology \nlikely combination of HTN, DM. \n# Hypothyroidism: Continued home levothyroxine 100 mcg daily\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Furosemide 40 mg PO 3X/WEEK (___) \n2. sevelamer CARBONATE 800 mg PO TID W/MEALS \n3. Minoxidil 2.5 mg PO DAILY \n4. Levothyroxine Sodium 100 mcg PO DAILY \n5. CARVedilol 37.5 mg PO BID \n6. amLODIPine 10 mg PO DAILY \n7. Albuterol Inhaler 2 PUFF IH Q6H \n8. Jardiance (empagliflozin) 10 mg oral DAILY \n9. Victoza 3-Pak (liraglutide) 1.2 mg subcutaneous DAILY']","Based on the provided medical context, for patients with Hypothyroidism, alongside multiple comorbidities such as Hypertension, IDDM (Insulin-Dependent Diabetes Mellitus), and CKD (Chronic Kidney Disease), the continued home dosage of Levothyroxine is consistently noted as 100mcg daily. This dosage is mentioned across different patient scenarios, suggesting a standard approach for Hypothyroidism management in these complex cases, under the care coordination observed.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Standard Dosage of Levothyroxine for Hypothyroidism with Comorbidities:**

In the context of the provided documents, which highlight multiple comorbidities for Patient/Subject ID **13180007** (notably mentioned across all documents, indicating consistency in patient identification), the standard dosage of Levothyroxine for Hypothyroidism is observed as follows:

- **Dosage:** 100 mcg PO (orally) DAILY

**Source Documents:**
- **Document 1**: Under ""* CHRONIC PROBLEMS"" > **Hypothyroidism**
- **Document 2**: Identical to Document 1, under ""* CHRONIC PROBLEMS"" > **Hypothyroidism** (suggesting either duplication or confirmation across records)
- **Document 3**: Listed as item ""8."" among medications, reinforcing the dosage.
- **Document 5**: Listed as item ""8."" under ""* Medications to Take as Prescribed:*"", further confirming the consistent dosage across different aspects of the patient's care.

**Comorbidities Context:**
While the question asks for the dosage in the context of multiple comorbidities (e.g., Hypertension, IDDM, CKD), the provided documents directly mention:
- **Hypothyroidism** (all documents)
- **History of CVA (Cerebrovascular Accident)** (Documents 1 & 2)
- **IDDM (Insulin-Dependent Diabetes Mellitus)** (Document 4)
- **Acute on Chronic Anemia** (Document 4), which might imply CKD (Chronic Kidney Disease) or at least worsening renal function as a possible cause.

However, the dosage of Levothyroxine (100 mcg PO DAILY) remains consistent across all mentions, without specific adjustments highlighted for the comorbidities in the provided documents.

**Metadata Consistency:**
- **Patient/Subject ID:** Consistently **13180007** across all documents.
- **Note ID, Admission ID, Chart Time, and Store Time** are also consistent or not applicable (N/A) across all documents, indicating these records pertain to the same patient encounter or assessment period.","['Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D', 'Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D', '8. Levothyroxine Sodium 100 mcg PO DAILY\n\t\t9. Minoxidil 10 mg PO DAILY\n\t\t10. Polyethylene Glycol 17 g PO DAILY:PRN\n\t\t11. Sevelamer Carbonate 800 mg PO TID W/MEALS\n\t\t12. Victoza (Liraglutide) 0.6 mg/0.', '### 5. **Acute on Chronic Anemia**\n\n* **Presentation:** Hb 7.4 on admission\n* **Possible Causes:** Worsening renal function or dilutional iso heart failure\n* **Management:**\n\t+ Received 3 doses of Fer', '* **Medications to Take as Prescribed:**\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (30 Units Breakfast, 10 Units Lunch)\n\t3. Albuterol Inhaler 2 PUFF IH Q8H:PRN\n\t4. Amlodipine 10 mg PO DAILY\n\t5. ']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What are the relevent medicashuns and ther underlaying efectivness for a pashent with a Hx of CAD, ischemic CVA, CKD (likely due to HTN, DM), and Hypothyroidism, consiederin the pashent is alredy on carvedilol, ASA, and high dose atorvastatin?","['8c0badb1-fe3b-4585-8010-1ef4ba8fdd98\n\n================\n# Hx of CAD \n# Hx of ischemic CVA\nStress test in ___ with area of inducible ischemia in LCx \ndistribution. Trop peaked at 0.06 (iso CKD) and then \ndowntrended. No EKG changes seen. Continued home carvedilol, ASA \nand high dose atorvastatin. \n# CKD: Cr at presentation close to baseline. Underlying etiology \nlikely combination of HTN, DM. \n# Hypothyroidism: Continued home levothyroxine 100 mcg daily\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Furosemide 40 mg PO 3X/WEEK (___) \n2. sevelamer CARBONATE 800 mg PO TID W/MEALS \n3. Minoxidil 2.5 mg PO DAILY \n4. Levothyroxine Sodium 100 mcg PO DAILY \n5. CARVedilol 37.5 mg PO BID \n6. amLODIPine 10 mg PO DAILY \n7. Albuterol Inhaler 2 PUFF IH Q6H \n8. Jardiance (empagliflozin) 10 mg oral DAILY \n9. Victoza 3-Pak (liraglutide) 1.2 mg subcutaneous DAILY']","Based on the provided context, the patient's relevant medications and their underlying effectiveness for the mentioned conditions are as follows:  - **For CAD and Ischemic CVA Prevention:**   - **Carvedilol (CARVedilol 37.5 mg PO BID):** Continued for heart-related conditions, indicating its ongoing effectiveness.   - **ASA (Aspirin, dosage not specified in the context but mentioned as continued):** For antiplatelet effects to prevent further ischemic events.   - **Atorvastatin (dosage not specified, but mentioned as high dose):** For managing cholesterol, crucial in CAD management.  - **For CKD (with likely underlying etiology of HTN, DM):**   - **Furosemide 40 mg PO 3X/WEEK:** For fluid management in CKD.   - **Sevelamer CARBONATE 800 mg PO TID W/MEALS:** To control phosphorus levels in CKD patients.   - **Minoxidil 2.5 mg PO DAILY:** For blood pressure management (HTN).   - **AmLODIPine 10 mg PO DAILY:** Also for HTN management.   - **Jardiance (Empagliflozin) 10 mg oral DAILY:** Specifically for DM management, with the added benefit of renal protection in CKD.  - **For Hypothyroidism:**   - **Levothyroxine Sodium 100 mcg PO DAILY:** Continued for thyroid hormone replacement.  - **Additional for DM (as part of the themes):**   - **Victoza 3-Pak (Liraglutide) 1.2 mg subcutaneous DAILY:** For DM management, helping with glucose control and possibly aiding in weight management, which can be beneficial for overall cardiovascular health.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, I'll address the question to the best of my abilities. Please note that the question contains several abbreviations and typos, which I'll interpret as follows:

* ""medicashuns"" => Medications
* ""efectivness"" => Effectiveness
* ""pashent"" => Patient
* ""Hx"" => History
* ""CAD"" => Coronary Artery Disease (not explicitly mentioned in the documents, but inferred from the context)
* ""CVA"" => Cerebrovascular Accident (confirmed in the documents)
* ""CKD"" => Chronic Kidney Disease (confirmed in the documents)
* ""HTN"" => Hypertension (confirmed in the documents)
* ""DM"" => Diabetes Mellitus (confirmed in the documents as ""IDDM"" - Insulin-Dependent Diabetes Mellitus)
* ""Hypothyroidism"" => Confirmed in the documents

**Patient Identification:**
Based on the metadata, all documents (1 to 5) share the same:
* **Patient/Subject ID:** `13180007`
* **Note ID:** `13180007-DS-19`
* **Admission ID:** `20774429`

**Relevant Medications and Underlying Effectiveness:**

1. **Already prescribed medications (from the question and documents):**
	* **Carvedilol**: Not mentioned in the provided documents, but listed in the question.
	* **ASA (Aspirin)**: 81 mg PO DAILY (continued from home) - **Effectiveness:** Antiplatelet therapy for CVA and CAD prevention.
	* **High-dose Atorvastatin**: 80 mg PO QPM (continued from home) - **Effectiveness:** Cholesterol-lowering therapy for CAD prevention and management.

2. **Additional medications mentioned in the documents:**
	* **Levothyroxine Sodium**: 100 mcg PO DAILY (for Hypothyroidism) - **Effectiveness:** Hormone replacement for hypothyroidism management.
	* **Torsemide**: 100 mg daily (for HF exacerbation, as per Document 4) - **Effectiveness:** Loop diuretic for managing fluid overload in Heart Failure.
	* **IV Lasix (Furosemide)**: 80 mg (for HF exacerbation, as per Document 4) - **Effectiveness:** Loop diuretic for acute fluid overload management in Heart Failure.

3. **Medications not explicitly mentioned but potentially relevant for the patient's conditions:**
	* **Antihypertensive medications** (beyond Carvedilol, if applicable): Not specified in the documents, but important for HTN management.
	* **Medications for IDDM (A1c 11.4%)**: Not specified in the documents, but intensification of diabetes management might be necessary.
	* **CKD management medications**: Not specified in the documents, but depending on the CKD stage, additional medications might be beneficial.

**Limitations and Recommendations:**
- The documents do not provide a comprehensive medication list or detailed treatment plans for all the patient's conditions.
- Effectiveness assessments are based on standard medical practices and might vary depending on the patient's specific situation.
- A thorough review of the patient's entire medical record, along with consultation from the healthcare team, is necessary for a comprehensive treatment plan.","['Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D', 'Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D', '### 2. **Chest Pain**\n\n* **Presentation:** Chest pain with mild troponin elevation (0.03)\n* **Interpretation:** Difficult due to CKD, levels similar to prior months\n* **Findings:**\n\t+ No evidence of d', '* **Patient Profile**: ___ male with history of HFpEF (EF 55-60%), prior CVA, CKD, DM, hypertension, and carotid artery disease\n* **Presentation**: 1 day of dyspnea and discomfort, admitted for HF exa', '* **Acute Problems Addressed**:\n\t1. **Acute on Chronic HFpEF**\n\t2. **Chest Pain** (mild troponin elevation, likely related to CKD)\n\t3. **CKD** (elevated Cr, possibly due to renal congestion)\n\t4. **Hyp']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What changes, if any, occurred in the patient's Furosemide dosage from admission to discharge, and what could be the clinical rationale behind such adjustments for a patient initially presenting with worsening shortness of breath, increased leg swelling, and weight gain?","['8c579626-76a5-4cd0-9f53-1feadb6904be\n\nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath \n2. amLODIPine 10 mg PO DAILY \n3. Atorvastatin 80 mg PO QPM \n4. CARVedilol 50 mg PO BID \n5. Furosemide 80 mg PO DAILY \n6. 70/30 30 Units Breakfast\n70/30 10 Units Lunch\n7. Levothyroxine Sodium 100 mcg PO DAILY \n8. Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY \n9. Minoxidil 10 mg PO DAILY \n10. Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine \n11. sevelamer CARBONATE 800 mg PO TID W/MEALS \n12. Aspirin 81 mg PO DAILY \n13. Vitamin D 1000 UNIT PO DAILY \n \nDischarge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast', 'cd30826d-ad9e-4a08-8b63-15e1e3bbfe0c\n\nYou were admitted to the hospital because:\n================================\n-You had worsening shortness of breath, with increased leg \nswelling and weight gain.\nDuring your stay:\n============\n-You had too much volume onboard so you were given IV diuretic \nmedications,. You improved significantly.\nAfter your discharge:\n================\n-Please continue taking all medications as prescribed (see \nbelow).\n-Please stop taking Lisinopril and metoprolol.\n-Please continue taking insulin according to the regimen you \nwere following before this admission.\n-New medications:\n  - Aspirin 81mg once daily\n  - Carvedilol 25mg twice daily\n  - Furosemide 40mg twice daily\n  - Hydralazine 100mg three times daily\n-Please attend any upcoming outpatient appointments you have \n(see below).\nWe wish you the very best!']","Upon admission, the patient was taking Furosemide 80 mg PO DAILY. At discharge, the medication regimen was adjusted to Furosemide 40mg twice daily. The initial presentation of worsening shortness of breath, increased leg swelling, and weight gain suggests fluid overload, for which IV diuretic medications were effectively administered during the hospital stay. The adjustment to a twice-daily regimen at a lower cumulative daily dose (40mg twice daily equals 80mg total daily) might reflect a clinical decision to maintain diuretic efficacy while minimizing potential side effects, considering the patient's improved condition following in-hospital diuretic treatment. This adjustment could also be tailored to manage outpatient fluid balance, given the patient's response to diuretics during the hospitalization.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Changes in Furosemide Dosage:**
None explicitly mentioned in the transition from admission to discharge regarding Furosemide. However, there is a mention of a medication change related to diuretic treatment:

* **Admission (implied from Document 5's CONTENT, under ""Findings""):** IV Lasix (Furosemide) 80mg
* **Discharge (as per Documents 1, 2, 3, and 4's CONTENT):** PO (oral) Torsemide 100mg daily

**Clinical Rationale for the Adjustment:**
The switch from IV Furosemide (Lasix) to oral Torsemide could be based on several clinical considerations for a patient presenting with worsening shortness of breath, increased leg swelling, and weight gain (indicative of volume overload, likely due to heart failure with reduced or preserved ejection fraction, given the diastolic dysfunction mentioned in Document 5):

1. **Transition to Oral Therapy for Outpatient Management:** IV Furosemide is typically used in the acute setting to rapidly reduce volume overload. Switching to an oral diuretic (Torsemide) at discharge facilitates ongoing management at home.
   
2. **Torsemide's Pharmacokinetic Profile:** Torsemide has a longer duration of action compared to Furosemide, which might provide a more sustained diuretic effect, potentially improving patient compliance with once-daily dosing.

3. **Efficacy and Tolerability:** The choice of Torsemide over continuing Furosemide might also be influenced by the patient's response to the medication, side effect profile, or specific clinical characteristics (e.g., Torsemide may have a more favorable effect on blood pressure or less disturbance of electrolyte balance in some patients).

**Metadata Observations:**

* **Patient/Subject ID, Note ID, and Admission ID Consistency:** All documents (1 through 5) share the same **Patient/Subject ID (13180007)**, **Note ID (13180007-DS-19)**, and **Admission ID (20774429)**, indicating they pertain to the same patient's single admission and note series.
* **Chart Time and Store Time:** Both are listed as **N/A** across all documents, suggesting either this information was not captured or is not relevant to the provided documents.","['3. **Discharge**: Symptoms improved, but still slightly volume up (JVP ~12, 1+ edema to ankles)\n* **Discharge Details**:\n\t+ **Weight**: 166.6lb\n\t+ **Creatinine (Cr)**: 2.9 (elevated from baseline 1.8-', '3. **Discharge**: Symptoms improved, but still slightly volume up (JVP ~12, 1+ edema to ankles)\n* **Discharge Details**:\n\t+ **Weight**: 166.6lb\n\t+ **Creatinine (Cr)**: 2.9 (elevated from baseline 1.8-', '**Key Metrics at Discharge**\n\n* **Weight**: 166.6lb\n* **Creatinine (Cr)**: 2.9 (elevated from baseline 1.8-2.2)\n* **Diuretic**: Torsemide 100mg daily\n\n**Action Items**\n\n* **Follow-up Labs**: To be dra', '* **Discharge Status:**\n\t+ Symptoms associated with volume overload had subsided, but patient was still slightly volume up on exam.\n\t+ 1+ edema to ankles bilaterally.\n\t+ JVP of 12cm.\n* **Medications a', '* **Presentation:** Dyspnea, lower extremity edema, volume overload\n* **Trigger:** Unclear, possible medication non-compliance\n* **Findings:**\n\t+ EF 65% (TTE)\n\t+ Diastolic dysfunction\n\t+ Iron studies:']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What is the role of Hydralazine in the treatment regimen for a patient discharged with a primary diagnosis of Acute on chronic heart failure with preserved ejection fraction, and how is its dosage administered?","['5d1619ab-197a-416d-b0af-616eff82199c\n\n#*60 Tablet Refills:*0 \n12.  HydrALAZINE 100 mg PO TID \nRX *hydralazine 100 mg 1 tablet(s) by mouth three times a day \nDisp #*90 Tablet Refills:*0 \n13.  Levothyroxine Sodium 100 mcg PO DAILY \nRX *levothyroxine 100 mcg 1 tablet(s) by mouth once a day Disp \n#*30 Tablet Refills:*0 \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPRIMARY DIAGNOSIS\n==================\nAcute on chronic heart failure with preserved ejection fraction\nSECONDARY DIAGNOSES\n====================\nAcute kidney injury\nCoronary artery disease\nType 2 Diabetes Mellitus\nHyperkalemia', 'ab26554b-50b4-4fe8-adc0-d18910279c6b\n\n=============== \n#Acute exacerbation of HFpEF (EF 57%)\nLikely ___s possible ischemia given his \npositive stress in ___. Also possibly triggered by \npneumonia. Did endorse occasional angina symptoms, but trop was \nflat with no EKG changes. TTE showed no regional wall motion \nabnormalities and no mitral regurgitation. He was actively \ndiuresed. His lisinopril was held due to ___. His heart failure \nregimen upon discharge:\nDIURESIS: Torsemide 40 mg QD\nAFTERLOAD: Hydralazine 100 mg TID\nClonidine 0.2 mg BID\nHeld lisinopril given ___\nAmlodipine 10 mg QD\nNHBK: Carvedilol 37.5 mg BID; \n- Discharge weight: 72.7 kg (160.27 lb) \n- Discharge Cr: 3.7\n___ on CKD:\n#Hyperkalemia:\nInitially due to venous congestion, then likely due to \noverdiuresis. He had underlying CKD and his creatinine did not \nreturn to his baseline upon discharge. We suspect that he will \nneed to initiate HD in the near future. His K rose to about 5.8 \nthe week prior to discharge, but this improved with Lasix IV, \nkayexelate, and low potassium diet.']","According to the patient's discharge information, Hydralazine plays a role in the 'AFTERLOAD' component of the heart failure treatment regimen. The dosage of Hydralazine is specifically 100 mg, administered three times a day (TID). This is part of a broader regimen that includes DIURESIS with Torsemide, additional blood pressure management with Clonidine and Amlodipine, and NHBK (likely referring to Neurohormonal Blockade) with Carvedilol. The use of Hydralazine in this context suggests its application in managing afterload reduction, crucial for heart failure management, especially in a patient with preserved ejection fraction and other complicating factors like coronary artery disease and hyperkalemia.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Role of Hydralazine and Dosage Administration:**
* **Role in Treatment Regimen:** NOT MENTIONED in any of the provided documents (Document 1 through Document 5) as part of the treatment regimen for the patient with a primary diagnosis of Acute on chronic diastolic heart failure exacerbation (implied to be Heart failure with preserved ejection fraction, HFpEF, in Document 3).
* **Dosage Administration:** NOT PROVIDED, as Hydralazine is not mentioned in the treatment plans outlined in the documents.

**Additional Observations Relevant to the Patient’s Treatment Regimen:**

* **Primary Diagnosis:** Acute on chronic diastolic heart failure exacerbation (implied to be HFpEF in Document 3).
* **Mentioned Treatments for Heart Failure or Related Conditions:**
	+ **Ferric Gluconate** for Acute on Chronic Anemia (Document 4 and Document 5).
	+ **Torsemide 100mg daily** as a discharge diuretic (Document 4), which is relevant to heart failure management.

**Metadata Consistency Across Documents:**

* **Patient/Subject ID:** Consistently listed as **13180007** across all documents (Document 1 through Document 5).
* **Note ID and Admission ID:** Also consistent across all documents, listed as **13180007-DS-19** and **20774429**, respectively.
* **Chart Time and Store Time:** Both are **N/A** in all provided documents.","['* **Discharge Location**: Home With Service\n* **Facility**: [REDACTED]\n* **Discharge Diagnosis**:\n\t+ **Primary Diagnosis**: Acute on chronic diastolic heart failure exacerbation\n\t+ **Secondary Diagnos', '* **Discharge Location**: Home With Service\n* **Facility**: [REDACTED]\n* **Discharge Diagnosis**:\n\t+ **Primary Diagnosis**: Acute on chronic diastolic heart failure exacerbation\n\t+ **Secondary Diagnos', '* **Primary Diagnosis:**\n\t+ **Condition:** Acute on chronic diastolic heart failure exacerbation\n\t+ **Implication:** Heart failure with preserved ejection fraction (HFpEF) exacerbation, as noted in Hi', '* **Additional Recommendations:**\n\t+ Consider completing the 4-day course of **ferric gluconate** (started during admission; received 2 doses of 250mg IV on **[NOT PROVIDED]**).\n\t+ One additional infu', '### 5. **Acute on Chronic Anemia**\n\n* **Presentation:** Hb 7.4 on admission\n* **Possible Causes:** Worsening renal function or dilutional iso heart failure\n* **Management:**\n\t+ Received 3 doses of Fer']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
Whats the ushual dose of Vitimin D prescribd to pashents in thes hospitl recrds?,"['080dba33-29e9-4409-89cb-54a03af0e470\n\n8.  Levothyroxine Sodium 100 mcg PO DAILY  \n9.  Minoxidil 10 mg PO DAILY  \n10.  Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine  \n11.  sevelamer CARBONATE 800 mg PO TID W/MEALS  \n12.  Torsemide 100 mg PO DAILY  \n13.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n14.  Vitamin D 1000 UNIT PO DAILY  \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPRIMARY DIAGNSOIS:\n==================\nAcute Hypoxemic Respiratory Failure\nAcute on Chronic Diastolic Heart Failure\nHyperglycemia, Type 2 Diabetes \n___ on CKD \nSECONDARY DIAGNOSIS:', '9c9ab9ab-4a9f-4e03-8ad8-d377af91b9d0\n\n11.  Tresiba U-100 Insulin (insulin degludec) 50 units \nsubcutaneous DAILY  \n12.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n13.  Vitamin D ___ UNIT PO 1X/WEEK (WE)  \n14. HELD- CloNIDine 0.4 mg PO BID  This medication was held. Do \nnot restart CloNIDine until see what BP is at PCP visit, to see \nif need more meds\n15. HELD- Gabapentin 400 mg PO TID  This medication was held. Do \nnot restart Gabapentin until you discuss with PCP the need for \nit, was not needed during this hospital stay\n16. HELD- HydrALAZINE 100 mg PO TID  This medication was held. \nDo not restart HydrALAZINE until discuss with primary care \ndoctor\n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nType II diabetes']","Based on the provided hospital records, two different dosages of Vitamin D are mentioned for patients:               1. **1000 UNIT PO DAILY** (Record: 080dba33-29e9-4409-89cb-54a03af0e470)              2. **___ UNIT PO 1X/WEEK (WE)** (Record: 9c9ab9ab-4a9f-4e03-8ad8-d377af91b9d0) - *Note: The exact unit dosage is not specified in this record.*",custom_multi_hop_query_synthesizer,"Based on the provided instructions, I'll answer your question focusing on the content since the question pertains to medication dosage, which is found in the CONTENT section of the documents, rather than the METADATA.

**Question:** What's the usual dose of Vitamin D prescribed to patients in these hospital records?

**Answer:**

After analyzing the CONTENT of all provided documents (Document 1 through Document 5), the usual dose of Vitamin D prescribed to the patient (with Patient/Subject ID: **13180007**, consistently across all documents) is:

* **Dose:** **1000 UNIT**
* **Frequency:** **PO (Orally) DAILY**

This dosage and frequency are consistently mentioned across all documents (1, 2, 3, 4, and 5) for Vitamin D, indicating that for this patient, the usual prescribed dose is 1000 units orally once a day. 

**Metadata Relevance to Answer:** None directly, as the question pertains to medication dosage, not IDs or dates. However, it's noted that the patient's ID (**13180007**), Note ID (**13180007-DS-19**), and Admission ID (**20774429**) are consistent across all documents, confirming that these medication details pertain to the same patient's record.","['11. Sevelamer CARBONATE 800 mg PO TID W/MEALS\n\t12. Victoza (Liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) subcutaneous DAILY\n\t13. Vitamin D 1000 UNIT PO DAILY\n* **Follow-up Appointments:**\n\t+ **Lab Follow-u', '10. **Polyethylene Glycol**\n\t* Dose: 17 g\n\t* Frequency: PO DAILY:PRN (as needed) for Constipation - First Line\n11. **Sevelamer Carbonate**\n\t* Dose: 800 mg\n\t* Frequency: PO TID (three times a day) W/ME', '8. Levothyroxine Sodium 100 mcg PO DAILY\n\t\t9. Minoxidil 10 mg PO DAILY\n\t\t10. Polyethylene Glycol 17 g PO DAILY:PRN\n\t\t11. Sevelamer Carbonate 800 mg PO TID W/MEALS\n\t\t12. Victoza (Liraglutide) 0.6 mg/0.', '9. Minoxidil 10 mg PO DAILY\n\t10. Polyethylene Glycol 17 g PO DAILY:PRN\n\t11. Sevelamer CARBONATE 800 mg PO TID W/MEALS\n\t12. Victoza (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) subcutaneous DAILY\n\t13. Vita', '8. **Liraglutide (Victoza)**\n\t* Dose: 0.6 mg/0.1 mL (18 mg/3 mL) subcutaneous DAILY\n9. **Minoxidil**\n\t* Dose: 10 mg PO DAILY\n10. **Polyethylene Glycol**\n\t* Dose: 17 g PO DAILY\n\t* Indication: PRN Const']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
Whats the perscribd dose of Asprin for the pashent in the givn clinikal kontext?,"['5a643f48-aebd-476f-bd5e-af9cd241686d\n\nCORE MEASURES\n==============\n#CODE: Full\n#CONTACT: ___ daughter HCP\n \n___ on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Lisinopril 2.5 mg PO DAILY \n2. CloNIDine 0.2 mg PO BID \n3. amLODIPine 10 mg PO EVERY OTHER DAY \n4. HydrALAZINE 100 mg PO TID \n5. Aspirin 81 mg PO DAILY \n6. CARVedilol 25 mg PO BID \n7. Atorvastatin 80 mg PO QPM \n8. liraglutide 1.2 mg subcutaneous DAILY \n9. Levothyroxine Sodium 100 mcg PO DAILY \n10. Glargine 55 Units Breakfast\n11. Furosemide 40 mg PO BID \n12. Albuterol Inhaler ___ PUFF IH Q6H:PRN wheezing, SOB \n \nDischarge Medications:\n1.  BD Ultra-Fine Short Pen Needle (pen needle, diabetic) 31 \ngauge x ___ miscellaneous ASDIR  \n2.  Fluticasone-Salmeterol Diskus (250/50)  1 INH IH BID \nRX *fluticasone-salmeterol [Advair Diskus] 250 mcg-50 mcg/dose 1', 'c91e9f73-a3db-4de7-b32b-2595064882de\n\ndose inhaled twice a day Disp #*1 Disk Refills:*0 \n3.  sevelamer CARBONATE 800 mg PO TID W/MEALS \nRX *sevelamer carbonate 800 mg 1 tablet(s) by mouth three times \na day with meals Disp #*90 Tablet Refills:*0 \n4.  Torsemide 40 mg PO DAILY \nRX *torsemide 20 mg 2 tablet(s) by mouth once a day Disp #*60 \nTablet Refills:*0 \n5.  amLODIPine 10 mg PO DAILY  \n6.  CARVedilol 37.5 mg PO BID \nRX *carvedilol 25 mg 1.5 tablet(s) by mouth twice a day Disp \n#*90 Tablet Refills:*0 \n7.  Glargine 30 Units Breakfast\nGlargine 10 Units Bedtime\nHumalog 5 Units Breakfast\nHumalog 5 Units Lunch\nHumalog 5 Units Dinner\nInsulin SC Sliding Scale using HUM Insulin \n8.  Albuterol Inhaler ___ PUFF IH Q6H:PRN wheezing, SOB  \n9.  Aspirin 81 mg PO DAILY \nRX *aspirin 81 mg 1 tablet(s) by mouth once a day Disp #*30 \nTablet Refills:*0 \n10.  Atorvastatin 80 mg PO QPM \nRX *atorvastatin 80 mg 1 tablet(s) by mouth once a day Disp #*30 \nTablet Refills:*0 \n11.  CloNIDine 0.2 mg PO BID \nRX *clonidine HCl 0.2 mg 1 tablet(s) by mouth twice a day Disp']","According to the provided clinical context, the prescribed dose of Aspirin is 81 mg PO (orally) DAILY. This is consistent across both the preadmission medication list (context node: 5a643f48-aebd-476f-bd5e-af9cd241686d, item 5) and the discharge medications (context node: c91e9f73-a3db-4de7-b32b-2595064882de, item 9), with the latter specifying a dispensing quantity of *30 tablets with 0 refills.",custom_multi_hop_query_synthesizer,"Based on the provided instructions, here's the answer to the question:

**Question:** What's the prescribed dose of Aspirin for the patient in the given clinical context?

**Answer:**

* **Prescribed Dose of Aspirin:** 81 mg
* **Frequency:** PO DAILY (Oral, Once a Day)
* **Source:** This information is consistently found across multiple documents' **CONTENT** sections, specifically:
	+ Document 1: **Medications to Take as Prescribed** > 5. Aspirin 81 mg PO DAILY
	+ Document 2: **Discharge Medications** > 5. Aspirin 81 mg PO DAILY
	+ Document 5: **Aspirin** > * Dose: 81 mg * Frequency: PO DAILY

**Metadata Relevance for this Question:** None, as the question pertains to the prescribed medication dose, which is found in the **CONTENT** sections of the documents. Metadata primarily provides identification and timing information, which is not relevant to answering the specific question about the Aspirin dose.","['* **Medications to Take as Prescribed:**\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (30 Units Breakfast, 10 Units Lunch)\n\t3. Albuterol Inhaler 2 PUFF IH Q8H:PRN\n\t4. Amlodipine 10 mg PO DAILY\n\t5. ', '+ **Follow-up Appointments**: [NOT PROVIDED]\n* **Discharge Medications** (same as listed in the original document):\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (dosage and timing)\n\t3. Albuterol In', '1. **Albuterol Inhaler**\n\t* Dose: 2 PUFF IH Q8H\n\t* Indication: PRN shortness of breath\n2. **Amlodipine**\n\t* Dose: 10 mg PO DAILY\n3. **Atorvastatin**\n\t* Dose: 80 mg PO QPM\n4. **Carvedilol**\n\t* Dose: 50', '* **Additional Recommendations:**\n\t+ Consider completing the 4-day course of **ferric gluconate** (started during admission; received 2 doses of 250mg IV on **[NOT PROVIDED]**).\n\t+ One additional infu', '* Dose: 10 mg\n\t* Frequency: PO DAILY\n5. **Aspirin**\n\t* Dose: 81 mg\n\t* Frequency: PO DAILY\n6. **Atorvastatin**\n\t* Dose: 80 mg\n\t* Frequency: PO QPM (every evening)\n7. **Carvedilol**\n\t* Dose: 50 mg\n\t* Fr']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
What is the prescribed dosage and administration schedule for CloNIDine upon admission and at discharge?,"['44d8d766-27ad-43f8-9511-d17ad9f10f4d\n\nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. amLODIPine 10 mg PO DAILY \n2. Atorvastatin 80 mg PO QPM \n3. CloNIDine 0.2 mg PO BID \n4. Gabapentin 400 mg PO TID \n5. Lisinopril 40 mg PO DAILY \n6. MetFORMIN (Glucophage) 850 mg PO TID \n7. Metoprolol Tartrate 25 mg PO BID \n8. Basaglar (Glargine) 30 Units Breakfast\n9. Albuterol Inhaler 2 PUFF IH Q4H \n10. Levothyroxine Sodium 100 mcg PO DAILY \n11. Vitamin D ___ UNIT PO WEEKLY \n \nDischarge Medications:\n1.  Aspirin 81 mg PO DAILY \nRX *aspirin 81 mg 1 tablet(s) by mouth once daily Disp #*30 \nTablet Refills:*0 \n2.  Carvedilol 25 mg PO BID \nRX *carvedilol 25 mg 1 tablet(s) by mouth twice daily Disp #*60 \nTablet Refills:*0 \n3.  Furosemide 40 mg PO BID \nRX *furosemide 40 mg 1 tablet(s) by mouth twice daily Disp #*60 \nTablet Refills:*0', 'c91e9f73-a3db-4de7-b32b-2595064882de\n\ndose inhaled twice a day Disp #*1 Disk Refills:*0 \n3.  sevelamer CARBONATE 800 mg PO TID W/MEALS \nRX *sevelamer carbonate 800 mg 1 tablet(s) by mouth three times \na day with meals Disp #*90 Tablet Refills:*0 \n4.  Torsemide 40 mg PO DAILY \nRX *torsemide 20 mg 2 tablet(s) by mouth once a day Disp #*60 \nTablet Refills:*0 \n5.  amLODIPine 10 mg PO DAILY  \n6.  CARVedilol 37.5 mg PO BID \nRX *carvedilol 25 mg 1.5 tablet(s) by mouth twice a day Disp \n#*90 Tablet Refills:*0 \n7.  Glargine 30 Units Breakfast\nGlargine 10 Units Bedtime\nHumalog 5 Units Breakfast\nHumalog 5 Units Lunch\nHumalog 5 Units Dinner\nInsulin SC Sliding Scale using HUM Insulin \n8.  Albuterol Inhaler ___ PUFF IH Q6H:PRN wheezing, SOB  \n9.  Aspirin 81 mg PO DAILY \nRX *aspirin 81 mg 1 tablet(s) by mouth once a day Disp #*30 \nTablet Refills:*0 \n10.  Atorvastatin 80 mg PO QPM \nRX *atorvastatin 80 mg 1 tablet(s) by mouth once a day Disp #*30 \nTablet Refills:*0 \n11.  CloNIDine 0.2 mg PO BID \nRX *clonidine HCl 0.2 mg 1 tablet(s) by mouth twice a day Disp']","According to the provided medication lists, the prescribed dosage and administration schedule for CloNIDine are consistent across both admission and discharge: **CloNIDine 0.2 mg PO (orally) BID (twice a day)**. No changes in dosage or administration schedule are noted between admission and discharge medications.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, here is the response to the question:

**Question:** What is the prescribed dosage and administration schedule for CloNIDine upon admission and at discharge?

**Answer:**

* **CloNIDine is not mentioned in any of the documents** (Content sections of all documents) as a prescribed medication upon admission or at discharge. 
* **However, a similarly named medication, Minoxidil**, is listed in:
	+ Document 1: **Minoxidil 10 mg PO DAILY** (under Discharge Medications)
	+ Document 4: **Minoxidil 10 mg PO DAILY** (under Medications to Take as Prescribed)
* **No information on CloNIDine is available** in the provided documents (both metadata and content).

**Metadata Observations (as per instruction 3):**
- The same **Patient/Subject ID (13180007)**, **Note ID (13180007-DS-19)**, and **Admission ID (20774429)** appear in all documents (Document 1 through Document 5).
- **Chart Time** and **Store Time** are listed as **N/A** in all documents.","['+ **Follow-up Appointments**: [NOT PROVIDED]\n* **Discharge Medications** (same as listed in the original document):\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (dosage and timing)\n\t3. Albuterol In', '1. **Medications**:\n\t* List of discharge medications (13 items, see below)\n\t* **Note**: Take all medications as prescribed\n\t* **Discharge Medications List**:\n\t\t1. Torsemide 100 mg PO DAILY\n\t\t2. 70/30 ', '* **Additional Recommendations:**\n\t+ Consider completing the 4-day course of **ferric gluconate** (started during admission; received 2 doses of 250mg IV on **[NOT PROVIDED]**).\n\t+ One additional infu', '* **Medications to Take as Prescribed:**\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (30 Units Breakfast, 10 Units Lunch)\n\t3. Albuterol Inhaler 2 PUFF IH Q8H:PRN\n\t4. Amlodipine 10 mg PO DAILY\n\t5. ', '**DISCHARGE SUMMARY (related to condition)**\n\n* **Discharge Weight**: 166.6lb\n* **Discharge Creatinine (Cr) Level**: 2.9\n* **Discharge Diuretic**: Torsemide 100mg daily (for active diuresis, with appr']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What is the role of Aspirin in the treatment of a patient with multiple conditions including hypertension, CAD with inducible ischemia, and NSTEMI, based on the provided medical context?","['5a643f48-aebd-476f-bd5e-af9cd241686d\n\nCORE MEASURES\n==============\n#CODE: Full\n#CONTACT: ___ daughter HCP\n \n___ on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Lisinopril 2.5 mg PO DAILY \n2. CloNIDine 0.2 mg PO BID \n3. amLODIPine 10 mg PO EVERY OTHER DAY \n4. HydrALAZINE 100 mg PO TID \n5. Aspirin 81 mg PO DAILY \n6. CARVedilol 25 mg PO BID \n7. Atorvastatin 80 mg PO QPM \n8. liraglutide 1.2 mg subcutaneous DAILY \n9. Levothyroxine Sodium 100 mcg PO DAILY \n10. Glargine 55 Units Breakfast\n11. Furosemide 40 mg PO BID \n12. Albuterol Inhaler ___ PUFF IH Q6H:PRN wheezing, SOB \n \nDischarge Medications:\n1.  BD Ultra-Fine Short Pen Needle (pen needle, diabetic) 31 \ngauge x ___ miscellaneous ASDIR  \n2.  Fluticasone-Salmeterol Diskus (250/50)  1 INH IH BID \nRX *fluticasone-salmeterol [Advair Diskus] 250 mcg-50 mcg/dose 1', '5afc91e0-6481-46b3-aa3c-473b2c2e6895\n\n#Community acquired pneumonia\nCough, worsened SOB, hypoxemia (although alternate explanation) \nbut no leukocytosis or fevers; influenza negative. Legionella \nand strep were negative. Patient was given a 5-day course of \nceftriaxone and azithromycin. \n#Hypertension\nGoal <130/80. As patient is on several anti-hypertensives with \nstill an elevated blood pressure, he underwent a secondary \nhypertension workup. His last renal ultrasound in ___ was \nwithin normal limits. He was placed on continuous O2 monitoring \novernight, and patient did not desaturate. His aldosterone to \nrenin ratio was 0.13, indicating no primary hyperaldosteronism. \n24 hour urine metanephrines and catecholamines were within \nnormal limits.\n#CAD w/ inducible ischemia\n#NSTEMI\nTroponin peaked at 0.02, thought to be type 2 due to volume \noverload. Continued aspirin, atorvastatin, carvedilol. The \ndecision was made to hold off on coronary angiogram due to \nkidney function and the suspicion that this was type 2.\n#H/o CVA\nPatient had an episode while in hospital with dysarthria,']","Based on the provided context, Aspirin (81 mg PO DAILY) is continued as part of the patient's treatment regimen for CAD with inducible ischemia and NSTEMI. Specifically, for NSTEMI, which was considered type 2 due to volume overload (with a troponin peak at 0.02), Aspirin is maintained alongside atorvastatin and carvedilol. This indicates its importance in managing cardiac conditions, likely for antiplatelet effects to prevent further cardiac events, although the context does not explicitly state its rationale beyond continuation in treatment.",custom_multi_hop_query_synthesizer,"Based on the provided medical context and following the instructions, here's the analysis to answer the question about the role of Aspirin:

**Question Analysis:**
The question asks for the role of Aspirin in treating a patient with multiple conditions, including hypertension, CAD with inducible ischemia, and NSTEMI. However, the provided documents do not explicitly mention CAD with inducible ischemia or NSTEMI. They do mention **History of CVA (Cerebrovascular Accident)**, **Hypertension** (in Document 5, as ""History of hypertension, currently well controlled""), and other conditions.

**Role of Aspirin as per Provided Documents:**

1. **For Hypertension (Document 5):** Aspirin is not explicitly mentioned in the management of hypertension. The management listed includes Amlodipine, Coreg (Carvedilol), and Minoxidil.

2. **For History of CVA (Cerebrovascular Accident) (Documents 1 & 2):** 
   - **Medication:** Aspirin 81 mg PO DAILY (continued from home)
   - **Inference:** The role of Aspirin in this context is likely for **secondary prevention** of another cerebrovascular event, given the patient's history of CVA. Aspirin is commonly used as an antiplatelet agent to reduce the risk of further strokes in patients with a history of CVA.

3. **General Presence Across Documents:**
   - Aspirin is consistently mentioned across Documents 1, 2, 3, and 4 with the same dosage (81 mg PO DAILY), indicating its ongoing role in the patient's treatment plan.

**Answer to the Question (tailored to the provided context):**
Given the provided medical context, the role of Aspirin appears to be primarily for **secondary prevention of cerebrovascular events** due to the patient's **History of CVA (Cerebrovascular Accident)**. While the patient also has hypertension, the documents do not explicitly link Aspirin to hypertension management in this case. The conditions of CAD with inducible ischemia and NSTEMI are not mentioned in the provided documents.

**ID Consistency (as per instruction 3):**
- **Patient/Subject ID:** 13180007 (consistent across all documents)
- **Note ID:** 13180007-DS-19 (consistent across all documents)
- **Admission ID:** 20774429 (consistent across all documents)","['Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D', 'Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D', '* **Medications to Take as Prescribed:**\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (30 Units Breakfast, 10 Units Lunch)\n\t3. Albuterol Inhaler 2 PUFF IH Q8H:PRN\n\t4. Amlodipine 10 mg PO DAILY\n\t5. ', '+ **Follow-up Appointments**: [NOT PROVIDED]\n* **Discharge Medications** (same as listed in the original document):\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (dosage and timing)\n\t3. Albuterol In', '### 3. **Acute on Chronic Kidney Disease (CKD)**\n\n* **Presentation:** Elevated Cr (2.6 from baseline 1.8-2.2)\n* **Concerns:** Renal congestion causing renal dysfunction\n* **Status at Discharge:** Cr 2']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What are the primary reasons for hospital admission and the corresponding in-hospital treatments for patients with conditions related to uncontrolled diabetes and heart failure, based on recent discharge summaries?","['462328c3-90c8-4169-90f0-27fed5e6b04f\n\nDischarge Instructions:\nDear ___, \nIt was a pleasure caring for you here at ___ \n___!\nWHY WAS I IN THE HOSPITAL?\n================================\n- You were admitted to the hospital due to uncontrolled diabetes \nwith blood glucose in a dangerous range. \nWHAT HAPPENED IN THE HOSPITAL?\n================================\n- You were given an insulin drip acutely to lower your glucose, \nfollowed by observation/stabilization on the medicine floor.\n- The ___ diabetes doctors came to help you with your insulin \nregimen; we gave you long acting insulin and insulin with your \ndaily meals. The ___ diabetes doctors talked with your \ndaughters and you to continue 2 medications at home with 2 \ninjections. We monitored your blood sugars here and made sure \nyou ate a healthy diet.\n- You were also given medication to lower your total volume in \nthe body.   \nWHAT SHOULD I DO WHEN I LEAVE THE HOSPITAL?', 'bc70aec9-8d49-462b-9afd-e5bb15b22e94\n\nDischarge Condition:\nMental Status: Clear and coherent.\nLevel of Consciousness: Alert and interactive.\nActivity Status: Ambulatory - Independent.\n \nDischarge Instructions:\nDear ___,  \nIt was a pleasure participating in your care. Please read \nthrough the following information.\nWHY WAS I ADMITTED TO THE HOSPITAL? \n- You were admitted to the hospital because you had been feeling \nshort of breath and you were found to have fluid on your lungs. \nThis was felt to be due to a condition called heart failure, \nwhere your heart does not pump hard enough and fluid backs up \ninto your lungs. \nWHAT HAPPENED WHILE I WAS IN THE HOSPITAL? \n- You were given a diuretic medication through the IV to help \nget the fluid out. You improved considerably and were ready to \nleave the hospital.  \n- You underwent an echocardiogram, which is an ultrasound of']","Based on recent discharge summaries, two primary reasons for hospital admission and their corresponding in-hospital treatments are as follows: nn1. **Uncontrolled Diabetes:**n   - **Reason for Admission:** Uncontrolled diabetes with blood glucose in a dangerous range.n   - **In-Hospital Treatment:** Patients were given an insulin drip to lower glucose levels, followed by observation and stabilization. Specialist diabetes doctors adjusted the patient's insulin regimen, including long-acting insulin and mealtime insulin, with educational support for patients and their families.nn2. **Heart Failure (leading to fluid on the lungs):**n   - **Reason for Admission:** Shortness of breath due to fluid buildup in the lungs, attributed to heart failure where the heart doesn't pump sufficiently.n   - **In-Hospital Treatment:** Administration of diuretic medication intravenously to reduce fluid, significantly improving the patient's condition. Additionally, an echocardiogram (ultrasound of the heart) was performed for further assessment.",custom_multi_hop_query_synthesizer,"**Response to Current Question**

**Primary Reasons for Hospital Admission and Corresponding In-Hospital Treatments**

Based on the provided discharge summaries (Documents 1 through 5), all pertaining to the same patient due to matching metadata IDs, we can deduce the following information relevant to the question:

### **Matching Metadata IDs Across Documents:**
- **Patient/Subject ID:** 13180007 (consistent across all documents)
- **Note ID:** 13180007-DS-19 (consistent across all documents)
- **Admission ID:** 20774429 (consistent across all documents)

### **Primary Reasons for Hospital Admission:**

1. **Swelling in legs due to fluid accumulation caused by heart failure** (Document 2: **Reason for Hospital Admission**)
2. **Implications of uncontrolled diabetes are not explicitly stated as the primary reason for admission but are noted as a significant comorbidity** (Type 2 Diabetes Mellitus mentioned in Documents 1, 3, 4, and 5)

### **Corresponding In-Hospital Treatments for Mentioned Conditions:**

#### For Heart Failure (Acute on Chronic Diastolic Heart Failure Exacerbation):
- **Medications were administered to reduce fluid accumulation, leading to improved symptoms** (Document 2: **Summary of Hospital Stay**)

#### For Uncontrolled Diabetes (Type 2 Diabetes Mellitus) and Related Conditions:
- **Improved glucose control:** Glucose levels improved from 287 at admission to 164 at discharge (Document 5)
- **Management of Acute on Chronic Anemia (possibly related to worsening renal function or dilutional iso heart failure, which can be comorbid with diabetes):**
  - Received 3 doses of Ferric Gluconate 250 mg IV (Document 3)
  - Hemoglobin (Hb) levels slightly improved from 7.4 at admission to 7.6 at discharge (Documents 3 and 5)

#### For Other Mentioned Conditions (with treatments implied but not always explicitly stated for the condition in question):
- **Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD):** No specific treatments mentioned in the provided documents, but implied to be part of the overall management.
- **Hypertension:** Described as ""well-controlled"" (Document 4), suggesting effective management was in place, but specifics not provided.

**Limitations:**
- Specific treatments for some conditions (e.g., AKI, CKD, Hypertension) are not detailed in the provided documents.
- The question's focus on ""recent discharge summaries"" is assumed to be met by the provided documents, given no date information is available to assess recency.","['* **Discharge Location**: Home With Service\n* **Facility**: [REDACTED]\n* **Discharge Diagnosis**:\n\t+ **Primary Diagnosis**: Acute on chronic diastolic heart failure exacerbation\n\t+ **Secondary Diagnos', 'Here is the extracted and summarized information for the ""* DISCHARGE INSTRUCTIONS"" subheading:\n\n**DISCHARGE INSTRUCTIONS**\n\n* **Reason for Hospital Admission**: Swelling in legs due to fluid accumula', '### 5. **Acute on Chronic Anemia**\n\n* **Presentation:** Hb 7.4 on admission\n* **Possible Causes:** Worsening renal function or dilutional iso heart failure\n* **Management:**\n\t+ Received 3 doses of Fer', '* **Acute Problems Addressed**:\n\t1. **Acute on Chronic HFpEF**\n\t2. **Chest Pain** (mild troponin elevation, likely related to CKD)\n\t3. **CKD** (elevated Cr, possibly due to renal congestion)\n\t4. **Hyp', '2. **Condition:** Acute on chronic anemia\n\t\t- **Relevant Lab Values:**\n\t\t\t- Admission: Hgb 7.4\n\t\t\t- Discharge: Hgb 7.6\n\t3. **Condition:** Type 2 Diabetes Mellitus\n\t\t- **Relevant Lab Values:**\n\t\t\t- Adm']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
What are the notable trends and abnormalities in the patient's calcium levels based on the provided lab results?,"[""88b52764-61ad-4740-9004-35da4cf9a996\n\nAbsMono-0.42 AbsEos-0.09 AbsBaso-0.03\n___ 11:00AM BLOOD Glucose-98 UreaN-32* Creat-2.3* Na-139 \nK-4.1 Cl-100 HCO3-25 AnGap-14\n___ 11:00AM BLOOD ALT-8 AST-9 CK(CPK)-110 AlkPhos-144* \nTotBili-<0.2\n___ 11:00AM BLOOD Albumin-3.5 Calcium-9.2 Mg-2.3\nDISCHARGE LABS:\n___ 06:22AM BLOOD WBC-5.6 RBC-3.86* Hgb-10.1* Hct-32.1* \nMCV-83 MCH-26.2 MCHC-31.5* RDW-14.3 RDWSD-43.4 Plt ___\n___ 06:08AM BLOOD Glucose-157* UreaN-33* Creat-1.9* Na-138 \nK-4.5 Cl-100 HCO3-22 AnGap-16\nIMPORTANT RESULTS:\n___ 11:00AM BLOOD %HbA1c-14.4* eAG-367*\n___ 09:00PM BLOOD TSH-1.3\n___ 11:11AM BLOOD Lactate-1.6\n___ 11:00AM BLOOD CK-MB-4 proBNP-754*\nIMAGING:\nChest X-ray: \nComparison to ___.  On today's radiograph, a small\npleural left-sided calcification is seen.  There also is a small"", '9a673ed7-18d2-4d47-9b22-110fb9514b9b\n\nK-4.2 Cl-103 HCO3-22 AnGap-18\n___ 03:10PM BLOOD Glucose-236* UreaN-29* Creat-2.2* Na-135 \nK-4.1 Cl-96 HCO3-25 AnGap-14\n___ 07:27AM BLOOD Glucose-185* UreaN-27* Creat-2.1* Na-137 \nK-4.3 Cl-97 HCO3-27 AnGap-13\n___ 02:50PM BLOOD Glucose-248* UreaN-31* Creat-2.1* Na-137 \nK-4.6 Cl-97 HCO3-27 AnGap-13\n___ 06:45AM BLOOD Glucose-165* UreaN-27* Creat-2.0* Na-138 \nK-4.3 Cl-98 HCO3-26 AnGap-14\n___ 07:44AM BLOOD Calcium-9.0 Phos-4.4 Mg-1.7\n___ 05:00PM BLOOD Calcium-9.2 Phos-4.8* Mg-3.2*\n___ 07:00AM BLOOD Calcium-8.9 Phos-5.0* Mg-2.3\n___ 02:48PM BLOOD Calcium-9.0 Phos-5.3* Mg-2.2\n___ 07:35AM BLOOD Calcium-8.4 Phos-5.1* Mg-2.0\n___ 03:10PM BLOOD Calcium-8.8 Phos-5.0* Mg-2.1\n___ 07:27AM BLOOD Calcium-8.9 Phos-4.4 Mg-2.0\n___ 02:50PM BLOOD Calcium-8.5 Phos-4.4 Mg-2.1\n___ 06:45AM BLOOD Calcium-8.6 Phos-4.0 Mg-2.0\nLFTs\n___ 09:10AM BLOOD ALT-31 AST-25 AlkPhos-111 TotBili-<0.2\n___ 07:44AM BLOOD CK(CPK)-531*\n___ 07:00AM BLOOD CK(CPK)-509*\nCARDIAC ENZYMES:\n___ 09:10AM BLOOD proBNP-1140*']","Based on the lab results, here are the notable trends and abnormalities in the patient's calcium levels:      - **Variation in Calcium Levels:** Calcium levels fluctuated between 8.4 mg/dL (07:35 AM) and 9.2 mg/dL (05:00 PM and 11:00 AM in the first context node), indicating some variability throughout the day.     - **Abnormalities:** None of the calcium levels provided fall outside the typical normal range (approximately 8.6 to 10.2 mg/dL, though reference ranges may slightly vary). However, it's crucial to consider these in the context of the patient's overall health and other lab results.     - **Associated Abnormalities:** Notably, Phosphate (Phos) levels were occasionally elevated (* denotes abnormality), which can be related to calcium metabolism and may warrant further investigation. For example, a Phos level of 5.3* mg/dL at 02:48 PM is above the normal range (typically about 2.5 to 4.5 mg/dL for adults), which might suggest an imbalance in calcium-phosphate homeostasis.",custom_multi_hop_query_synthesizer,"**Response to Current Question**

**Notable Trends and Abnormalities in Calcium Levels:**

Based on the provided lab results across all documents, here are the notable trends and abnormalities in the patient's calcium levels:

* **Document with Relevant Calcium Information:** Document 3
* **Patient/Subject ID (as per metadata, consistent across all documents):** 13180007
* **Note ID (as per metadata, identical across all documents):** 13180007-DS-19
* **Calcium Level:**
	+ **Value:** 8.4
	+ **Notable Trend/Abnormality:** **None Indicated** (within normal range, typically 8.6-10.2 mg/dL, but slight variations in normal ranges exist across labs; this value is at the lower end but not flagged as abnormal in the document)

**Additional Observations:**

* Calcium levels are only reported in **Document 3**. There is no trending information available since it's a single data point across the provided documents.
* The patient's calcium level (8.4) is not flagged with an asterisk (\*) in **Document 3**, which, based on the document's notation system, suggests it does not indicate a potential clinically significant abnormality according to the reporting criteria used.

**Metadata Consistency Note:**
- The **Patient/Subject ID**, **Note ID**, and **Admission ID** are consistent across all documents (1 through 5), indicating these documents pertain to the same patient encounter. 
- **Chart Time** and **Store Time** are listed as **N/A** in all documents.","['**Key Findings:**\n\n* Slightly improved Hemoglobin (Hgb) level from admission (7.4 to 7.6)\n* Elevated Creatinine (Cr) level at discharge (2.9), indicating persistent renal impairment\n* Abnormal glucose', '**Key Findings:**\n\n* Slightly improved Hemoglobin (Hgb) level from admission (7.4 to 7.6)\n* Elevated Creatinine (Cr) level at discharge (2.9), indicating persistent renal impairment\n* Abnormal glucose', '- Glucose: 164*\n\t\t- UreaN (BUN): 51*\n\t\t- Creat (Cr): 2.9* (elevated from baseline 1.8-2.2)\n\t\t- Na: 140\n\t\t- K: 4.6\n\t\t- Cl: 99\n\t\t- HCO3: 25\n\t\t- AnGap: 16\n\t+ **Electrolytes & Minerals:**\n\t\t- Calcium: 8.4', '* **Discharge Status:**\n\t+ Symptoms associated with volume overload had subsided, but patient was still slightly volume up on exam.\n\t+ 1+ edema to ankles bilaterally.\n\t+ JVP of 12cm.\n* **Medications a', '3. **Discharge**: Symptoms improved, but still slightly volume up (JVP ~12, 1+ edema to ankles)\n* **Discharge Details**:\n\t+ **Weight**: 166.6lb\n\t+ **Creatinine (Cr)**: 2.9 (elevated from baseline 1.8-']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
Whats the perscribed dose of HydrALAZINE for this patient??,"['058d90f2-3d7b-4d29-bca6-e70e3cb19e4d\n\n4.  HydrALAZINE 100 mg PO TID \nRX *hydralazine 100 mg 1 tablet(s) by mouth three times daily \nDisp #*90 Tablet Refills:*0 \n5.  Glargine 30 Units Breakfast \n6.  Albuterol Inhaler 2 PUFF IH Q4H  \n7.  amLODIPine 10 mg PO DAILY  \n8.  Atorvastatin 80 mg PO QPM  \n9.  CloNIDine 0.2 mg PO BID  \n10.  Gabapentin 400 mg PO TID  \n11.  Levothyroxine Sodium 100 mcg PO DAILY  \n12.  MetFORMIN (Glucophage) 850 mg PO TID  \n13.  Vitamin D ___ UNIT PO WEEKLY  \n14. HELD- Lisinopril 40 mg PO DAILY  This medication was held. \nDo not restart Lisinopril until told to do so by your doctor\n15.Outpatient Lab Work\nChem-7 to be draw ___\nICD 10: I50.3: Diastolic (congestive) heart failure\nFax results to: ___ ATTN: ___\n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___', '5a643f48-aebd-476f-bd5e-af9cd241686d\n\nCORE MEASURES\n==============\n#CODE: Full\n#CONTACT: ___ daughter HCP\n \n___ on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Lisinopril 2.5 mg PO DAILY \n2. CloNIDine 0.2 mg PO BID \n3. amLODIPine 10 mg PO EVERY OTHER DAY \n4. HydrALAZINE 100 mg PO TID \n5. Aspirin 81 mg PO DAILY \n6. CARVedilol 25 mg PO BID \n7. Atorvastatin 80 mg PO QPM \n8. liraglutide 1.2 mg subcutaneous DAILY \n9. Levothyroxine Sodium 100 mcg PO DAILY \n10. Glargine 55 Units Breakfast\n11. Furosemide 40 mg PO BID \n12. Albuterol Inhaler ___ PUFF IH Q6H:PRN wheezing, SOB \n \nDischarge Medications:\n1.  BD Ultra-Fine Short Pen Needle (pen needle, diabetic) 31 \ngauge x ___ miscellaneous ASDIR  \n2.  Fluticasone-Salmeterol Diskus (250/50)  1 INH IH BID \nRX *fluticasone-salmeterol [Advair Diskus] 250 mcg-50 mcg/dose 1']","According to the medical records, the prescribed dose of HydrALAZINE for this patient is 100 mg, taken orally (PO) three times daily (TID). This is consistent across both the initial medication list (context ID: 058d90f2-3d7b-4d29-bca6-e70e3cb19e4d, item 4) and the CORE MEASURES list (context ID: 5a643f48-aebd-476f-bd5e-af9cd241686d, item 4).",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, here is the answer to the question:

**Question:** What's the prescribed dose of HydrALAZINE for this patient??

**Answer:**

* **Prescribed Dose of HydrALAZINE:** NOT MENTIONED

**Rationale:**

* After reviewing all provided documents (Document 1 through Document 5), there is no mention of **HydrALAZINE** in either the **METADATA** or the **CONTENT** sections.
* Since HydrALAZINE is not listed among the medications in any of the documents, it is not possible to provide a prescribed dose for this patient based on the information given.

**Additional Observations (as per instructions):**

* **Patient/Subject ID:** Consistently listed as **13180007** across all documents (Document 1 through Document 5).
* **Note ID** and **Admission ID:** Also consistent across all documents, listed as **13180007-DS-19** and **20774429**, respectively. 
* **Chart Time** and **Store Time:** Listed as **N/A** in all documents.","['* **Medications to Take as Prescribed:**\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (30 Units Breakfast, 10 Units Lunch)\n\t3. Albuterol Inhaler 2 PUFF IH Q8H:PRN\n\t4. Amlodipine 10 mg PO DAILY\n\t5. ', '* **Medications to Take as Prescribed:**\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (30 Units Breakfast, 10 Units Lunch)\n\t3. Albuterol Inhaler 2 PUFF IH Q8H:PRN\n\t4. Amlodipine 10 mg PO DAILY\n\t5. ', '+ **Follow-up Appointments**: [NOT PROVIDED]\n* **Discharge Medications** (same as listed in the original document):\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (dosage and timing)\n\t3. Albuterol In', 'Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D', '* **Additional Recommendations:**\n\t+ Consider completing the 4-day course of **ferric gluconate** (started during admission; received 2 doses of 250mg IV on **[NOT PROVIDED]**).\n\t+ One additional infu']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What are the key findings and management strategies for a patient with a history of Coronary Artery Disease (CAD) and other comorbidities, as evident from recent hospital admissions and medication lists?","['2574c42a-a6ef-418e-ac90-a21855611d18\n\npulmonary edema. No pneumonia, no pneumothorax.  The lateral \nradiograph shows mild flattening of the hemidiaphragms, \npotentially as a consequence of functional obstruction.\n___ CT HEAD -\n1. No evidence of acute intracranial abnormality.\n2. Unchanged appearance of chronic infarcts within the right \nfrontal lobe and left occipital lobe.\n3. Chronic lacunar infarcts within the right basal ganglia.\n4. Re-demonstration of few calcifications within the pons, \nfindings which are unchanged in appearance and likely sequela of \nprior ischemic or inflammatory process.\nMICRO:\n___ 3:38 pm URINE\n                            **FINAL REPORT ___\n   URINE CULTURE (Final ___:    < 10,000 CFU/mL. \n \nBrief Hospital Course:\nMr. ___ is a ___ ___ speaking male with a \nPMH of prior CVA ___, residual emotional lability, \ndysarthria), HFpEF, uncontrolled DM2, HTN, CAD, CKD, \n?hypothyroidism, asthma, mild cognitive impairment who presented', '8c0badb1-fe3b-4585-8010-1ef4ba8fdd98\n\n================\n# Hx of CAD \n# Hx of ischemic CVA\nStress test in ___ with area of inducible ischemia in LCx \ndistribution. Trop peaked at 0.06 (iso CKD) and then \ndowntrended. No EKG changes seen. Continued home carvedilol, ASA \nand high dose atorvastatin. \n# CKD: Cr at presentation close to baseline. Underlying etiology \nlikely combination of HTN, DM. \n# Hypothyroidism: Continued home levothyroxine 100 mcg daily\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Furosemide 40 mg PO 3X/WEEK (___) \n2. sevelamer CARBONATE 800 mg PO TID W/MEALS \n3. Minoxidil 2.5 mg PO DAILY \n4. Levothyroxine Sodium 100 mcg PO DAILY \n5. CARVedilol 37.5 mg PO BID \n6. amLODIPine 10 mg PO DAILY \n7. Albuterol Inhaler 2 PUFF IH Q6H \n8. Jardiance (empagliflozin) 10 mg oral DAILY \n9. Victoza 3-Pak (liraglutide) 1.2 mg subcutaneous DAILY']","Based on the provided context, key findings for the patient with a history of CAD include:    - **History of CAD** with a past stress test showing inducible ischemia in the LCx distribution, managed with carvedilol, ASA, and high-dose atorvastatin.   - **Comorbidities**: History of ischemic CVA, HFpEF, uncontrolled DM2, HTN, CKD, possible hypothyroidism, asthma, and mild cognitive impairment.   - **Recent Hospital Findings**: No acute intracranial abnormalities on CT HEAD, chronic infarcts in the right frontal and left occipital lobes, and unchanged calcifications within the pons.   - **Medication Management**: The patient is on a comprehensive medication regimen including diuretics (furosemide), sevelamer carbonate for CKD, minoxidil, levothyroxine for hypothyroidism, carvedilol and amlodipine for CAD and HTN, inhalers for asthma, and empagliflozin and liraglutide for DM2 management.   - **Urine Culture**: Showed < 10,000 CFU/mL, indicating no significant urinary tract infection.   Management strategies appear to focus on multifaceted pharmacological intervention to control the patient’s various comorbid conditions, alongside monitoring for any progression of CAD or other diseases.",custom_multi_hop_query_synthesizer,"**Response to Current Question with Provided Documents**

**Note:** Based on the provided documents, there is **no explicit mention of Coronary Artery Disease (CAD)** in the content of any document. However, we can infer key findings and management strategies for the patient's actual listed conditions, which include Carotid Artery Disease (among others), and provide an analysis based on the available information.

### **Key Findings:**

1. **Patient/Subject ID:** Consistently **13180007** across all documents (Document 1 through Document 5).
2. **Conditions:**
   - **Carotid Artery Disease** (not CAD, but mentioned in Document 1 and Document 2).
   - **Secundum ASD (Atrial Septal Defect)** and **Mild AR (Aortic Regurgitation)**: Mentioned in Past Medical History (Document 1 and Document 2).
   - **Acute on Chronic Kidney Disease (CKD)**, **Hypertension**, and **Acute on Chronic Anemia**: Detailed in Document 3 and Document 4.
   - **HFpEF (Heart Failure with preserved Ejection Fraction)**, **prior CVA (Cerebrovascular Accident)**, **DM (Diabetes Mellitus)**: Mentioned in the patient's profile (Document 5).

### **Management Strategies (as per the documents):**

1. **For Acute on Chronic Kidney Disease (CKD)**:
   - **Management at Discharge:** Continued on home Sevelamer (Document 3 and Document 4).

2. **For Hypertension**:
   - **Status:** Currently well controlled.
   - **Management:** Continued on home Amlodipine 10, Coreg 50 BID, and Minoxidil 10 daily (Document 3 and Document 4).

3. **For Heart Failure Exacerbation (HFpEF)**:
   - **Treatment Outcome:** Symptoms improved with IV Lasix 80; discharged on torsemide 100 daily for active diuresis (Document 5).

### **Observations and Limitations:**

- **Consistency in Metadata:** All documents share the same Patient/Subject ID, Note ID, and Admission ID, indicating they pertain to the same patient event.
- **Lack of CAD Mention:** Despite the question's focus on CAD, it is not mentioned in any provided document. Carotid Artery Disease is noted instead.
- **Medication Lists:** Primarily provided for CKD, Hypertension, and HF exacerbation management. No specific medications are listed for Carotid Artery Disease, Secundum ASD, or Mild AR in the discharge context.

**To accurately address the original question regarding Coronary Artery Disease (CAD), additional documents or information specifically mentioning CAD and its management for this patient would be required.**","['6. **Carotid Artery Disease** (mentioned in Past Medical History, no specific medications listed in discharge medications)\n7. **Secundum ASD (Atrial Septal Defect)** (mentioned in Past Medical History', '6. **Carotid Artery Disease** (mentioned in Past Medical History, no specific medications listed in discharge medications)\n7. **Secundum ASD (Atrial Septal Defect)** (mentioned in Past Medical History', '### 3. **Acute on Chronic Kidney Disease (CKD)**\n\n* **Presentation:** Elevated Cr (2.6 from baseline 1.8-2.2)\n* **Concerns:** Renal congestion causing renal dysfunction\n* **Status at Discharge:** Cr 2', '### 3. **Acute on Chronic Kidney Disease (CKD)**\n\n* **Presentation:** Elevated Cr (2.6 from baseline 1.8-2.2)\n* **Concerns:** Renal congestion causing renal dysfunction\n* **Status at Discharge:** Cr 2', '* **Patient Profile**: ___ male with history of HFpEF (EF 55-60%), prior CVA, CKD, DM, hypertension, and carotid artery disease\n* **Presentation**: 1 day of dyspnea and discomfort, admitted for HF exa']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What lab values indicate poor management of Diabetes Mellitus (DM) in the hospitalized male patient with HFpEF, and how might these relate to his discharge medication for diuresis?","['8d31665e-700b-4b64-8af5-51456ad55ff5\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-140 \nK-4.6 Cl-99 HCO3-25 AnGap-16\n___ 06:35AM BLOOD Calcium-8.4 Phos-6.0* Mg-2.1\n \nBrief Hospital Course:\nSUMMARY\n=======\n___ male with history of HFpEF (EF 55-60% in ___,\nprior CVA, CKD, DM, hypertension, and carotid artery disease\nwho presented with 1 day of dyspnea and discomfort, and was\nadmitted for HF exacerbation. The trigger was unclear, possible \nmedication non-compliance. He was diuresed with several doses of \nIV Lasix 80 and by time of discharge symptoms had improved. He \nwas still slightly volume up on exam, with JVP ~12 and 1+ edema \nto ankles.\nTRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally and JVP of 12cm. He is being \ndischarged on torsemide 100 daily for active diuresis, with \nabout 3lb of fluid still left to lose.']","Based on the provided context, lab values indicating poor management of Diabetes Mellitus (DM) include: Glucose-164* (elevated, suggesting hyperglycemia), Hgb-7.6* and Hct-24.3* (indicating anemia, which can be a complication of poorly managed DM), and Phos-6.0* (elevated phosphate, which can be seen in diabetic patients due to kidney impairment, as hinted at by CKD in the patient's history). The discharge medication, torsemide 100 daily for active diuresis, aims to reduce volume overload (noted by 1+ edema to ankles and JVP of 12cm at discharge). While torsemide does not directly manage DM, effective diuresis can help in managing fluid overload associated with diabetic nephropathy, indirectly benefiting DM management by reducing the body's fluid volume and, consequently, the workload on the kidneys.",custom_multi_hop_query_synthesizer,"**Answer:**

**Patient Identification (as per instruction 1 & 2):**
* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, 2, 3, 4, and 5)
* **Note ID:** 13180007-DS-19 (consistent across all documents)
* **Admission ID:** 20774429 (consistent across all documents)

**Lab Values Indicating Poor Management of Diabetes Mellitus (DM):**
Based on the provided documents, the lab values indicating poor management of Diabetes Mellitus (DM) in the hospitalized male patient with HFpEF are:

1. **Admission Glucose Level:** 287 (Document 3) - This high glucose level upon admission suggests poor blood sugar control prior to hospitalization.
2. **%HbA1c:** 11.4% (Document 3, admission value) - This significantly elevated HbA1c level indicates poor long-term glycemic control. For context, the American Diabetes Association generally recommends an HbA1c target below 7% for most adults with diabetes.
3. **Discharge Glucose Level:** 164 (Document 3 and implied in Document 4 as ""Abnormal glucose level"") - Although improved from the admission value, this level is still elevated, suggesting that optimal glucose control was not fully achieved during the hospital stay.

**Relation to Discharge Medication for Diuresis:**
The patient was discharged on **torsemide 100mg daily for active diuresis** (Document 1 and summarized in Document 2). The relationship between the lab values indicating poor DM management and the discharge diuresis medication is indirect but clinically relevant:

* **Poor DM Control and Diuresis:** The elevated glucose levels (especially the high HbA1c) suggest the patient's diabetes was not well-managed, which can exacerbate fluid overload and worsen heart failure symptoms (given the patient's HFpEF). Diuresis with torsemide helps manage fluid overload, a common complication in both heart failure and poorly controlled diabetes.
* **Monitoring Consideration:** Given the patient's discharge on torsemide and the context of poorly controlled diabetes, close monitoring of both glucose levels and renal function (since torsemide can affect kidney function, and the patient has a noted elevated Creatinine level at discharge - Document 4) would be crucial in outpatient management.

**Additional Observations:**
- The patient's conditions (HFpEF, CKD, DM, etc.) highlight the complexity of their care, necessitating careful medication management and monitoring.
- Document 5 incorrectly labels the patient's condition as ""IDDM (Insulin-Dependent Diabetes Mellitus),"" while other documents accurately describe it as ""Type 2 Diabetes Mellitus"" or ""DM.""","['* **Patient Profile**: ___ male with history of HFpEF (EF 55-60%), prior CVA, CKD, DM, hypertension, and carotid artery disease\n* **Presentation**: 1 day of dyspnea and discomfort, admitted for HF exa', '* **Summary**: \n\t+ Patient with HFpEF (EF 55-60%) admitted for HF exacerbation with dyspnea and discomfort\n\t+ Trigger unclear, possibly medication non-compliance\n\t+ Symptoms improved with IV Lasix; di', '2. **Condition:** Acute on chronic anemia\n\t\t- **Relevant Lab Values:**\n\t\t\t- Admission: Hgb 7.4\n\t\t\t- Discharge: Hgb 7.6\n\t3. **Condition:** Type 2 Diabetes Mellitus\n\t\t- **Relevant Lab Values:**\n\t\t\t- Adm', '**Key Findings:**\n\n* Slightly improved Hemoglobin (Hgb) level from admission (7.4 to 7.6)\n* Elevated Creatinine (Cr) level at discharge (2.9), indicating persistent renal impairment\n* Abnormal glucose', '### 5. **Acute on Chronic Anemia**\n\n* **Presentation:** Hb 7.4 on admission\n* **Possible Causes:** Worsening renal function or dilutional iso heart failure\n* **Management:**\n\t+ Received 3 doses of Fer']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What is the current management and recommendation for the patient's hypertension, specifically regarding the use of hydralazine, given its prior discontinuation by the primary care physician before admission?","['71b11357-64d1-43f3-b5b3-9e2b962adaf4\n\n# Volume overload\n# HFpEF, LVEF 55-60% in ___\nVolume overload on exam. Diuresis began while in ICU, net \nnegative 1.8L prior to transfer. Dry weight appears to be \n154-157. s/p Lasix 80mg x 2 so far. 163.4 lb on ___ A-Strict \nI/Os, daily weights. Continued home carvedilol at increased dose \nas below. He was sent home with PO 60 mg Lasix daily and was net \neven in the hospital. \n# HTN\nBlood pressure medications initially held when he was started on \npropofol. Anti-HTN meds started on day of transfer. Persistently \nhypertensive. Increased carvedilol to 50 mg BID and increased \nminoxidil to 5 mg and continued amlodipine 10 mg QD. Of note, he \nhad been on clonidine and hydralazine but these were stopped by \nPCP just prior to admission. He remained mostly normotensive \nalthough goal SBP <130 and should continue to be goal as an \noutpatient. \n# Normocytic Anemia\nBaseline of ___, secondary to CKD and possible AoCD. Required \n1u pRBC on arrival. Hb stable. \nCHRONIC ISSUES:', '9c9ab9ab-4a9f-4e03-8ad8-d377af91b9d0\n\n11.  Tresiba U-100 Insulin (insulin degludec) 50 units \nsubcutaneous DAILY  \n12.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n13.  Vitamin D ___ UNIT PO 1X/WEEK (WE)  \n14. HELD- CloNIDine 0.4 mg PO BID  This medication was held. Do \nnot restart CloNIDine until see what BP is at PCP visit, to see \nif need more meds\n15. HELD- Gabapentin 400 mg PO TID  This medication was held. Do \nnot restart Gabapentin until you discuss with PCP the need for \nit, was not needed during this hospital stay\n16. HELD- HydrALAZINE 100 mg PO TID  This medication was held. \nDo not restart HydrALAZINE until discuss with primary care \ndoctor\n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nType II diabetes']","According to the provided context, hydralazine (100 mg PO TID) was held during the hospital stay. The patient's hypertension management was adjusted by increasing carvedilol to 50 mg BID and minoxidil to 5 mg, continuing amlodipine 10 mg QD, which resulted in mostly normotensive readings, though aiming for SBP <130. The recommendation is not to restart hydralazine until discussed with the primary care doctor, implying that outpatient follow-up will determine the necessity of its reinitiation or alternative adjustments to achieve the desired blood pressure goal.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, here's the response to the question:

**Question:** What is the current management and recommendation for the patient's hypertension, specifically regarding the use of hydralazine, given its prior discontinuation by the primary care physician before admission?

**Answer:**

1. **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, and Document 5)
2. **Current Management for Hypertension:**
   - As per **Document 1**, **Document 2** (which are identical in content), and **Document 4**, the patient's hypertension is managed with:
     * Amlodipine 10 mg PO DAILY
     * Carvedilol (referred to as Coreg in **Document 4**) 50 mg PO BID
     * Minoxidil 10 mg PO DAILY
   - **Status:** Currently well controlled (**Document 4**)

3. **Regarding Hydralazine:**
   - There is **NO MENTION** of hydralazine in any of the provided documents (**Document 1** through **Document 5**), including its prior discontinuation by the primary care physician before admission or any recommendation for its use.

**Conclusion:** Based on the provided documents, the current management for the patient's hypertension does not include hydralazine, and there are no recommendations or mentions of it in the context of prior discontinuation or future use. The patient's hypertension is currently managed with Amlodipine, Carvedilol (Coreg), and Minoxidil, and is noted to be well controlled.","['1. **Hypertension**\n\t* Medications: \n\t\t+ Amlodipine 10 mg PO DAILY (continued from home)\n\t\t+ Carvedilol 50 mg PO BID (continued from home)\n\t\t+ Minoxidil 10 mg PO DAILY (continued from home)\n2. **Diabe', '1. **Hypertension**\n\t* Medications: \n\t\t+ Amlodipine 10 mg PO DAILY (continued from home)\n\t\t+ Carvedilol 50 mg PO BID (continued from home)\n\t\t+ Minoxidil 10 mg PO DAILY (continued from home)\n2. **Diabe', '+ **Follow-up Appointments**: [NOT PROVIDED]\n* **Discharge Medications** (same as listed in the original document):\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (dosage and timing)\n\t3. Albuterol In', '### 3. **Acute on Chronic Kidney Disease (CKD)**\n\n* **Presentation:** Elevated Cr (2.6 from baseline 1.8-2.2)\n* **Concerns:** Renal congestion causing renal dysfunction\n* **Status at Discharge:** Cr 2', '* **Discharge Status:**\n\t+ Symptoms associated with volume overload had subsided, but patient was still slightly volume up on exam.\n\t+ 1+ edema to ankles bilaterally.\n\t+ JVP of 12cm.\n* **Medications a']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What are the key considerations and potential complications for a patient with asthma, presenting with no current respiratory distress, but having a complex past medical history including cardiac risk factors and cerebrovascular disease, in a long-term healthcare management context?","['281ec1ee-1c32-43a3-8667-6c9eaa2f4734\n\nEKG:  SR, NL axis, NIs, TWIs laterally (c/w prior) \nLabs/studies notable for:  proBNP: 1140, Cr 1.9\nPatient was given:  IV Furosemide 10mg\nOn the floor...  \n---------------\nStates that he feels better than he did when he came to the\nhospital. No SOB, CP, or palpitations. Only complaint is the\nburning/itching in his lower extremities. \n \nPast Medical History:\n1. CARDIAC RISK FACTORS  \n- Type 2 Diabetes Mellitus\n- Hypertension  \n- Dyslipidemia  \n- Coronary artery disease\n2. CARDIAC HISTORY  \n- Secondum ASD\n- Mild AR\n3. OTHER PAST MEDICAL HISTORY  \n- Extensive intracranial atherosclerosis, worse in the right\nMCA territory.\n- Cerebrovascular disease, status post CVA in ___\n- Asthma\n- OSteoarthritis', '3a943d1f-0e52-4cc8-939c-42f2386be179\n\n- Cerebrovascular disease, status post CVA in ___\n- Asthma\n- OSteoarthritis\n \nSocial History:\n___\nFamily History:\nBoth parents have heart disease. Mother-___ w/ heart problems and\ndiabetes & father is ___ w/ diabetes. 16 brothers and sisters. No\nknown hx of early coronary artery disease or sudden cardiac \ndeath.\n \nPhysical Exam:\nADMISSION EXAM:\nVS: ___ Temp: 97.3 PO BP: 168/78 HR: 85 RR: 18 O2 sat:\n97% O2 delivery: RA Dyspnea: 0 RASS: 0 Pain Score: ___ \nGEN: alert and interactive, comfortable, no acute distress\nHEENT: PERRL, anicteric, conjunctiva pink, oropharynx without\nlesion or exudate, moist mucus membranes, ears without lesions \nor\napparent trauma\nLYMPH: no anterior/posterior cervical, supraclavicular \nadenopathy']","Based on the provided context, key considerations for managing a patient with asthma, like the one described, include monitoring for potential exacerbations, especially given the patient's complex past medical history. Notably, the patient's current presentation without SOB (shortness of breath), CP (chest pain), or palpitations, but with a complaint of burning/itching in lower extremities, suggests that asthma is not currently the primary acute concern. However, the patient's history of cardiac risk factors (Type 2 Diabetes Mellitus, Hypertension, Dyslipidemia, Coronary artery disease), cardiac history (Secondum ASD, Mild AR), and cerebrovascular disease (status post CVA), alongside extensive intracranial atherosclerosis, necessitates a holistic approach. This includes careful management of medications (e.g., the IV Furosemide given for an unspecified but likely cardiac-related issue, given the proBNP and Cr levels), regular monitoring for signs of cardiac decompensation or stroke, and adjusting asthma management to prevent triggering other conditions. The patient's family history of heart disease and diabetes also warrants close long-term monitoring for early signs of these conditions. Physical exams, like the one documented, are crucial for ongoing assessment, particularly focusing on the patient's comfort, distress levels, and specific systemic evaluations (e.g., HEENT, Lymphatic).",custom_multi_hop_query_synthesizer,"**Response to Current Question with Provided Document Analysis**

**Note:** The provided documents (1-5) primarily focus on a patient's discharge information, medications, and acute problems addressed during a hospital stay. While the documents provide valuable insights into the patient's complex medical history, they do not explicitly mention cerebrovascular disease or the absence/presence of current respiratory distress. However, we can infer key considerations and potential complications for a patient with asthma, given the context of complex past medical history including cardiac risk factors (implied by conditions like Chronic Kidney Disease (CKD), Hypertension, and Acute on Chronic Heart Failure with preserved Ejection Fraction (HFpEF) mentioned in the documents).

**Key Considerations for Long-term Healthcare Management:**

1. **Cardiac-Asthma Interaction**: Given the patient's history of **Asthma** and cardiac risk factors (**HFpEF**, **Hypertension**, and **CKD**), managing asthma exacerbations is crucial to prevent cardiac complications. Monitoring for signs of heart failure exacerbation (e.g., worsening edema, shortness of breath) is implied in **Document 3 & 4** under ""Symptoms to Report (Danger Signs)"".

2. **Renal Implications**: **CKD** (mentioned in **Documents 1 & 2**) requires careful medication management, including the use of Sevelamer Carbonate. Asthma medications (e.g., Albuterol) are generally not nephrotoxic, but overall renal function should be monitored, especially with **CKD** and **Acute on Chronic Anemia** (**Document 5**).

3. **Glycemic Control**: Although **IDDM (Insulin-Dependent Diabetes Mellitus)** with poor control (**A1c 11.4%**, **Document 5**) is not directly related to asthma, overall metabolic control is essential for preventing complications that could indirectly affect asthma management (e.g., increased susceptibility to infections).

4. **Polypharmacy and Medication Adherence**: With multiple chronic conditions (**Asthma**, **CKD**, **Osteoarthritis**, **HFpEF**, **Hypertension**, **IDDM**, and **Acute on Chronic Anemia**), ensuring medication adherence and monitoring for potential drug interactions (e.g., between asthma medications and other prescribed drugs) is vital.

**Potential Complications:**

- **Asthma Exacerbation Leading to Cardiac Complications**: Untreated or poorly managed asthma could lead to increased respiratory distress, potentially exacerbating heart failure or leading to other cardiac complications.
- **Renal Function Decline**: Inadequate management of CKD or interactions between medications could result in further decline of renal function.
- **Infections and Metabolic Deterioration**: Poorly controlled IDDM increases the risk of infections, which could complicate asthma, and worsen the overall metabolic state.

**Metadata Observations:**

- **Patient/Subject ID**: Consistently listed as **13180007** across all documents (**Documents 1-5**).
- **Note ID** and **Admission ID**: Also consistent across all documents as **13180007-DS-19** and **20774429**, respectively.
- **Chart Time** and **Store Time**: Listed as **N/A** in all provided documents (**Documents 1-5**).","['3. **Chronic Kidney Disease (CKD)**\n\t* Medication: Sevelamer Carbonate 800 mg PO TID W/MEALS (continued from home)\n4. **Asthma**\n\t* Medication: Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath ', '3. **Chronic Kidney Disease (CKD)**\n\t* Medication: Sevelamer Carbonate 800 mg PO TID W/MEALS (continued from home)\n4. **Asthma**\n\t* Medication: Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath ', '+ **Symptoms to Report (Danger Signs)**: Not explicitly listed under Discharge Condition, but implied to be monitored based on hospital course (e.g., worsening edema, shortness of breath, chest pain)', '+ **Symptoms to Report (Danger Signs)**: Not explicitly listed under Discharge Condition, but implied to be monitored based on hospital course (e.g., worsening edema, shortness of breath, chest pain)', '* **Acute Problems Addressed**:\n\t1. **Acute on Chronic HFpEF**\n\t2. **Chest Pain** (mild troponin elevation, likely related to CKD)\n\t3. **CKD** (elevated Cr, possibly due to renal congestion)\n\t4. **Hyp']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
What is the prescribed dosage of Hydralazine for a patient post-hospital discharge for managing hypertension alongside other conditions?,"['71b11357-64d1-43f3-b5b3-9e2b962adaf4\n\n# Volume overload\n# HFpEF, LVEF 55-60% in ___\nVolume overload on exam. Diuresis began while in ICU, net \nnegative 1.8L prior to transfer. Dry weight appears to be \n154-157. s/p Lasix 80mg x 2 so far. 163.4 lb on ___ A-Strict \nI/Os, daily weights. Continued home carvedilol at increased dose \nas below. He was sent home with PO 60 mg Lasix daily and was net \neven in the hospital. \n# HTN\nBlood pressure medications initially held when he was started on \npropofol. Anti-HTN meds started on day of transfer. Persistently \nhypertensive. Increased carvedilol to 50 mg BID and increased \nminoxidil to 5 mg and continued amlodipine 10 mg QD. Of note, he \nhad been on clonidine and hydralazine but these were stopped by \nPCP just prior to admission. He remained mostly normotensive \nalthough goal SBP <130 and should continue to be goal as an \noutpatient. \n# Normocytic Anemia\nBaseline of ___, secondary to CKD and possible AoCD. Required \n1u pRBC on arrival. Hb stable. \nCHRONIC ISSUES:', 'cd30826d-ad9e-4a08-8b63-15e1e3bbfe0c\n\nYou were admitted to the hospital because:\n================================\n-You had worsening shortness of breath, with increased leg \nswelling and weight gain.\nDuring your stay:\n============\n-You had too much volume onboard so you were given IV diuretic \nmedications,. You improved significantly.\nAfter your discharge:\n================\n-Please continue taking all medications as prescribed (see \nbelow).\n-Please stop taking Lisinopril and metoprolol.\n-Please continue taking insulin according to the regimen you \nwere following before this admission.\n-New medications:\n  - Aspirin 81mg once daily\n  - Carvedilol 25mg twice daily\n  - Furosemide 40mg twice daily\n  - Hydralazine 100mg three times daily\n-Please attend any upcoming outpatient appointments you have \n(see below).\nWe wish you the very best!']","According to the discharge instructions, the patient is prescribed Hydralazine 100mg three times daily, in addition to other medications such as Carvedilol and Furosemide, for managing conditions that include hypertension, indicating a return to this medication after it was stopped by the PCP just prior to the hospital admission.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Prescribed Dosage of Hydralazine for Hypertension Management Post-Discharge:**

* **Dosage:** NOT PROVIDED
* **Medication Presence:** Hydralazine is NOT MENTIONED in any of the provided documents (Document 1 through Document 5) as part of the discharge medications for managing hypertension or any other condition.

**Relevant Information from Documents for Context (Hypertension Management):**

* **Hypertension Management Medications (as per Document 4):**
	+ Amlodipine 10 mg PO DAILY
	+ Carvedilol 50 mg PO BID
	+ Minoxidil 10 mg PO DAILY

**Metadata Consistency Across Documents:**

* **Patient/Subject ID:** Consistently listed as **13180007** across all documents (Document 1 through Document 5).
* **Note ID:** Consistently listed as **13180007-DS-19** across all documents.
* **Admission ID:** Consistently listed as **20774429** across all documents.
* **Chart Time & Store Time:** Listed as **N/A** across all documents.","['+ **Follow-up Appointments**: [NOT PROVIDED]\n* **Discharge Medications** (same as listed in the original document):\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (dosage and timing)\n\t3. Albuterol In', '+ **Follow-up Appointments**: [NOT PROVIDED]\n* **Discharge Medications** (same as listed in the original document):\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (dosage and timing)\n\t3. Albuterol In', '* **Discharge Status:**\n\t+ Symptoms associated with volume overload had subsided, but patient was still slightly volume up on exam.\n\t+ 1+ edema to ankles bilaterally.\n\t+ JVP of 12cm.\n* **Medications a', '1. **Hypertension**\n\t* Medications: \n\t\t+ Amlodipine 10 mg PO DAILY (continued from home)\n\t\t+ Carvedilol 50 mg PO BID (continued from home)\n\t\t+ Minoxidil 10 mg PO DAILY (continued from home)\n2. **Diabe', '1. **Medications**:\n\t* List of discharge medications (13 items, see below)\n\t* **Note**: Take all medications as prescribed\n\t* **Discharge Medications List**:\n\t\t1. Torsemide 100 mg PO DAILY\n\t\t2. 70/30 ']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What treatment approach was taken for patient with CAD w/ inducible ischemia & NSTEMI, considering kidney function?","['5afc91e0-6481-46b3-aa3c-473b2c2e6895\n\n#Community acquired pneumonia\nCough, worsened SOB, hypoxemia (although alternate explanation) \nbut no leukocytosis or fevers; influenza negative. Legionella \nand strep were negative. Patient was given a 5-day course of \nceftriaxone and azithromycin. \n#Hypertension\nGoal <130/80. As patient is on several anti-hypertensives with \nstill an elevated blood pressure, he underwent a secondary \nhypertension workup. His last renal ultrasound in ___ was \nwithin normal limits. He was placed on continuous O2 monitoring \novernight, and patient did not desaturate. His aldosterone to \nrenin ratio was 0.13, indicating no primary hyperaldosteronism. \n24 hour urine metanephrines and catecholamines were within \nnormal limits.\n#CAD w/ inducible ischemia\n#NSTEMI\nTroponin peaked at 0.02, thought to be type 2 due to volume \noverload. Continued aspirin, atorvastatin, carvedilol. The \ndecision was made to hold off on coronary angiogram due to \nkidney function and the suspicion that this was type 2.\n#H/o CVA\nPatient had an episode while in hospital with dysarthria,', 'd2113a66-fe4f-4869-b3c0-73646862b32b\n\ngluconate (received 3 doses ___. Upon review of recent \noutpatient visit notes, it appears his volume exam is similar to \nbaseline, and patient was asymptomatic during hospital course. \nHe was diuresed effectively with IV Lasix 80. He was \ntransitioned to PO torsemide 100. His BP was well controlled \nwith regimen as described below.\n# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\nat or lower than levels earlier this year. He has denied chest\npain during admission. He does have risk factors for ischemia \nand\nhas not had stress since ___. However, findings and history \nto\ndate are not suggestive of ischemia and he has an ___. TTE did \nnot show evidence of focal wall motion abnormalities or other \nfindings suggestive of ischemia, so further workup was not \npursued. He was continued on ASA and atorvastatin.\n# ___ on CKD:\nCr elevated to 2.6 on admission from baseline of 1.8-2.2. Given\nevidence of congestion elsewhere, concerns for renal congestion\ncausing renal dysfunction. Cr remained stable and was 2.9 on day \nof discharge. He was continued on home sevelamer.']","For the patient with CAD w/ inducible ischemia & NSTEMI, the decision was made to hold off on coronary angiogram due to kidney function concerns and the suspicion that the NSTEMI was type 2 (likely due to volume overload, as troponin peaked at 0.02). The patient was continued on aspirin, atorvastatin, and carvedilol.",custom_multi_hop_query_synthesizer,"I must point out that the question doesn't align with the provided documents. Here's a breakdown of the discrepancy and an attempt to provide a relevant response based on the instructions:

**Discrepancy:**
1. The question mentions ""CAD w/ inducible ischemia & NSTEMI"" (Coronary Artery Disease with inducible ischemia and Non-ST-Elevation Myocardial Infarction), but none of the documents explicitly mention CAD, inducible ischemia, or NSTEMI.
2. The question asks about the treatment approach considering kidney function, which is relevant to the documents since they mention kidney-related issues (e.g., Acute on Chronic Kidney Disease (CKD), Acute Kidney Injury).

**Response Based on Provided Documents (Focusing on Kidney Function and Treatment Approaches Mentioned):**

Given the mismatch, I'll provide an analysis related to kidney function and treatment approaches mentioned in the documents, which might indirectly address the question's intent regarding kidney function consideration:

* **Patient/Subject ID:** 13180007 (consistent across all documents)
* **Note ID, Admission ID:** Also consistent across all documents (13180007-DS-19, 20774429, respectively)
* **Kidney Function Consideration and Treatment Approaches:**
	+ **Condition:** Acute on Chronic Kidney Disease (CKD) / Acute Kidney Injury (mentioned in Documents 1, 2, and 5)
	+ **Treatment Approaches Considering Kidney Function:**
		- **Medications:**
			- **Sevelamer Carbonate** (for CKD, mentioned in Document 3)
			- **Torsemide 100mg daily** (for active diuresis, mentioned in Document 2; implies consideration of fluid overload, a common issue in kidney disease)
		- **Monitoring:** Emphasis on **Creatinine (Cr) monitoring** (mentioned in Document 2), indicating close observation of kidney function post-discharge

**Direct Answer to the Question as Posed (Given the Information Provided):**
* **Treatment Approach for CAD w/ Inducible Ischemia & NSTEMI Considering Kidney Function:** **Not Specifiable** based on the provided documents, as the conditions (CAD, inducible ischemia, NSTEMI) are not mentioned.

**Recommendation for Further Analysis:**
To accurately answer the posed question, additional documents or information that specifically address the patient's CAD, inducible ischemia, NSTEMI, and the treatment approaches taken in consideration of their kidney function would be necessary.","['### 3. **Acute on Chronic Kidney Disease (CKD)**\n\n* **Presentation:** Elevated Cr (2.6 from baseline 1.8-2.2)\n* **Concerns:** Renal congestion causing renal dysfunction\n* **Status at Discharge:** Cr 2', '* **Discharge Status:**\n\t+ Symptoms associated with volume overload had subsided, but patient was still slightly volume up on exam.\n\t+ 1+ edema to ankles bilaterally.\n\t+ JVP of 12cm.\n* **Medications a', '3. **Chronic Kidney Disease (CKD)**\n\t* Medication: Sevelamer Carbonate 800 mg PO TID W/MEALS (continued from home)\n4. **Asthma**\n\t* Medication: Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath ', '* **Patient Profile**: ___ male with history of HFpEF (EF 55-60%), prior CVA, CKD, DM, hypertension, and carotid artery disease\n* **Presentation**: 1 day of dyspnea and discomfort, admitted for HF exa', '* **Discharge Location**: Home With Service\n* **Facility**: [REDACTED]\n* **Discharge Diagnosis**:\n\t+ **Primary Diagnosis**: Acute on chronic diastolic heart failure exacerbation\n\t+ **Secondary Diagnos']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What are the key findigns from the CT scans (head, abd/pelvis, C spine) for a patient with edema, and how do these relait to possibl aspiration or pneumonia, based on the providd medikal imagig reports?","['a0523bf3-a15e-4abc-bd78-1c98b6c5dc7e\n\nedema.  No\nevidence of displaced fracture.\nCT head ___:\nThere is no evidence of infarction, hemorrhage, edema,or midline \nshift.  There\nis prominence of the ventricles and sulci suggestive of \ninvolutional changes.\n \nThere is no evidence of fracture.  Opacification of the mastoid \nair cells. \nThe visualized portion of the paranasal sinuses, mastoid air \ncells, and middle\near cavities are clear.  The visualized portion of the orbits \nare\nunremarkable.\nCT abd/pelvis ___:\n1. Bilateral lower lobe opacities, concerning for aspiration or \npneumonia.\n2. No acute finding in the abdomen or pelvis.\nCT C spine ___:\nNG tube and endotracheal tube are noted.  Alignment is normal. \nNo fractures\nare identified. There is no evidence of high-grade spinal canal', 'dd2587c0-7ebc-4cd2-878e-f8cd5d8d0c1b\n\nBMP - Na 135, K 5, Cr 2.0 (baseline ___, HCO3 20, BG 625, AG 16\nCa 8, phos 6.6\nUA - neg leuk, neg nitr, 7 WBC, neg ketone, 1000 glucose\nUrine tox negative\nTSH pending\nBCx, UCx\nTrop 0.03 -> 0.06\nEKG with T-wave inversion in lateral leads, unchanged from prior\nImaging:  \n- CT head w/o contrast:\n1. No evidence of intracranial bleed. No evidence of acute\nintracranial abnormality.\n2. Opacification of the mastoid air cells.\n- CT C-spine w/o contrast\nNo evidence of acute fracture or malalignment\n- CT A/P w/o contrast\n1. No evidence of acute abdominal or pelvic abnormality. \n2. Extensive bibasilar atelectasis. \n3. Small left pleural effusion. \n- CXR\nSmall left pleural effusion. Opacities likely represent\natelectasis however pneumonia cannot be excluded in the correct\nclinical setting. \nConsults: none']","Based on the provided medical imaging reports, here are the key findings from the CT scans and their relation to possible aspiration or pneumonia:       1. **CT Head**: No evidence of infarction, hemorrhage, edema, or midline shift. Prominence of ventricles and sulci suggests involutional changes. No fracture, but opacification of mastoid air cells is noted.       2. **CT Abd/Pelvis**: **Key Finding Relevant to Aspiration/Pneumonia**: Bilateral lower lobe opacities, concerning for **aspiration or pneumonia**. No acute findings in the abdomen or pelvis.       3. **CT C Spine**: Normal alignment, no fractures, and no evidence of high-grade spinal canal stenosis. NG and endotracheal tubes are noted, which might relate to the patient's condition leading to or resulting from aspiration or pneumonia, but the CT C Spine itself does not directly indicate aspiration or pneumonia.       **Relation to Aspiration/Pneumonia**: The primary indicator from the CT scans for aspiration or pneumonia comes from the **CT Abd/Pelvis**, highlighting bilateral lower lobe opacities. This finding, coupled with the clinical context (e.g., edema, the presence of endotracheal tubes suggesting respiratory support), supports the concern for aspiration or pneumonia. The **CXR** from the second report further supports this with small left pleural effusion and opacities likely representing atelectasis, though it also cannot exclude pneumonia without the correct clinical setting.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, I must point out that:

1. **There are no CT scan reports (head, abd/pelvis, C spine) provided** in the documents (Document 1 through Document 5).
2. **No medical imaging reports are provided** that could relate to edema, aspiration, or pneumonia.
3. **The content primarily focuses on**:
	* Acute problems addressed (Documents 1 and 2, which are identical).
	* Cardiac findings (Documents 3 and 4, which are nearly identical).
	* Specific conditions with their presentation, concerns, and management (Document 5).

Given the above points, it's not possible to answer the question about key findings from CT scans or their relation to possible aspiration or pneumonia based on the provided documents.

**Metadata Observations (as per instruction 3):**
- **Patient/Subject ID**: Consistently **13180007** across all documents.
- **Note ID**: Consistently **13180007-DS-19** across all documents.
- **Admission ID**: Consistently **20774429** across all documents.
- **Chart Time** and **Store Time**: Both are **N/A** across all documents.

**Answer to the Question (given the constraints):**
- **Key findings from CT scans**: Not available.
- **Relation to possible aspiration or pneumonia**: Cannot be determined from the provided documents.","['* **Acute Problems Addressed**:\n\t1. **Acute on Chronic HFpEF**\n\t2. **Chest Pain** (mild troponin elevation, likely related to CKD)\n\t3. **CKD** (elevated Cr, possibly due to renal congestion)\n\t4. **Hyp', '* **Acute Problems Addressed**:\n\t1. **Acute on Chronic HFpEF**\n\t2. **Chest Pain** (mild troponin elevation, likely related to CKD)\n\t3. **CKD** (elevated Cr, possibly due to renal congestion)\n\t4. **Hyp', '- Mitral Valve: Mildly thickened leaflets, no prolapse, trivial regurgitation\n\t\t- Pulmonic Valve: Normal leaflets\n\t\t- Tricuspid Valve: Structurally normal, physiologic tricuspid regurgitation\n\t+ Estim', '+ **Mitral Valve Leaflets**: Mildly thickened, trivial regurgitation, no prolapse\n\t+ **Pulmonic Valve Leaflets**: Normal\n\t+ **Tricuspid Valve Leaflets**: Structurally normal, physiologic regurgitation', '### 3. **Acute on Chronic Kidney Disease (CKD)**\n\n* **Presentation:** Elevated Cr (2.6 from baseline 1.8-2.2)\n* **Concerns:** Renal congestion causing renal dysfunction\n* **Status at Discharge:** Cr 2']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What is the current treatment plan for a patient with Hypothyroidism, and how does it relate to their other chronic conditions like Hypertension and IDDM, considering their recent discharge diagnosis and condition?","['08e7114b-32bf-470b-a3c6-d919c6de4e69\n\n# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n# Acute on chronic anemia:\nHb on admission was 7.4. No evidence of bleeding per history or \nexam. Possibly related to worsening of his renal function vs \ndilutional iso heart failure. His Hb was 7.6 on discharge. He \nreceived 3 doses of ferric gluconate 250 mg IV on ___.\n#IDDM\nPoorly controlled. A1c 14.4 in ___ in ___ at ___. \nRepeat A1C ___ was 11.4%. He was given Lantus 30u night of \nadmission, then transitioned to home insulin ___ with 70/30 \n30u with breakfast and 20u with lunch. He was also on ISS while \ninpatient.\nCHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.', '8ffe5463-ba8e-4c92-be15-e075478499d9\n\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPRIMARY:\n=======================================\nHyperglycemic hyperosmolar syndrome \nType 2 diabetes mellitus\nSECONDARY: \n=======================================\nCoronary artery disease\nChronic kidney disease\nHypertension\nHeart failure preserved ejection fraction\nNormocytic Anemia\nHypothyroidism\n \nDischarge Condition:\nMental Status: Clear and coherent.\nLevel of Consciousness: Alert and interactive.\nActivity Status: Ambulatory - Independent.']","According to the patient's records, for Hypothyroidism, the patient is continued on home levothyroxine 100mcg daily. This treatment plan is managed alongside other chronic conditions. For Hypertension, the patient is on home amlodipine 10, Coreg 50 BID, and minoxidil 10 daily, with the condition currently well controlled. For IDDM (Poorly controlled with an A1c of 14.4, later improved to 11.4%), the patient was transitioned from Lantus 30u at night of admission to home insulin with 70/30 30u with breakfast and 20u with lunch, also utilizing ISS while inpatient. At discharge, the patient's mental status was clear and coherent, alert, interactive, and ambulatory-independent, with Hypothyroidism listed among the secondary discharge diagnoses, indicating its ongoing management as part of the patient's overall care plan.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Patient Identification:**
Based on the provided metadata, the patient's details are consistent across all documents:
* **Patient/Subject ID:** 13180007 (consistent across Documents 1-5)
* **Note ID:** 13180007-DS-19 (consistent across Documents 1-5)
* **Admission ID:** 20774429 (consistent across Documents 1-5)

**Current Treatment Plan for Hypothyroidism:**
As per **Document 1** and **Document 2** (which are identical in content):
* **Condition:** Hypothyroidism
* **Current Treatment:** Levothyroxine Sodium 100 mcg PO DAILY (continued from home)

**Relation to Other Chronic Conditions (Hypertension and IDDM):**
Based on **Document 3**:
* **Hypertension:**
	+ Medications: Amlodipine 10 mg PO DAILY, Carvedilol (referred to as Coreg in **Document 4**) 50 mg PO BID, and Minoxidil 10 mg PO DAILY.
	+ **Status at Last Update (Document 4):** History of hypertension, currently well controlled.
* **Diabetes Mellitus Type 2 (IDDM):**
	+ Medications: 70/30 Insulin (dosage varies, with adjustments), Victoza (Liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) subcutaneous DAILY.
	+ **No Direct Update in Documents 4 or 5;** the most recent information is from **Document 3**.

**Consideration of Recent Discharge Diagnosis and Condition:**
From **Documents 4 and 5** (which are identical in content), focusing on conditions that might interact with Hypothyroidism management or indicate the patient's overall health status:
* **Acute on Chronic Kidney Disease (CKD):** Elevated Cr levels at discharge (2.9), managed with Sevelamer.
* **Acute on Chronic Anemia:** Mentioned at discharge, but no specific treatment adjustments from the provided documents are directly linked to Hypothyroidism management.

**Conclusion:**
The patient's Hypothyroidism is managed with Levothyroxine Sodium. While there are other chronic conditions (Hypertension, IDDM, and CKD), the provided documents do not indicate a direct adjustment to the Hypothyroidism treatment plan based on the recent discharge diagnoses. Hypertension is noted as well-controlled, IDDM management is continued without specified adjustments, and CKD's acute management focuses on Sevelamer, without explicit interaction with Hypothyroidism treatment in the given documents. 

**Recommendation for Future Analysis:**
For a comprehensive understanding, review additional documents or the patient's full medical history to identify any potential interactions between these conditions and their treatments, especially considering the patient's renal function and its possible impact on medication metabolism and efficacy.","['Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D', 'Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D', '1. **Hypertension**\n\t* Medications: \n\t\t+ Amlodipine 10 mg PO DAILY (continued from home)\n\t\t+ Carvedilol 50 mg PO BID (continued from home)\n\t\t+ Minoxidil 10 mg PO DAILY (continued from home)\n2. **Diabe', '### 3. **Acute on Chronic Kidney Disease (CKD)**\n\n* **Presentation:** Elevated Cr (2.6 from baseline 1.8-2.2)\n* **Concerns:** Renal congestion causing renal dysfunction\n* **Status at Discharge:** Cr 2', '### 3. **Acute on Chronic Kidney Disease (CKD)**\n\n* **Presentation:** Elevated Cr (2.6 from baseline 1.8-2.2)\n* **Concerns:** Renal congestion causing renal dysfunction\n* **Status at Discharge:** Cr 2']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What specific adjustments were made to the patient's medication regimen during the recent hospitalization to manage poorly-controlled Type 2 Diabetes Mellitus (T2DM) with Hyperosmolar Hyperglycemic State (HHS), and what follow-up actions are recommended for the Clinical Care Coordinator to ensure the patient's continued care?","['386e4975-89d1-411a-99a3-9d225138df6c\n\n[] Ensure that patient was able to adhere to a diabetic diet\nPCP:\n[] Had elevated SBP in 130s-150s. Increased minoxidil to 5mg and \ncarvedilol to 50 mg BID. Please follow-up on blood pressures. \n[] Follow up on diuretics and volume status. Please get \nfollow-up labs BUN/Cr at follow-up appointment.\nNew meds: 70-30 novolog (30 units in AM, 20 units at dinner)\nStopped meds: none\nChanged meds: Carvedilol 50 mg twice a day, increased minoxidil \n5 mg daily \nACUTE ISSUES: \n=============== \n# HHS\n# T2DM\nPatient has history of poorly-controlled DM w/ A1c ~14. Based on \nlabs, determined to be in HHS likely precipitated by med \nnon-adherence or difficulty understanding multi-step process. No \nclear infection was identified. Of note, he tends to have high \ninsulin requirements. Pt was continued on insulin basal/bolus \nwhile inpatient. There was significant efforts to have him bring \nin home Victoza but he only had a half dose so he was continued \non basal/bolus course and made a plan for close outpatient \nfollow up and home 2 injections (Victoza and pre-mixed insulin).']","During the hospitalization, adjustments to the patient's medication regimen included increasing carvedilol to 50 mg twice a day and minoxidil to 5 mg daily. The patient was also continued on insulin basal/bolus. For discharge, a plan was made for close outpatient follow-up with the patient administering two injections at home: Victoza and pre-mixed insulin (70-30 novolog, with 30 units in the AM and 20 units at dinner). As the Clinical Care Coordinator, recommended follow-up actions include: (1) ensuring the patient adheres to the diabetic diet, (2) following up on blood pressures given the recent medication changes, (3) monitoring diuretics and volume status, and (4) obtaining follow-up labs (BUN/Cr) at the next appointment to assess the effectiveness of the current regimen and make any necessary adjustments.",custom_multi_hop_query_synthesizer,"**Response to Current Question**

**Patient Identification:**
* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, and Document 5)
* **Note ID:** 13180007-DS-19 (consistent across all documents)
* **Admission ID:** 20774429 (consistent across all documents)

**Medication Adjustments for Poorly-Controlled Type 2 Diabetes Mellitus (T2DM):**

Based on the provided documents, the specific adjustments made to the patient's medication regimen during the recent hospitalization to manage poorly-controlled T2DM are detailed as follows:

1. **Insulin Adjustment:**
	* **Initial Hospital Treatment:** Lantus 30u (administered the night of admission)
	* **Transition to Home Regimen:** Switched to 70/30 Insulin with a specified dosage regimen (30u with breakfast, 20u with lunch) as outlined in **Document 3** and **Document 4**.
2. **Additional Inpatient Medication:**
	* **ISS (Insulin Sliding Scale)**: Administered while the patient was inpatient, as mentioned in **Document 3** and **Document 4**, to manage blood glucose levels more dynamically.

**Pre-Existing Home Medications Continued:**
* **Victoza (Liraglutide)**: Continued from home, as noted in **Document 5**, under **Diabetes Mellitus Type 2 (IDDM)** management.

**Follow-up Actions for the Clinical Care Coordinator:**

1. **Verify Medication Adherence:**
	* Schedule a follow-up with the patient to ensure adherence to the adjusted insulin regimen (70/30 Insulin) and continued use of Victoza (Liraglutide).
2. **Monitor Blood Glucose Levels:**
	* Request the patient to track and report blood glucose levels to assess the effectiveness of the current medication regimen.
3. **Renal Function Monitoring:**
	* Given the patient's **Chronic Kidney Disease (CKD)** (noted in **Document 5**), schedule regular check-ups to monitor renal function, especially since the patient had an elevated Creatinine (Cr) level at discharge (as seen in **Document 1** and **Document 2**).
4. **Multidisciplinary Care Team Engagement:**
	* Coordinate with the patient’s healthcare team (including endocrinology, nephrology, and primary care) to ensure comprehensive management of T2DM, CKD, and hypertension.
5. **Patient Education:**
	* Provide or arrange for patient education on managing T2DM, recognizing signs of hyperglycemia and hypoglycemia, and the importance of consistent medication adherence and follow-up appointments.","['**Key Findings:**\n\n* Slightly improved Hemoglobin (Hgb) level from admission (7.4 to 7.6)\n* Elevated Creatinine (Cr) level at discharge (2.9), indicating persistent renal impairment\n* Abnormal glucose', '**Key Findings:**\n\n* Slightly improved Hemoglobin (Hgb) level from admission (7.4 to 7.6)\n* Elevated Creatinine (Cr) level at discharge (2.9), indicating persistent renal impairment\n* Abnormal glucose', '* **Status:** Poorly controlled\n* **Lab Results:**\n\t+ A1c 14.4 (prior) and 11.4% (current)\n\t+ eAG 280\n* **Management:**\n\t+ Given Lantus 30u night of admission, then transitioned to home insulin regime', '* **Status:** Poorly controlled\n* **Lab Results:**\n\t+ A1c 14.4 (prior) and 11.4% (current)\n\t+ eAG 280\n* **Management:**\n\t+ Given Lantus 30u night of admission, then transitioned to home insulin regime', '1. **Hypertension**\n\t* Medications: \n\t\t+ Amlodipine 10 mg PO DAILY (continued from home)\n\t\t+ Carvedilol 50 mg PO BID (continued from home)\n\t\t+ Minoxidil 10 mg PO DAILY (continued from home)\n2. **Diabe']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What is the ussage of Minoxidil in a patient with Hypertension (HTN) and other comorbidities, and what dose ajustments were made?","['08e7114b-32bf-470b-a3c6-d919c6de4e69\n\n# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n# Acute on chronic anemia:\nHb on admission was 7.4. No evidence of bleeding per history or \nexam. Possibly related to worsening of his renal function vs \ndilutional iso heart failure. His Hb was 7.6 on discharge. He \nreceived 3 doses of ferric gluconate 250 mg IV on ___.\n#IDDM\nPoorly controlled. A1c 14.4 in ___ in ___ at ___. \nRepeat A1C ___ was 11.4%. He was given Lantus 30u night of \nadmission, then transitioned to home insulin ___ with 70/30 \n30u with breakfast and 20u with lunch. He was also on ISS while \ninpatient.\nCHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.', '71b11357-64d1-43f3-b5b3-9e2b962adaf4\n\n# Volume overload\n# HFpEF, LVEF 55-60% in ___\nVolume overload on exam. Diuresis began while in ICU, net \nnegative 1.8L prior to transfer. Dry weight appears to be \n154-157. s/p Lasix 80mg x 2 so far. 163.4 lb on ___ A-Strict \nI/Os, daily weights. Continued home carvedilol at increased dose \nas below. He was sent home with PO 60 mg Lasix daily and was net \neven in the hospital. \n# HTN\nBlood pressure medications initially held when he was started on \npropofol. Anti-HTN meds started on day of transfer. Persistently \nhypertensive. Increased carvedilol to 50 mg BID and increased \nminoxidil to 5 mg and continued amlodipine 10 mg QD. Of note, he \nhad been on clonidine and hydralazine but these were stopped by \nPCP just prior to admission. He remained mostly normotensive \nalthough goal SBP <130 and should continue to be goal as an \noutpatient. \n# Normocytic Anemia\nBaseline of ___, secondary to CKD and possible AoCD. Required \n1u pRBC on arrival. Hb stable. \nCHRONIC ISSUES:']","Minoxidil was prescribed for a patient with a history of hypertension, among other conditions (Acute on chronic anemia, IDDM, Hypothyroidism, History of CVA, and later mentioned Volume overload, HFpEF, and Normocytic Anemia). Initially, the patient was on minoxidil 10mg daily. However, during the hospital stay, due to persistently hypertensive readings, the dose of minoxidil was adjusted to 5mg, alongside increases in carvedilol to 50mg BID and continuation of amlodipine 10mg QD, aiming for a goal SBP <130 as an outpatient.",custom_multi_hop_query_synthesizer,"Based on the provided documents, here's the answer to the question about Minoxidil's usage and dose adjustments in a patient with Hypertension (HTN) and other comorbidities:

**Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, and Document 5)

**Minoxidil Usage and Dose Adjustments for Hypertension (HTN):**

* **Usage:** Minoxidil is used for the management of **Hypertension (HTN)** in the patient.
* **Dose:** 10 mg PO DAILY
* **Dose Adjustments:** According to the provided documents, **no dose adjustments for Minoxidil are mentioned**. The dose is consistently listed as 10 mg PO DAILY across the documents where Minoxidil is mentioned, specifically:
	+ Document 1 (under **Hypertension** medications, noted as ""continued from home"")
	+ Document 3 (under **Discharge Medications**, same as originally listed)
	+ Document 5 does not explicitly mention the management of Hypertension but lists medications; however, Minoxidil is not detailed in Document 5's provided content snippet.

**Additional Context from Metadata:**
- **Note ID** and **Admission ID** are consistent across all documents (Note ID: 13180007-DS-19, Admission ID: 20774429), indicating these documents pertain to the same hospital admission or medical note series for the patient.
- **Chart Time** and **Store Time** are listed as N/A across all documents, providing no additional timing context for the Minoxidil treatment adjustments.","['1. **Hypertension**\n\t* Medications: \n\t\t+ Amlodipine 10 mg PO DAILY (continued from home)\n\t\t+ Carvedilol 50 mg PO BID (continued from home)\n\t\t+ Minoxidil 10 mg PO DAILY (continued from home)\n2. **Diabe', '* **Presentation:** Dyspnea, lower extremity edema, volume overload\n* **Trigger:** Unclear, possible medication non-compliance\n* **Findings:**\n\t+ EF 65% (TTE)\n\t+ Diastolic dysfunction\n\t+ Iron studies:', '+ **Follow-up Appointments**: [NOT PROVIDED]\n* **Discharge Medications** (same as listed in the original document):\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (dosage and timing)\n\t3. Albuterol In', '* **Discharge Status:**\n\t+ Symptoms associated with volume overload had subsided, but patient was still slightly volume up on exam.\n\t+ 1+ edema to ankles bilaterally.\n\t+ JVP of 12cm.\n* **Medications a', '1. **Albuterol Inhaler**\n\t* Dose: 2 PUFF IH Q8H\n\t* Indication: PRN shortness of breath\n2. **Amlodipine**\n\t* Dose: 10 mg PO DAILY\n3. **Atorvastatin**\n\t* Dose: 80 mg PO QPM\n4. **Carvedilol**\n\t* Dose: 50']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What is the prescribed dosage and administration schedule for Polyethylene Glycol in the provided patient discharge information, and what is the indicated use for this medication?","['784a4f17-941d-40ee-a5aa-7471e6a5f600\n\n70/30 10 Units Lunch \n3.  Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath  \n4.  amLODIPine 10 mg PO DAILY  \n5.  Aspirin 81 mg PO DAILY  \n6.  Atorvastatin 80 mg PO QPM  \n7.  CARVedilol 50 mg PO BID  \n8.  Levothyroxine Sodium 100 mcg PO DAILY  \n9.  Minoxidil 10 mg PO DAILY  \n10.  Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine  \n11.  sevelamer CARBONATE 800 mg PO TID W/MEALS  \n12.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n13.  Vitamin D 1000 UNIT PO DAILY  \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPrimary Diagnosis:\n-Acute on chronic diastolic heart failure exacerbation\nSecondary Diagnosis:', '8c579626-76a5-4cd0-9f53-1feadb6904be\n\nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath \n2. amLODIPine 10 mg PO DAILY \n3. Atorvastatin 80 mg PO QPM \n4. CARVedilol 50 mg PO BID \n5. Furosemide 80 mg PO DAILY \n6. 70/30 30 Units Breakfast\n70/30 10 Units Lunch\n7. Levothyroxine Sodium 100 mcg PO DAILY \n8. Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY \n9. Minoxidil 10 mg PO DAILY \n10. Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine \n11. sevelamer CARBONATE 800 mg PO TID W/MEALS \n12. Aspirin 81 mg PO DAILY \n13. Vitamin D 1000 UNIT PO DAILY \n \nDischarge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast']","According to the discharge medications list (not explicitly mentioned but inferred from the context of medications) and the medications on admission list, Polyethylene Glycol is prescribed as follows: **Dosage:** 17 g **Administration Schedule:** PO (orally) DAILY:PRN (as needed) **Indicated Use:** Constipation - First Line treatment.",custom_multi_hop_query_synthesizer,"**Answer to the Question**

* **Prescribed Dosage for Polyethylene Glycol:** NOT PROVIDED
* **Administration Schedule for Polyethylene Glycol:** NOT PROVIDED
* **Indicated Use for Polyethylene Glycol:** NOT PROVIDED

**Rationale for the Answer:**

* Upon reviewing the provided documents (Document 1 through Document 5), there is no mention of **Polyethylene Glycol** in either the **METADATA** or the **CONTENT** sections of any document.
* Since the medication is not listed, its prescribed dosage, administration schedule, and indicated use are also not available within the provided patient discharge information.

**Additional Observations (as per the instruction to report on IDs and dates):**

* **Patient/Subject ID:** Consistently listed as **13180007** across all documents (Document 1 through Document 5).
* **Note ID:** Consistently listed as **13180007-DS-19** across all documents (Document 1 through Document 5).
* **Admission ID:** Consistently listed as **20774429** across all documents (Document 1 through Document 5).
* **Chart Time** and **Store Time:** Listed as **N/A** in all documents (Document 1 through Document 5), indicating no specific chart or store time was provided for any of the documents.","['+ **Follow-up Appointments**: [NOT PROVIDED]\n* **Discharge Medications** (same as listed in the original document):\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (dosage and timing)\n\t3. Albuterol In', '+ **Follow-up Appointments**: [NOT PROVIDED]\n* **Discharge Medications** (same as listed in the original document):\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (dosage and timing)\n\t3. Albuterol In', '1. **Medications**:\n\t* List of discharge medications (13 items, see below)\n\t* **Note**: Take all medications as prescribed\n\t* **Discharge Medications List**:\n\t\t1. Torsemide 100 mg PO DAILY\n\t\t2. 70/30 ', '* **Additional Recommendations:**\n\t+ Consider completing the 4-day course of **ferric gluconate** (started during admission; received 2 doses of 250mg IV on **[NOT PROVIDED]**).\n\t+ One additional infu', '3. **Discharge**: Symptoms improved, but still slightly volume up (JVP ~12, 1+ edema to ankles)\n* **Discharge Details**:\n\t+ **Weight**: 166.6lb\n\t+ **Creatinine (Cr)**: 2.9 (elevated from baseline 1.8-']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What is the role of Aspirin in the medication regimen of patients with chronic conditions, as observed in the provided medical records, and what are the associated health conditions?","['499f5ec0-b3d8-4161-93fa-07c1b6a6de75\n\ncolonoscopy report in our system previously. Iron studies from \n___ with low normal ferritin (53), low iron, low normal \nTIBC - possibly consistent with anemia of chronic disease or \ninflammation, however hard to rule out concomitant iron \ndeficiency.\n# Hypothyroidism: TSH wnl. Continued home levothyroxine.\n# Asthma: Albuterol inhaler prn continued.\nTRANSITIONAL ISSUES:\n- consideration of outpatient colonoscopy referral if not up to \ndate with screening, particularly iso chronic anemia\n- re-check BP at next PCP appointment, decision on further med \ntitration as above (?increase BB, resuming another home agent\n- ?resume Veltassa if K elevated\n- PCP: consider referral to ___ clinic\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Aspirin 81 mg PO DAILY \n2. Atorvastatin 80 mg PO QPM \n3. CloNIDine 0.4 mg PO BID \n4. HydrALAZINE 100 mg PO TID \n5. Levothyroxine Sodium 100 mcg PO DAILY', '784a4f17-941d-40ee-a5aa-7471e6a5f600\n\n70/30 10 Units Lunch \n3.  Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath  \n4.  amLODIPine 10 mg PO DAILY  \n5.  Aspirin 81 mg PO DAILY  \n6.  Atorvastatin 80 mg PO QPM  \n7.  CARVedilol 50 mg PO BID  \n8.  Levothyroxine Sodium 100 mcg PO DAILY  \n9.  Minoxidil 10 mg PO DAILY  \n10.  Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine  \n11.  sevelamer CARBONATE 800 mg PO TID W/MEALS  \n12.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n13.  Vitamin D 1000 UNIT PO DAILY  \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPrimary Diagnosis:\n-Acute on chronic diastolic heart failure exacerbation\nSecondary Diagnosis:']","Based on the provided medical context, Aspirin (81 mg PO DAILY) is consistently present in the medication lists. Associated health conditions and considerations include:  - **Chronic Anemia**: Aspirin is mentioned alongside considerations for outpatient colonoscopy referral for screening, particularly in the context of chronic anemia. - **Cardiovascular Health**: The presence of Aspirin, alongside medications like Atorvastatin (for cholesterol), CARVedilol and HydrALAZINE (for blood pressure), and amLODIPine (for hypertension), suggests its role in managing cardiovascular risk. - **Diastolic Heart Failure Exacerbation**: Aspirin is part of the discharge medication list for a patient with a primary diagnosis of acute on chronic diastolic heart failure exacerbation, indicating its continued use in heart failure management. - **General Health Maintenance**: Aspirin's antiplatelet properties are beneficial for overall cardiovascular health, which is a common theme across the observed medical conditions.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Role of Aspirin in the Medication Regimen:**
Based on the provided medical records, Aspirin plays a role in the management of patients with a history of **Cerebrovascular Accident (CVA)**, commonly known as a stroke. Specifically, its use is indicated for **antiplatelet therapy**, aiming to prevent further cardiovascular events.

**Associated Health Conditions:**
As observed in the documents, Aspirin is associated with the management of:
1. **History of CVA (Cerebrovascular Accident)** - Document 1 and Document 2 (under ""CHRONIC PROBLEMS"")
2. **Implicitly with Cardiovascular Health** - Inferred from its common use in preventing further cardiovascular events in patients with a history of CVA, and its co-prescription with other cardiovascular medications (e.g., Atorvastatin, Amlodipine, Carvedilol) across Documents 3, 4, and 5.

**Metadata Observations Relevant to the Question:**
- **Patient/Subject ID**: Consistently listed as **13180007** across all documents (Documents 1 through 5), indicating that the observations regarding Aspirin's role pertain to the same patient.
- **Note ID and Admission ID**: Also consistent across all documents (**Note ID: 13180007-DS-19**, **Admission ID: 20774429**), suggesting that these records are part of the same clinical encounter or admission period for the patient.

**Dosage and Administration:**
Aspirin is prescribed as **81 mg PO DAILY** in all documents where its dosage is specified (Documents 1, 2, 3, 4, and 5).","['Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D', 'Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D', '* **Medications to Take as Prescribed:**\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (30 Units Breakfast, 10 Units Lunch)\n\t3. Albuterol Inhaler 2 PUFF IH Q8H:PRN\n\t4. Amlodipine 10 mg PO DAILY\n\t5. ', '+ **Follow-up Appointments**: [NOT PROVIDED]\n* **Discharge Medications** (same as listed in the original document):\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (dosage and timing)\n\t3. Albuterol In', '1. **Medications**:\n\t* List of discharge medications (13 items, see below)\n\t* **Note**: Take all medications as prescribed\n\t* **Discharge Medications List**:\n\t\t1. Torsemide 100 mg PO DAILY\n\t\t2. 70/30 ']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What are the trends and implications of CK-MB levels in the provided patient data, considering the fluctuations observed across different time points, and how do these levels correlate with other diagnostic findings such as cardiac silhouette size and pulmonary vascular congestion?","[""2b2ce4e1-1e51-4483-8a53-32a58ee918d2\n\nleft pleural effusion. Borderline size of the cardiac silhouette\nwithout pulmonary edema. No pneumonia, no pneumothorax.  The\nlateral radiograph shows mild flattening of the hemidiaphragms,\npotentially as a consequence of functional obstruction.\nHead CT: 1. No evidence of acute intracranial abnormality.\n2. Unchanged appearance of chronic infarcts within the right\nfrontal lobe and left occipital lobe.\n3. Chronic lacunar infarcts within the right basal ganglia.\n4. Redemonstration of few calcifications within the pons,\nfindings which are unchanged in appearance and likely sequela of\nprior ischemic or inflammatory process.\n___ 11:00AM BLOOD cTropnT-0.04*\n___ 09:00PM BLOOD cTropnT-0.02*\n___ 11:00AM BLOOD %HbA1c-14.4* eAG-367*\n___ 11:00AM BLOOD Lipase-73*\n___ 11:00AM BLOOD CK-MB-4 proBNP-754*\nIMAGING:\n___ CXR -\nComparison to ___.  On today's radiograph, a small \npleural\nleft-sided calcification is seen.  There also is a small left \npleural\neffusion.  Borderline size of the cardiac silhouette without"", 'db1f4cbf-c584-4ec8-b5c0-1cf04afe2fb4\n\n___ 07:44AM BLOOD CK-MB-7 cTropnT-0.03*\n___ 05:00PM BLOOD CK-MB-7 cTropnT-0.03*\n___ 07:00AM BLOOD CK-MB-6 cTropnT-0.02*\nTFTs:\n___ 09:10AM BLOOD TSH-9.6*\n___ 07:44AM BLOOD T4-6.5 T3-118 Free T4-1.0\nIMAGING:\n========\nCXR (___):\nFINDINGS:  \nThe lung volumes are low-normal.  There is no focal \nconsolidation.  There is mild prominence of the bilateral \npulmonary vessels suggestive of volume \noverload.  The heart is top-normal in size.  There is no large \neffusion or a pneumothorax.  There is no acute osseous \nabnormality, chronic left rib \nfractures are noted. \n  \nIMPRESSION:  \nStable top-normal heart size with mild pulmonary vascular \ncongestion. \nTTE (___):\nThe left atrial volume index is normal. There is no evidence for']","Based on the provided context, here are the observations and implications of CK-MB levels in relation to other diagnostic findings:           **CK-MB Levels Over Time:**      - **11:00 AM (initial context node):** CK-MB = 4, indicating a relatively low level of cardiac muscle damage.      - **07:44 AM, 05:00 PM, and 07:00 AM (subsequent context node):** CK-MB levels were consistently higher, at 7 (07:44 AM and 05:00 PM) and slightly lower at 6 (07:00 AM), suggesting an increase in cardiac muscle damage or stress over the initial measurement.           **Correlation with Cardiac Silhouette Size:**      - **Initial Context Node:** Describes a 'borderline size of the cardiac silhouette without pulmonary edema,' which, coupled with a CK-MB of 4, might suggest minimal to no acute cardiac injury at the time of the initial assessment.      - **Subsequent Context Node:** Mentions a 'top-normal heart size' with 'mild pulmonary vascular congestion.' The increased CK-MB levels (6 and 7) here could imply worsening cardiac function or additional cardiac stress, though the heart size is described as only top-normal.           **Implications and Considerations:**      - The fluctuations in CK-MB levels, particularly the increase observed in the subsequent measurements, warrant close monitoring of cardiac function.      - The correlation between CK-MB levels and cardiac silhouette size/pulmonary vascular congestion suggests that as CK-MB increases, there is a noticeable, though mild, impact on cardiac function and pulmonary vascular status.      - Further diagnostic workup, including but not limited to serial CK-MB measurements, detailed cardiac imaging (e.g., more frequent TTE), and clinical assessment, is crucial for accurately determining the prognosis and guiding management.",custom_multi_hop_query_synthesizer,"**Response to Current Question**

**CK-MB Levels Analysis**

* **Trend Observation:** Unfortunately, the provided documents (1 through 5) do not explicitly mention CK-MB levels across different time points. Document 3 mentions ""mild troponin elevation, likely related to CKD"" under **Chest Pain**, but CK-MB levels are not specified.
* **Implications:** Without CK-MB level data, implications regarding cardiac damage or stress cannot be directly inferred from the provided documents.
* **Correlation with Other Diagnostic Findings:**
	+ **Cardiac Silhouette Size:** Not mentioned in any of the provided documents.
	+ **Pulmonary Vascular Congestion:** Not directly mentioned, but **Acute on Chronic HFpEF (Heart Failure with preserved Ejection Fraction)** in Document 3 might imply some level of fluid overload or congestion, though specifics about pulmonary vascular congestion are not provided.

**Metadata Observations (as per instructions)**

* **Patient/Subject ID:** Consistently reported as **13180007** across all documents (1 through 5).
* **Note ID and Admission ID:** Also consistent across all documents, with **Note ID: 13180007-DS-19** and **Admission ID: 20774429**.
* **Chart Time and Store Time:** Reported as **N/A** in all documents.

**Recommendation for Further Analysis**

To accurately assess the trends and implications of CK-MB levels and their correlation with cardiac silhouette size and pulmonary vascular congestion, additional documents or data points that specifically include:

1. CK-MB levels at admission, during treatment, and at discharge.
2. Cardiac imaging reports detailing cardiac silhouette size.
3. Pulmonary vascular assessments (e.g., from chest X-rays, CT scans, or clinical evaluations) would be necessary.","['**Key Findings:**\n\n* Slightly improved Hemoglobin (Hgb) level from admission (7.4 to 7.6)\n* Elevated Creatinine (Cr) level at discharge (2.9), indicating persistent renal impairment\n* Abnormal glucose', '**Key Findings:**\n\n* Slightly improved Hemoglobin (Hgb) level from admission (7.4 to 7.6)\n* Elevated Creatinine (Cr) level at discharge (2.9), indicating persistent renal impairment\n* Abnormal glucose', '* **Acute Problems Addressed**:\n\t1. **Acute on Chronic HFpEF**\n\t2. **Chest Pain** (mild troponin elevation, likely related to CKD)\n\t3. **CKD** (elevated Cr, possibly due to renal congestion)\n\t4. **Hyp', '### 3. **Acute on Chronic Kidney Disease (CKD)**\n\n* **Presentation:** Elevated Cr (2.6 from baseline 1.8-2.2)\n* **Concerns:** Renal congestion causing renal dysfunction\n* **Status at Discharge:** Cr 2', '+ Tissue Doppler: Increased LV filling pressure (PCWP > 18 mmHg)\n\t+ Diastolic Dysfunction: Grade Indeterminate\n\t+ Right Ventricular (RV) Characteristics:\n\t\t- Normal RV cavity size\n\t\t- Normal free wall']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"Whats the plan for Asthma management for this patient, espeshally with Albuterol inhaler?","['499f5ec0-b3d8-4161-93fa-07c1b6a6de75\n\ncolonoscopy report in our system previously. Iron studies from \n___ with low normal ferritin (53), low iron, low normal \nTIBC - possibly consistent with anemia of chronic disease or \ninflammation, however hard to rule out concomitant iron \ndeficiency.\n# Hypothyroidism: TSH wnl. Continued home levothyroxine.\n# Asthma: Albuterol inhaler prn continued.\nTRANSITIONAL ISSUES:\n- consideration of outpatient colonoscopy referral if not up to \ndate with screening, particularly iso chronic anemia\n- re-check BP at next PCP appointment, decision on further med \ntitration as above (?increase BB, resuming another home agent\n- ?resume Veltassa if K elevated\n- PCP: consider referral to ___ clinic\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Aspirin 81 mg PO DAILY \n2. Atorvastatin 80 mg PO QPM \n3. CloNIDine 0.4 mg PO BID \n4. HydrALAZINE 100 mg PO TID \n5. Levothyroxine Sodium 100 mcg PO DAILY']","According to the patient's record, for Asthma management, the Albuterol inhaler is to be continued on an as-needed basis (prn). No changes or additional instructions are noted in the provided context beyond this continuation.",custom_multi_hop_query_synthesizer,"**Asthma Management Plan for Patient 13180007, focusing on Albuterol Inhaler:**

**Patient Identification:**
- **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, Document 5)
- **Note ID:** 13180007-DS-19 (consistent across all documents)
- **Admission ID:** 20774429 (consistent across all documents)

**Asthma Management with Albuterol Inhaler:**

1. **Medication:** Albuterol Inhaler
2. **Dose:** 2 PUFF
3. **Frequency/Usage:**
	* **Document 1 & Document 3 & Document 4:** IH Q8H:PRN (every 8 hours as needed) for shortness of breath
	* **Document 2:** Q8H (every 8 hours), with the indication for PRN shortness of breath
	* **Document 5:** IH Q8H:PRN, specifically for shortness of breath, reinforcing the consistent PRN (as needed) basis across documents
4. **Additional Context for Asthma Management:**
	* **Document 1** mentions Asthma in the patient's medical history but only lists the Albuterol Inhaler management plan without additional asthma-specific treatments.
	* **Osteoarthritis** is also mentioned in Document 1, but no medications for it are listed in the discharge medications, which might imply a focus on managing more immediate or severe conditions like Asthma and CKD through the prescribed medications.

**Conclusion:**
The patient's Asthma management plan, as per the provided documents, primarily involves the use of an Albuterol Inhaler on an as-needed (PRN) basis for shortness of breath, with a consistent dosage of 2 PUFF every 8 hours as needed across the documents. No additional asthma-specific treatments are mentioned beyond the Albuterol Inhaler in the provided discharge medications lists.","['3. **Chronic Kidney Disease (CKD)**\n\t* Medication: Sevelamer Carbonate 800 mg PO TID W/MEALS (continued from home)\n4. **Asthma**\n\t* Medication: Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath ', '1. **Albuterol Inhaler**\n\t* Dose: 2 PUFF IH Q8H\n\t* Indication: PRN shortness of breath\n2. **Amlodipine**\n\t* Dose: 10 mg PO DAILY\n3. **Atorvastatin**\n\t* Dose: 80 mg PO QPM\n4. **Carvedilol**\n\t* Dose: 50', '* **Medications to Take as Prescribed:**\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (30 Units Breakfast, 10 Units Lunch)\n\t3. Albuterol Inhaler 2 PUFF IH Q8H:PRN\n\t4. Amlodipine 10 mg PO DAILY\n\t5. ', '+ **Follow-up Appointments**: [NOT PROVIDED]\n* **Discharge Medications** (same as listed in the original document):\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (dosage and timing)\n\t3. Albuterol In', '1. **Torsemide**\n\t* Dose: 100 mg\n\t* Frequency: PO DAILY\n\t* Additional Info: *torsemide 20 mg 5 tablet(s) by mouth once a day, Disp #*70, Tablet Refills:*0\n2. **70/30 Insulin**\n\t* Dose: \n\t\t+ 30 Units w']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What are the patient's vital signs (VS) upon discharge, and are there any notable findings in the cardiovascular examination?","['0070a23b-dc9f-483f-a66d-a8d84a4b995b\n\nCARDIOVASCULAR: Regular rate and rhythm with late ___ systolic\nmurmur at RUSB, no rubs or gallops\nLUNGS: clear to auscultation bilaterally without rhonchi,\nwheezes, or crackles\nGI: soft, nontender, without rebounding or guarding, \nnondistended\nwith normal active bowel sounds, no hepatomegaly\nEXTREMITIES: no clubbing, cyanosis, or edema\nGU: no foley\nSKIN: no rashes, petechia, lesions, or echymoses; warm to\npalpation\nNEURO: Alert and interactive to person, ___ (daughters\nstated that this is a hospital before pt named it), ___, but\nthinks that it is ___, cranial nerves II-XII intact, strength \nis\n___ in RUE, RLE, LLE, ___ in LUE elbow flexion/extension and\nhand grip. Gait is WNL, negative Romberg, negative pronator\ndrift.\nPSYCH: normal mood and affect\nDISCHARGE EXAM\nVS: 97.9 PO 151 / 65 64 18 99 RA \nGEN: Alert and interactive, comfortable, no acute distress\nHEENT: PERRL, anicteric, conjunctiva pink, oropharynx without\nlesion or exudate, moist mucus membranes, ears without lesions \nor', '29d118b8-9203-4616-bc9a-07f5566771d6\n\nVS: \n24 HR Data (last updated ___ @ 817)\n    Temp: 98.3 (Tm 98.4), BP: 136/56 (135-164/56-69), HR: 78\n(57-84), RR: 20 (___), O2 sat: 97% (95-97), O2 delivery: RA  \n24 HR Data (last updated ___ @ 817)\n    Temp: 98.3 (Tm 98.4), BP: 136/56 (135-164/56-69), HR: 78\n(57-84), RR: 20 (___), O2 sat: 97% (95-97), O2 delivery: RA  \nFluid Balance (last updated ___ @ 600) \n  Last 8 hours  Total cumulative -405ml\n    IN: Total 120ml, PO Amt 120ml\n    OUT:  Total 525ml, Urine Amt 525ml\n  Last 24 hours  Total cumulative -725ml\n    IN: Total 1000ml, PO Amt 900ml, IV Amt Infused 100ml\n    OUT:  Total 1725ml, Urine Amt 1725ml     \nWEIGHT: 74.3 kg (75.6 kg)\n \nGENERAL: Sitting up in a chair next to bed. NAD.\nNECK: JVP 7-8 cm. \nCARDIAC: Regular rate and rhythm. Normal S1, S2. Right upper\nborder systolic murmur III/VI. \nLUNGS: Respiration is unlabored with no accessory muscle use.\nCTAB. No wheezes/rales/rhonchi. \nABDOMEN: +BS. Distended but soft. Non-tender to palpation.\nEXTREMITIES: Warm. 1+ edema L > RLE.']","Upon discharge, the patient's vital signs (VS) were: Temperature (Temp) = 97.9, Pulse (PO) = 151, Blood Pressure (BP) = 65/64, Respiratory Rate (RR) = 18, Oxygen Saturation (O2 sat) = 99% on Room Air (RA). Notably, the cardiovascular examination revealed a regular rate and rhythm with a late systolic murmur at the Right Upper Sternal Border (RUSB), but no rubs or gallops were detected.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Patient's Vital Signs (VS) upon Discharge:**
* **Not explicitly provided** in any of the documents (1 through 5) as a traditional set of vital signs (e.g., temperature, pulse, blood pressure, respiratory rate, oxygen saturation).

**Notable Findings in the Cardiovascular Examination upon Discharge:**
* **Jugular Venous Pressure (JVP) of 12cm**: Indicative of potential fluid overload or cardiac dysfunction (Document 1).
* **1+ Edema to ankles bilaterally**: Suggests some degree of fluid retention (Document 1).
* **Echocardiogram/Imaging Findings** (Document 5):
	+ **Increased Left Ventricular (LV) Filling Pressure** (PCWP > 18 mmHg): Indicates diastolic dysfunction, consistent with the discharge diagnosis of acute on chronic diastolic heart failure exacerbation.
	+ **Diastolic Dysfunction: Grade Indeterminate**: Further evaluation may be needed for a definitive grading.
	+ **Normal Right Ventricular (RV) Characteristics**: Suggests that the cardiac issue may be more left-sided.
	+ **Mildly Thickened Aortic Valve Leaflets without Stenosis or Regurgitation**: A notable but non-obstructive valvular finding.

**Metadata Observations (as per instruction 3):**
* The **Patient/Subject ID (13180007)**, **Note ID (13180007-DS-19)**, and **Admission ID (20774429)** are **consistent across all five documents**, indicating they pertain to the same patient event. 
* **Chart Time** and **Store Time** are listed as **N/A** in all documents.","['* **Discharge Status:**\n\t+ Symptoms associated with volume overload had subsided, but patient was still slightly volume up on exam.\n\t+ 1+ edema to ankles bilaterally.\n\t+ JVP of 12cm.\n* **Medications a', '+ **Symptoms to Report (Danger Signs)**: Not explicitly listed under Discharge Condition, but implied to be monitored based on hospital course (e.g., worsening edema, shortness of breath, chest pain)', '* **Discharge Location**: Home With Service\n* **Facility**: [REDACTED]\n* **Discharge Diagnosis**:\n\t+ **Primary Diagnosis**: Acute on chronic diastolic heart failure exacerbation\n\t+ **Secondary Diagnos', '**Key Findings:**\n\n* Slightly improved Hemoglobin (Hgb) level from admission (7.4 to 7.6)\n* Elevated Creatinine (Cr) level at discharge (2.9), indicating persistent renal impairment\n* Abnormal glucose', '+ Tissue Doppler: Increased LV filling pressure (PCWP > 18 mmHg)\n\t+ Diastolic Dysfunction: Grade Indeterminate\n\t+ Right Ventricular (RV) Characteristics:\n\t\t- Normal RV cavity size\n\t\t- Normal free wall']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What happen to patient come to ED for asthma but family say no asthma, have weight loss, chills, hand and leg cramping, and history of CVA, what all test and meds patient have in ED?","['33441964-a7d6-441d-ac8e-c600d6bf9f69\n\nED Course:\nExam: no focal neuro deficits. \nVS: T96.1, HR 80, BP 114/50, RR 16, 99% on room air. \nLabs: TropT 0.04, proBNP: 754, Cr 2.3, WBC 5.6, Hgb 10.6\nCultures: urine culture pending. \nMeds: acetaminophen 1g, NS 500mL.\nImaging: CT head: no acute intracranial abnormality. chronic\ninfarcts. \nOn arrival to the floor, pt states that he came to the ED \nbecause\nof his asthma. His daughters are present and state that asthma \nis\nnot, in fact, the reason for his ED presentation. They also\ndescribe anorexia with weight loss. They believe that he looks\nlike he has lost weight, but no clear idea of how much. He\nendorses chills without fevers, which seems to be chronic since\nhis CVA. He has not mentioned chest pain, but has endorsed hand\nand leg cramping. He did have a transient headache which has now\nresolved. \nAt baseline, ___ work full time jobs and have\ntheir own families; pt lives with his wife, who is on HD. ___\ncomes to the house once a week, and pt is followed by RN/BSN \nfrom', ""a6e734ef-1c30-4cb6-ba6d-41227251d4d0\n\nWhen he came home to ___, he apparently thought that he was\nstill in ___, confused his wife for his daughter. On\n___ morning, he fell again. He was confused about the\nconfiguration of the bathroom (no tub in bathroom in PR), so he\ntripped and fell, called his daughter in tears (he often gets\nemotional since his CVA). She booked an appointment for same \nday,\nat which his FSBG>500, HbA1c (point of care, not in OMR) was\n15.0%. He declined to be transferred to the ED. Daughter ___\nwas on vacation from work, and so was able to check on him\nregularly. During these visits, she again established that he is\nnot taking prescribed medications. On the morning of\npresentation, pt's wife called daughter ___, concerned that \npt\nwas increasingly confused. FSBG was >500, and administered\nTresiba 50u at about 8 am. Pt called ___ about 15 minutes\nlater, at which time she again noted confusion and slurred\nspeech, which has intermittently been present since his CVA.\nDecision was made to bring him to the ED. \nOf note, during his last hospitalization ___, he had an\nepisode of dysarthria with confusion and mild expressive and\nreceptive aphasia for which code stroke was called. MRI/MRA \nbrain\nand EEG were unrevealing, with chronic changes and EEG slowing\nonly. He was continued on ASA and atorvastatin.""]","Patient, with history of CVA, presented to ED with claimed asthma, but family denied this, reporting anorexia with weight loss instead. Key findings and actions in ED include:      * **Exam:** No focal neuro deficits.      * **Vital Signs (VS):** T96.1, HR 80, BP 114/50, RR 16, 99% on room air.      * **Labs:** TropT 0.04 (indicating no acute myocardial infarction), proBNP 754 (elevated, suggesting heart failure), Cr 2.3 (elevated, indicating renal impairment), WBC 5.6 (within normal range), Hgb 10.6 (mild anemia). Urine culture pending.      * **Meds Administered in ED:** Acetaminophen 1g, Normal Saline (NS) 500mL.      * **Imaging:** CT head showed no acute intracranial abnormality but chronic infarcts.      * **Symptoms:** Chills without fevers (chronic since CVA), hand and leg cramping, transient headache (now resolved). No chest pain.      * **Pre-ED Context:** Had an episode of confusion, slurred speech, and hyperglycemia (FSBG>500, HbA1c 15.0%) before ED arrival. Was on Tresiba 50u. History of similar neurological episodes, including dysarthria, confusion, and aphasia, during last hospitalization with unrevealing MRI/MRA and EEG, leading to continued ASA and atorvastatin.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and the content of the documents, I must point out that the question you've asked doesn't directly relate to the information provided in the documents. The question pertains to a patient presenting to the ED with symptoms (asthma denial by family, weight loss, chills, hand and leg cramping, and a history of CVA) that are not described in the content of the provided documents (Document 1 through Document 5). However, I will attempt to provide a structured response that adheres to your instructions as closely as possible, highlighting the discrepancy and providing any tangentially relevant information from the documents.

### Response Structure:

1. **IDs and Dates (Metadata Analysis)**
2. **Relevant Content from Documents (if applicable)**
3. **Addressing the Question Directly**
4. **Speculative Approach to the Question (given the mismatch)**

### 1. IDs and Dates (Metadata Analysis)

- **Patient/Subject ID:** 13180007 (consistent across all documents)
- **Note ID:** 13180007-DS-19 (consistent across all documents)
- **Admission ID:** 20774429 (consistent across all documents)
- **Chart Time & Store Time:** N/A (consistent across all documents)

### 2. Relevant Content from Documents (if applicable)

- **Asthma Mention:** Document 1 mentions ""Asthma"" with a medication (Albuterol Inhaler) continued from home. **No mention of weight loss, chills, hand and leg cramping, or CVA in any document.**

### 3. Addressing the Question Directly

- **Tests and Meds for the Described ED Visit:** Since the symptoms (weight loss, chills, hand and leg cramping, and history of CVA) and the context (denial of asthma by family) are not described in the provided documents, **there is no direct information available to answer this question** based on the given documents.

### 4. Speculative Approach to the Question (given the mismatch)

- **Hypothetical ED Approach for the Described Symptoms:**
  - **Tests Might Include:**
    - Complete Blood Count (CBC) for infection or blood disorders
    - Basic Metabolic Panel (BMP) and Comprehensive Metabolic Panel (CMP) for electrolyte imbalance (given hand and leg cramping)
    - Renal Function Tests (already a concern with CKD mentioned in Document 1)
    - Imaging for CVA history if relevant to current symptoms (e.g., CT/MRI of the brain)
    - Possibly a Chest X-Ray for respiratory symptoms if asthma or another condition is suspected
  - **Meds Might Include (Speculative, Based on Symptoms Alone):**
    - For chills and potential infection: Antibiotics (type dependent on diagnosis)
    - For hand and leg cramping: Electrolyte supplements (e.g., potassium, magnesium)
    - For weight loss and depending on underlying cause: Nutritional support
    - **Note:** These are highly speculative and not grounded in the provided documents.

**Conclusion:** The provided documents do not contain information about the patient's ED visit for the described symptoms (weight loss, chills, hand and leg cramping, and history of CVA with family denial of asthma). Any response to the question about specific tests and medications for this scenario would be speculative and not based on the content of Documents 1 through 5.","['3. **Chronic Kidney Disease (CKD)**\n\t* Medication: Sevelamer Carbonate 800 mg PO TID W/MEALS (continued from home)\n4. **Asthma**\n\t* Medication: Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath ', '+ **Symptoms to Report (Danger Signs)**: Not explicitly listed under Discharge Condition, but implied to be monitored based on hospital course (e.g., worsening edema, shortness of breath, chest pain)', '**Additional Medication Administration on Admission:**\n\n* **IV Lasix 80mg** (received in the ED, as mentioned in the History of Present Illness section)', '* **Presentation:** Dyspnea, lower extremity edema, volume overload\n* **Trigger:** Unclear, possible medication non-compliance\n* **Findings:**\n\t+ EF 65% (TTE)\n\t+ Diastolic dysfunction\n\t+ Iron studies:', '* **Discharge Status:**\n\t+ Symptoms associated with volume overload had subsided, but patient was still slightly volume up on exam.\n\t+ 1+ edema to ankles bilaterally.\n\t+ JVP of 12cm.\n* **Medications a']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
Wha CK-MB level mean for patient wit chest pain but no ischemia sign?,"[""2b2ce4e1-1e51-4483-8a53-32a58ee918d2\n\nleft pleural effusion. Borderline size of the cardiac silhouette\nwithout pulmonary edema. No pneumonia, no pneumothorax.  The\nlateral radiograph shows mild flattening of the hemidiaphragms,\npotentially as a consequence of functional obstruction.\nHead CT: 1. No evidence of acute intracranial abnormality.\n2. Unchanged appearance of chronic infarcts within the right\nfrontal lobe and left occipital lobe.\n3. Chronic lacunar infarcts within the right basal ganglia.\n4. Redemonstration of few calcifications within the pons,\nfindings which are unchanged in appearance and likely sequela of\nprior ischemic or inflammatory process.\n___ 11:00AM BLOOD cTropnT-0.04*\n___ 09:00PM BLOOD cTropnT-0.02*\n___ 11:00AM BLOOD %HbA1c-14.4* eAG-367*\n___ 11:00AM BLOOD Lipase-73*\n___ 11:00AM BLOOD CK-MB-4 proBNP-754*\nIMAGING:\n___ CXR -\nComparison to ___.  On today's radiograph, a small \npleural\nleft-sided calcification is seen.  There also is a small left \npleural\neffusion.  Borderline size of the cardiac silhouette without"", 'd2113a66-fe4f-4869-b3c0-73646862b32b\n\ngluconate (received 3 doses ___. Upon review of recent \noutpatient visit notes, it appears his volume exam is similar to \nbaseline, and patient was asymptomatic during hospital course. \nHe was diuresed effectively with IV Lasix 80. He was \ntransitioned to PO torsemide 100. His BP was well controlled \nwith regimen as described below.\n# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\nat or lower than levels earlier this year. He has denied chest\npain during admission. He does have risk factors for ischemia \nand\nhas not had stress since ___. However, findings and history \nto\ndate are not suggestive of ischemia and he has an ___. TTE did \nnot show evidence of focal wall motion abnormalities or other \nfindings suggestive of ischemia, so further workup was not \npursued. He was continued on ASA and atorvastatin.\n# ___ on CKD:\nCr elevated to 2.6 on admission from baseline of 1.8-2.2. Given\nevidence of congestion elsewhere, concerns for renal congestion\ncausing renal dysfunction. Cr remained stable and was 2.9 on day \nof discharge. He was continued on home sevelamer.']","Patient have flat CK-MB with mild troponin elevation. CK-MB level specifically mentioned as 4. This, combined with other findings, not suggestive of ischemia. Patient continued on ASA and atorvastatin. Note: CK-MB interpretation in context of patient's Chronic Kidney Disease (CKD) should be considered, though direct implications not detailed in provided context.",custom_multi_hop_query_synthesizer,"Based on the provided instructions, I'll address the question step by step, focusing on the requested information about the CK-MB level for a patient with chest pain but no ischemia signs.

**Question Breakdown:**
- **What does the CK-MB level mean** for a patient with:
  1. **Chest Pain**
  2. **No ischemia signs**

**Relevant Document Identification (Based on Metadata and Content Relevance):**
- **Patient/Subject ID:** 13180007 (consistent across all documents, indicating they all pertain to the same patient)
- **Relevant Documents for Question:**
  - **Document 1** and **Document 2** (both contain information about chest pain and relevant test findings, including CK-MB)

**Answer to the Question:**

1. **Presence of Chest Pain and No Ischemia Signs:**
   - **Confirmed in:** Document 1 and Document 2, under ""**2. Chest Pain**""
   - **Key Finding:** ""TTE: No focal wall motion abnormalities or signs of ischemia""

2. **CK-MB Level Meaning in This Context:**
   - **CK-MB Level Mentioned in:** Document 1 and Document 2, under ""**Findings**"" for Chest Pain
   - **CK-MB Result:** ""Flat CK-MB""
   - **Interpretation in Context:**
     - **""Flat CK-MB""** suggests that the CK-MB enzyme levels were not significantly elevated. CK-MB is a marker used to assess heart damage, among other things. Elevated levels often indicate myocardial infarction (heart attack) or other cardiac injuries.
     - **In the context of this patient with chest pain but no signs of ischemia (as per TTE findings), a ""flat"" (essentially, normal or not significantly elevated) CK-MB level supports the clinical interpretation that the chest pain is unlikely due to an acute myocardial infarction or significant heart muscle damage.** The presence of CKD (Chronic Kidney Disease) and the mention of mild troponin elevation (0.03) with levels similar to prior months, further complicate the heart-related diagnostic picture, but the flat CK-MB specifically points away from acute cardiac muscle injury as the cause of the chest pain.

**Metadata Values for Context (as per instruction 2):**
- **Patient/Subject ID:** 13180007
- **Note ID:** 13180007-DS-19 (common across all documents, indicating these are parts of the same note or assessment)
- **Admission ID:** 20774429 (consistent across documents, linking to the same admission)","['### 2. **Chest Pain**\n\n* **Presentation:** Chest pain with mild troponin elevation (0.03)\n* **Interpretation:** Difficult due to CKD, levels similar to prior months\n* **Findings:**\n\t+ No evidence of d', '### 2. **Chest Pain**\n\n* **Presentation:** Chest pain with mild troponin elevation (0.03)\n* **Interpretation:** Difficult due to CKD, levels similar to prior months\n* **Findings:**\n\t+ No evidence of d', '* **Acute Problems Addressed**:\n\t1. **Acute on Chronic HFpEF**\n\t2. **Chest Pain** (mild troponin elevation, likely related to CKD)\n\t3. **CKD** (elevated Cr, possibly due to renal congestion)\n\t4. **Hyp', '+ **Symptoms to Report (Danger Signs)**: Not explicitly listed under Discharge Condition, but implied to be monitored based on hospital course (e.g., worsening edema, shortness of breath, chest pain)', '**Key Findings:**\n\n* Slightly improved Hemoglobin (Hgb) level from admission (7.4 to 7.6)\n* Elevated Creatinine (Cr) level at discharge (2.9), indicating persistent renal impairment\n* Abnormal glucose']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What are the key findings from the patient's Transthoracic Echocardiogram (TTE) regarding ventricular function, valve conditions, and comparisons to prior TTE results, from a medical researcher's analytical perspective?","['6947fbec-1aff-4c0a-8eb5-fe9953adbb08\n\nventricular cavity size with normal free wall motion. The aortic \nsinus diameter is normal for gender with normal ascending aorta \ndiameter for gender. The aortic valve leaflets (3) appear \nstructurally normal. There is no aortic valve stenosis. There is \ntrace aortic regurgitation. The mitral valve leaflets appear \nstructurally normal with no mitral valve prolapse. There is \ntrivial mitral regurgitation. The pulmonic valve leaflets are \nnormal. The tricuspid valve leaflets appear structurally normal. \nThere is physiologic tricuspid regurgitation. The pulmonary \nartery systolic pressure could not be estimated. There is a \ntrivial pericardial effusion.\nIMPRESSION: Mild symmetric left ventricular hypertrophy with \nnormal cavity size and regional/global biventricular systolic \nfunction. No significant mitral regurgitation.\nCompared with the prior TTE ___, the findings are \nsimilar.\nMRI/MRA HEAD AND NECK (___)\nIMPRESSION:\n \n \n1. No hemorrhage or acute infarct.\n2. Chronic infarcts within the subcortical right frontal lobe \nand left\ntemporal and occipital lobes.\n3. Atrophic pons likely a sequela of prior infarcts.', 'db1f4cbf-c584-4ec8-b5c0-1cf04afe2fb4\n\n___ 07:44AM BLOOD CK-MB-7 cTropnT-0.03*\n___ 05:00PM BLOOD CK-MB-7 cTropnT-0.03*\n___ 07:00AM BLOOD CK-MB-6 cTropnT-0.02*\nTFTs:\n___ 09:10AM BLOOD TSH-9.6*\n___ 07:44AM BLOOD T4-6.5 T3-118 Free T4-1.0\nIMAGING:\n========\nCXR (___):\nFINDINGS:  \nThe lung volumes are low-normal.  There is no focal \nconsolidation.  There is mild prominence of the bilateral \npulmonary vessels suggestive of volume \noverload.  The heart is top-normal in size.  There is no large \neffusion or a pneumothorax.  There is no acute osseous \nabnormality, chronic left rib \nfractures are noted. \n  \nIMPRESSION:  \nStable top-normal heart size with mild pulmonary vascular \ncongestion. \nTTE (___):\nThe left atrial volume index is normal. There is no evidence for']","Based on the provided TTE findings, the key observations include:  1. **Mild symmetric left ventricular hypertrophy** with normal cavity size. 2. **Normal regional/global biventricular systolic function**. 3. **Structurally normal valve leaflets** for aortic, mitral, pulmonic, and tricuspid valves. 4. **Trace aortic regurgitation** and **trivial mitral regurgitation** with **physiologic tricuspid regurgitation**. 5. A **trivial pericardial effusion** was noted. 6. **Comparison to prior TTE** shows similar findings, indicating stability in the observed conditions. These findings suggest a relatively stable cardiac condition with some minor abnormalities, but no significant deterioration or new major issues compared to the previous TTE.",custom_multi_hop_query_synthesizer,"**Analytical Response as a Medical Document Assistant**

**Patient Identification:**
* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, 2, 3, 4, and 5)
* **Note ID:** 13180007-DS-19 (consistent across all documents, indicating these are related notes)
* **Admission ID:** 20774429 (consistent across all documents, confirming a single admission period for these findings)

**Key TTE Findings:**

### **Ventricular Function:**
* **Left Ventricular (LV) Characteristics:**
	+ Mild symmetric LV hypertrophy
	+ Normal cavity size
	+ Normal regional and global LV systolic function
	+ **Visually estimated LV Ejection Fraction (EF): 65%** (Document 1, 2, and referenced in Document 5)
* **Right Ventricular (RV) Function:** Not directly described in terms of hypertrophy or systolic function, but:
	+ **Estimated Right Atrial Pressure:** [NOT PROVIDED] (Document 1 and 2)
	+ **Pulmonary Artery Systolic Pressure:** Normal (Document 3 and 4)
	+ **Physiologic Tricuspid Regurgitation** suggests some degree of normal RV function (Document 3 and 4)

### **Valve Conditions:**
* **Mitral Valve Leaflets:** Mildly thickened, trivial regurgitation, no prolapse (Document 3 and 4)
* **Pulmonic Valve Leaflets:** Normal (Document 3 and 4)
* **Tricuspid Valve Leaflets:** Structurally normal, physiologic regurgitation (Document 3 and 4)
* **No resting Left Ventricular Outflow Tract (LVOT) gradient** (Document 1 and 2)

### **Comparisons to Prior TTE Results:**
* **No prior TTE results** are provided within these documents for direct comparison.

### **Additional Insights from Non-TTE Findings:**
* **Diastolic Dysfunction** noted in Document 5, which, in conjunction with the TTE findings, provides a more comprehensive view of the patient's cardiac function.
* **Small Pericardial Effusion** and **Increased Respiratory Variation in Transmitral/Transtricuspid Inflow** (Document 3 and 4) offer additional context to the patient's cardiac status.

**Limitations and Recommendations for Further Analysis:**
- The absence of prior TTE results limits the ability to assess changes in cardiac function over time.
- The lack of detailed right ventricular function assessment and the non-provided estimated right atrial pressure value (Document 1 and 2) are notable gaps in the comprehensive evaluation of ventricular function.
- Consider integrating laboratory results (e.g., iron studies from Document 5) with imaging findings for a holistic patient assessment.","['* **Echocardiogram (TTE) Findings:**\n\t+ Left Atrial Volume Index: Normal\n\t+ Estimated Right Atrial Pressure: **[NOT PROVIDED]**\n\t+ Left Ventricular (LV) Characteristics:\n\t\t- Mild symmetric LV hypertro', '* **Echocardiogram (TTE) Findings:**\n\t+ Left Atrial Volume Index: Normal\n\t+ Estimated Right Atrial Pressure: **[NOT PROVIDED]**\n\t+ Left Ventricular (LV) Characteristics:\n\t\t- Mild symmetric LV hypertro', '+ **Mitral Valve Leaflets**: Mildly thickened, trivial regurgitation, no prolapse\n\t+ **Pulmonic Valve Leaflets**: Normal\n\t+ **Tricuspid Valve Leaflets**: Structurally normal, physiologic regurgitation', '+ **Mitral Valve Leaflets**: Mildly thickened, trivial regurgitation, no prolapse\n\t+ **Pulmonic Valve Leaflets**: Normal\n\t+ **Tricuspid Valve Leaflets**: Structurally normal, physiologic regurgitation', '* **Presentation:** Dyspnea, lower extremity edema, volume overload\n* **Trigger:** Unclear, possible medication non-compliance\n* **Findings:**\n\t+ EF 65% (TTE)\n\t+ Diastolic dysfunction\n\t+ Iron studies:']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What are the key considerations and current plans for managing the patient's cardiovascular health, particularly regarding the known inducible ischemia in the LCX distribution, in the context of their complex medical history including CKD and recent medication adjustments?","['3854e9c9-f299-4327-94b1-3dc260a4fc6f\n\nLying HR: 68 RR: 20 O2 sat: 98% O2 delivery: 3LNC Dyspnea: 3\nRASS: 0 Pain Score: ___ \n \n  Of note, since ___, he has had known inducible ischemia on\nLCX distribution from stress test. The risks (including dialysis\nafter contrast load) and benefits were discussed with primary\ncardiologist Dr. ___. Coronary angiogram was deferred. \n  He also had a recent admission to the heart failure service\nwith uptitration of blood pressure control agents. Coronary\nangiogram was deferred at that time. ACEi was stopped (prior\nlisinopril 40mg) given worsened CKD vs ___.  Low dose lisinopril\nwas reinitiated at last visit with Dr. ___. \n  Multiple notes in OMR describe issues with ensuring consistent\nsupply of medications. The patient and his family confirm this.\nHowever, they state recently no change in medications, ___ comes\nonce per week.  He describes his diet as healthy but family\nconcerned about salt intake. No h/o arrhythmia, no palpitations. \n On the floor, he reports ongoing mild wheeze, improving\nshortness of breath, no current chest pain. \nREVIEW OF SYSTEMS:  \nPositive per HPI.', '4b3d7a96-6534-434e-8295-b8356c5ca64d\n\nbasal/bolus four times daily regimen. However, this is not a \nsustainable regimen for patient on discharge. Discussed \npossibility of switching to 70/30 mix BID, however currently \npatient cannot be guaranteed to eat regular meal after each \ninsulin injection therefore currently not a tenable plan. In the \nfuture, if patient able to be placed in a day program, \npotentially could switch to this but for now will we continued \nhis prior home regimen (EXCEPT for Jardiance, which was \ndiscontinued due to contraindication with chronic kidney \ndisease) on discharge, with very close ___ follow-up and ___ \nservices to help increase compliance. With regards to his more \nsubacute mental status decompensation, would benefit from \nreferral for outpatient neurocognitive evaluation.\n# Hx of CAD: \n# Hx of ischemic CVA:\nStress test in ___ with area of inducible ischemia in LCx \ndistribution, in setting of multiple risk factors. Has been \nmedically optimized by prescribed medications, but as above it \nseems that pt has been taking these medications. TnT 0.04->0.02 \nin setting of CKD stage III-IV. Continued home aspirin, \natorvastatin, and carvedilol. Note that he was once on \nlisinopril (most recently filled in ___ for 2.5mg dose) \nhowever seems that this has since been discontinued.\n# CKD stage III:']","The patient has known inducible ischemia in the LCX distribution from a previous stress test, alongside multiple risk factors. Management considerations include:         - **Coronary Angiogram Deferral**: Recently deferred due to risks, including dialysis after contrast load, as discussed with Dr. ___.        - **Medication Adjustments**:           - **ACEi (Lisinopril)**: Initially stopped due to worsened CKD, then reinitiated at a low dose.          - **Continued Medications**: Home aspirin, atorvastatin, and carvedilol are continued.          - **Discontinued**: Jardiance, due to contraindication with chronic kidney disease.        - **Future Plans**: Potential switch to a more sustainable insulin regimen (e.g., 70/30 mix BID) if the patient can be placed in a day program, emphasizing close follow-up and compliance services upon discharge.        - **Additional Recommendations**: Outpatient neurocognitive evaluation for subacute mental status decompensation.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, here's a structured response to the question, highlighting key considerations and plans for managing the patient's cardiovascular health, given the context:

**Response**

* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, 2, 3, 4, and 5)
* **Note ID and Admission ID:** Both are consistent across all documents (Note ID: 13180007-DS-19, Admission ID: 20774429), indicating these documents pertain to the same hospital admission.

**Key Considerations for Cardiovascular Health:**

1. **Complex Medical History:**
	* **CKD (Chronic Kidney Disease):** Elevated Cr levels (2.6 from baseline 1.8-2.2, increased to 2.9 at discharge) indicate ongoing renal dysfunction. (Document 1 & 2)
	* **Hypertension:** History of hypertension, currently well-controlled with Amlodipine 10, Coreg 50 BID, and Minoxidil 10 daily. (Document 1 & 2)
	* **HFpEF (Heart Failure with preserved Ejection Fraction):** EF 55-60%, with a recent exacerbation. (Document 4 & 5)
	* **IDDM (Insulin-Dependent Diabetes Mellitus):** Poorly controlled, with an A1c of 11.4%. (Document 4)
	* **Carotid Artery Disease and Prior CVA (Cerebrovascular Accident):** Highlighted in the patient's profile. (Document 5)
2. **Recent Medication Adjustments and Interventions:**
	* **IV Lasix 80mg:** Administered on admission for HF exacerbation, with symptoms improving. (Document 3 & 5)
	* **Discharge Medication for Diuresis:** Torsemide 100 daily. (Document 5)
	* **Continued Medications:** Sevelamer for CKD, Amlodipine, Coreg, and Minoxidil for hypertension. (Document 1 & 2)

**Known Inducible Ischemia in the LCX Distribution:**
* **No Direct Mention:** In the provided documents, there is no direct mention of known inducible ischemia in the LCX (Left Circumflex) distribution or specific plans for its management in the context of the patient's complex medical history and recent medication adjustments.

**Current Plans for Managing Cardiovascular Health (as per provided documents):**
* **Symptomatic Management of HFpEF:** With torsemide for active diuresis, addressing recent exacerbation. (Document 5)
* **Control of Hypertension:** Continued management with current medications. (Document 1 & 2)
* **Management of CKD:** Continued use of Sevelamer. (Document 1 & 2)
* **No Documented Plan for Inducible Ischemia in LCX Distribution:** Suggests a need for further clinical evaluation or documentation not included in the provided set.

**Recommendation for Further Action:**
Given the absence of information regarding the management of known inducible ischemia in the LCX distribution within the provided documents, it is recommended to:
- Consult additional medical records or imaging studies for specific plans or recommendations related to this condition.
- Evaluate the patient's current cardiovascular risk profile, considering the complex medical history, to potentially adjust management strategies for optimal outcomes.","['### 3. **Acute on Chronic Kidney Disease (CKD)**\n\n* **Presentation:** Elevated Cr (2.6 from baseline 1.8-2.2)\n* **Concerns:** Renal congestion causing renal dysfunction\n* **Status at Discharge:** Cr 2', '### 3. **Acute on Chronic Kidney Disease (CKD)**\n\n* **Presentation:** Elevated Cr (2.6 from baseline 1.8-2.2)\n* **Concerns:** Renal congestion causing renal dysfunction\n* **Status at Discharge:** Cr 2', '**Additional Medication Administration on Admission:**\n\n* **IV Lasix 80mg** (received in the ED, as mentioned in the History of Present Illness section)', '* **Acute Problems Addressed**:\n\t1. **Acute on Chronic HFpEF**\n\t2. **Chest Pain** (mild troponin elevation, likely related to CKD)\n\t3. **CKD** (elevated Cr, possibly due to renal congestion)\n\t4. **Hyp', '* **Patient Profile**: ___ male with history of HFpEF (EF 55-60%), prior CVA, CKD, DM, hypertension, and carotid artery disease\n* **Presentation**: 1 day of dyspnea and discomfort, admitted for HF exa']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
What is the prescribed dosage of hydralazine for a patient with acute on chronic heart failure and hypertension?,"['5d1619ab-197a-416d-b0af-616eff82199c\n\n#*60 Tablet Refills:*0 \n12.  HydrALAZINE 100 mg PO TID \nRX *hydralazine 100 mg 1 tablet(s) by mouth three times a day \nDisp #*90 Tablet Refills:*0 \n13.  Levothyroxine Sodium 100 mcg PO DAILY \nRX *levothyroxine 100 mcg 1 tablet(s) by mouth once a day Disp \n#*30 Tablet Refills:*0 \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPRIMARY DIAGNOSIS\n==================\nAcute on chronic heart failure with preserved ejection fraction\nSECONDARY DIAGNOSES\n====================\nAcute kidney injury\nCoronary artery disease\nType 2 Diabetes Mellitus\nHyperkalemia', '71b11357-64d1-43f3-b5b3-9e2b962adaf4\n\n# Volume overload\n# HFpEF, LVEF 55-60% in ___\nVolume overload on exam. Diuresis began while in ICU, net \nnegative 1.8L prior to transfer. Dry weight appears to be \n154-157. s/p Lasix 80mg x 2 so far. 163.4 lb on ___ A-Strict \nI/Os, daily weights. Continued home carvedilol at increased dose \nas below. He was sent home with PO 60 mg Lasix daily and was net \neven in the hospital. \n# HTN\nBlood pressure medications initially held when he was started on \npropofol. Anti-HTN meds started on day of transfer. Persistently \nhypertensive. Increased carvedilol to 50 mg BID and increased \nminoxidil to 5 mg and continued amlodipine 10 mg QD. Of note, he \nhad been on clonidine and hydralazine but these were stopped by \nPCP just prior to admission. He remained mostly normotensive \nalthough goal SBP <130 and should continue to be goal as an \noutpatient. \n# Normocytic Anemia\nBaseline of ___, secondary to CKD and possible AoCD. Required \n1u pRBC on arrival. Hb stable. \nCHRONIC ISSUES:']","According to the provided medical context, the patient was previously on hydralazine but it was stopped by the PCP just prior to admission. However, a past prescription for hydralazine is mentioned in one of the discharge medications lists as: '12. HydrALAZINE 100 mg PO TID' which translates to 'hydralazine 100 mg, 1 tablet by mouth three times a day'. Please note, this might not reflect the current treatment plan as the medication was stopped prior to the described hospital stay.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

* **Prescribed Dosage of Hydralazine for a Patient with Acute on Chronic Heart Failure and Hypertension:**
	+ **Result:** NOT FOUND
	+ **Rationale:**
		- The condition ""Acute on Chronic Heart Failure"" is hinted at in Document 3 and Document 4 under ""Possible Causes"" for **Acute on Chronic Anemia**, but it is not explicitly listed as a condition with management details.
		- **Hydralazine** is not mentioned at all in any of the provided documents (Document 1 through Document 5) as part of the medication lists for the patient's conditions, including **Hypertension**.
		- For **Hypertension** (listed in Document 1 and Document 2), the prescribed medications are Amlodipine, Carvedilol, and Minoxidil, with their respective dosages. However, Hydralazine is not among them.

**Additional Observations Based on Instructions**

1. **IDs and Dates:**
	* **Patient/Subject ID:** Consistently listed as `13180007` across all documents.
	* **Note ID:** Identical across all documents as `13180007-DS-19`.
	* **Admission ID:** Same in all documents as `20774429`.
	* **Chart Time & Store Time:** Listed as `N/A` in all documents.
2. **Reporting Exact ID Values and Consistency:**
	* As observed, the IDs are consistent across all documents, with no variations.
3. **Prioritizing Metadata over Content for ID Values:**
	* Since the question about Hydralazine dosage doesn't involve ID values but rather medication dosage (which is part of the content), the answer is derived from the content. However, it's noted that for ID-related queries, the metadata would be the primary reference.","['1. **Hypertension**\n\t* Medications: \n\t\t+ Amlodipine 10 mg PO DAILY (continued from home)\n\t\t+ Carvedilol 50 mg PO BID (continued from home)\n\t\t+ Minoxidil 10 mg PO DAILY (continued from home)\n2. **Diabe', '1. **Hypertension**\n\t* Medications: \n\t\t+ Amlodipine 10 mg PO DAILY (continued from home)\n\t\t+ Carvedilol 50 mg PO BID (continued from home)\n\t\t+ Minoxidil 10 mg PO DAILY (continued from home)\n2. **Diabe', '### 5. **Acute on Chronic Anemia**\n\n* **Presentation:** Hb 7.4 on admission\n* **Possible Causes:** Worsening renal function or dilutional iso heart failure\n* **Management:**\n\t+ Received 3 doses of Fer', '### 5. **Acute on Chronic Anemia**\n\n* **Presentation:** Hb 7.4 on admission\n* **Possible Causes:** Worsening renal function or dilutional iso heart failure\n* **Management:**\n\t+ Received 3 doses of Fer', '1. **Albuterol Inhaler**\n\t* Dose: 2 PUFF IH Q8H\n\t* Indication: PRN shortness of breath\n2. **Amlodipine**\n\t* Dose: 10 mg PO DAILY\n3. **Atorvastatin**\n\t* Dose: 80 mg PO QPM\n4. **Carvedilol**\n\t* Dose: 50']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What are the key considerations for a Clinical Care Coordinator managing a patient with Mild Aortic Regurgitation (Mild AR) alongside other cardiac risk factors and extensive intracranial atherosclerosis, in terms of preventing repeated hospital admissions and managing home medications?","['07c9a41e-be29-4f49-810c-9cfabe64e237\n\nInterventions: \n3L LR, Vanc/Cefepime/Flagyl, insulin gtt, Propofol (changed to\nmidazolam for hypotension), fentanyl \nVS Prior to Transfer: temp 96.2, HR 61, BP 109/54, RR 24, O2 sat\n99% Intubation \nROS: Positives as per HPI; otherwise negative.  \n \n \nPast Medical History:\n1. CARDIAC RISK FACTORS  \n- Type 2 Diabetes Mellitus\n- Hypertension  \n- Dyslipidemia  \n- Coronary artery disease\n2. CARDIAC HISTORY  \n- Secondum ASD\n- Mild AR\n3. OTHER PAST MEDICAL HISTORY  \n- Extensive intracranial atherosclerosis, worse in the right\nMCA territory.\n- Cerebrovascular disease, status post CVA in ___\n- Asthma\n- OSteoarthritis', '2fefbd11-fef9-45c9-8e5f-7c57ff45ef50\n\nCase Management, ___, as outpatient. ___ and\n___ both feel that their father needs increased services at\nhome to prevent repeated admissions. They are both providing as\nmuch support as they can, in the setting of having their own \nfull\ntime jobs and families. ___ expresses concern that his home\nmedications will be resumed/uptitrated without the understanding\nthat he is not, in fact, taking them as prescribed; she\nrecognizes that this could result in major adverse events, if \nall\nhome medications were to be resumed at the same time in the\nhospital.\n \nPast Medical History:\n1. CARDIAC RISK FACTORS  \n- Type 2 Diabetes Mellitus\n- Hypertension  \n- Dyslipidemia  \n- Coronary artery disease\n2. CARDIAC HISTORY  \n- Secondum ASD\n- Mild AR\n3. OTHER PAST MEDICAL HISTORY  \n- Extensive intracranial atherosclerosis, worse in the right\nMCA territory.']","Based on the provided context, key considerations for managing such a patient include:  1. **Close Monitoring of Cardiac Condition**: Given the patient's history of Mild AR, Secondary ASD, Type 2 Diabetes Mellitus, Hypertension, Dyslipidemia, and Coronary Artery Disease, careful monitoring of cardiac health is crucial. 2. **Management of Intracranial Atherosclerosis**: The patient's extensive intracranial atherosclerosis, particularly worse in the right MCA territory, and history of CVA, necessitate careful management to prevent further cerebrovascular events. 3. **Preventing Repeated Admissions**: Increasing home services, as suggested by the patient's family, could help in preventing repeated hospital admissions by providing adequate support and monitoring. 4. **Safe Management of Home Medications**: It is critical to understand the patient's adherence to prescribed medications before resuming or uptitrating them post-hospitalization to avoid major adverse events. A tailored approach to medication management, possibly including education on proper medication use, is essential.",custom_multi_hop_query_synthesizer,"Based on the provided documents, here's a structured answer to the question, following the given instructions:

**Patient Identification for Context:**
* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, and Document 5)
* **Note ID:** 13180007-DS-19 (consistent across all documents)
* **Admission ID:** 20774429 (consistent across all documents)

**Key Considerations for Clinical Care Coordinator:**

Given the patient's conditions, as inferred from the documents (primarily Documents 1, 3, 4, and 5, since Document 2 is a duplicate of Document 1), the key considerations for managing a patient with **Mild Aortic Regurgitation (Mild AR)** alongside other mentioned conditions (e.g., **Carotid Artery Disease**, **Secundum ASD**, **Acute on Chronic Kidney Disease (CKD)**, **Hypertension**, **Acute on Chronic Anemia**, **Asthma**, and **Osteoarthritis**) to prevent repeated hospital admissions and manage home medications are:

1. **Multidisciplinary Care Team Engagement:**
	* Collaborate with cardiologists for **Mild AR**, **Carotid Artery Disease**, and **Secundum ASD** management.
	* Involve nephrologists for **Acute on Chronic Kidney Disease (CKD)**, ensuring optimal **Sevelamer** use.
	* Engage primary care for overall **Hypertension** management (e.g., **Amlodipine**, **Coreg**, **Minoxidil**).

2. **Medication Management and Adherence:**
	* **Home Medication List Review:** Ensure the patient understands and adheres to medications for all conditions, including **Sevelamer** for CKD, **Amlodipine**, **Coreg**, **Minoxidil** for hypertension, and **Albuterol Inhaler** for **Asthma**.
	* **Potential Interactions:** Monitor for potential interactions between medications for different conditions.

3. **Regular Monitoring and Follow-Ups:**
	* Schedule regular check-ups with relevant specialists to monitor the progression of **Mild AR**, **CKD**, **Hypertension**, and other conditions.
	* Implement a system for tracking **Cr (Creatinine)** levels, blood pressure, and other vital signs indicative of disease progression.

4. **Lifestyle Modifications and Patient Education:**
	* **Dietary Counseling:** For managing **CKD** and **Hypertension**.
	* **Exercise Plan:** Tailored to the patient's capabilities, considering **Osteoarthritis** and cardiac conditions.
	* **Smoking Cessation and Alcohol Reduction Strategies:** If applicable, to reduce overall cardiovascular and renal risk.

5. **Emergency Preparedness:**
	* Ensure the patient has a clear plan for emergency situations, including when to seek immediate medical attention for worsening symptoms of any condition.

**Preventing Repeated Hospital Admissions:**
- Close monitoring of condition progression.
- Proactive management of complications.
- Enhanced patient education on self-care and recognizing worsening symptoms.
- Regular multidisciplinary team reviews to adjust care plans as needed.","['6. **Carotid Artery Disease** (mentioned in Past Medical History, no specific medications listed in discharge medications)\n7. **Secundum ASD (Atrial Septal Defect)** (mentioned in Past Medical History', '6. **Carotid Artery Disease** (mentioned in Past Medical History, no specific medications listed in discharge medications)\n7. **Secundum ASD (Atrial Septal Defect)** (mentioned in Past Medical History', '### 3. **Acute on Chronic Kidney Disease (CKD)**\n\n* **Presentation:** Elevated Cr (2.6 from baseline 1.8-2.2)\n* **Concerns:** Renal congestion causing renal dysfunction\n* **Status at Discharge:** Cr 2', '### 3. **Acute on Chronic Kidney Disease (CKD)**\n\n* **Presentation:** Elevated Cr (2.6 from baseline 1.8-2.2)\n* **Concerns:** Renal congestion causing renal dysfunction\n* **Status at Discharge:** Cr 2', '3. **Chronic Kidney Disease (CKD)**\n\t* Medication: Sevelamer Carbonate 800 mg PO TID W/MEALS (continued from home)\n4. **Asthma**\n\t* Medication: Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath ']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
What are the key findings from the patient's Transthoracic Echocardiogram (TTE) regarding left ventricular function and structure?,"['81401d7e-0074-4c95-b4cf-e031f6b09906\n\nFindings are compatible with moderate pulmonary edema with a \nmoderate left\npleural effusion.  Underlying bibasilar atelectasis and/or \npneumonia in the\nappropriate clinical setting should also be considered.\nCT HEAD WO CON (___)\nIMPRESSION: \n \nArea of low-density left occipital ___ represent subacute \ninfarct, if there are clinical symptoms, consider brain MRI \nwithout contrast. Small chronic lacunar infarct right basal \nganglia. Few calcifications at the pons, nonspecific, may be \nsequela of prior\ninflammatory or ischemic process, cavernoma cannot be excluded.\nTTE (___)\n---------------\nCONCLUSION: The left atrial volume index is mildly increased. \nThere is mild symmetric left ventricular hypertrophy with a \nnormal cavity size. There is normal regional and global left \nventricular systolic function. The visually estimated left \nventricular ejection fraction is 55-60%. There is no resting \nleft ventricular outflow tract gradient. Normal right', 'd2113a66-fe4f-4869-b3c0-73646862b32b\n\ngluconate (received 3 doses ___. Upon review of recent \noutpatient visit notes, it appears his volume exam is similar to \nbaseline, and patient was asymptomatic during hospital course. \nHe was diuresed effectively with IV Lasix 80. He was \ntransitioned to PO torsemide 100. His BP was well controlled \nwith regimen as described below.\n# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\nat or lower than levels earlier this year. He has denied chest\npain during admission. He does have risk factors for ischemia \nand\nhas not had stress since ___. However, findings and history \nto\ndate are not suggestive of ischemia and he has an ___. TTE did \nnot show evidence of focal wall motion abnormalities or other \nfindings suggestive of ischemia, so further workup was not \npursued. He was continued on ASA and atorvastatin.\n# ___ on CKD:\nCr elevated to 2.6 on admission from baseline of 1.8-2.2. Given\nevidence of congestion elsewhere, concerns for renal congestion\ncausing renal dysfunction. Cr remained stable and was 2.9 on day \nof discharge. He was continued on home sevelamer.']","According to the TTE findings, the patient has:               1. **Mildly increased left atrial volume index**.              2. **Mild symmetric left ventricular hypertrophy** with a normal cavity size.              3. **Normal regional and global left ventricular systolic function**.              4. A **visually estimated left ventricular ejection fraction of 55-60%**.              5. **No resting left ventricular outflow tract gradient**.              Additionally, the TTE did not show evidence of focal wall motion abnormalities or other findings suggestive of ischemia.",custom_multi_hop_query_synthesizer,"**Answer to Current Question**

**Patient Identification (from METADATA, as per instruction 1):**
* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, 2, 3, 4, and 5)
* **Note ID:** 13180007-DS-19 (consistent across all documents, indicating these are likely duplicate or slightly varied reports of the same examination)
* **Admission ID:** 20774429 (consistent across all documents)

**Key Findings from Transthoracic Echocardiogram (TTE) regarding Left Ventricular Function and Structure:**

* **Left Ventricular (LV) Structure:**
	+ **Hypertrophy:** Mild, symmetric (Document 1, 2, 3, and 4)
	+ **Cavity Size:** Normal (Document 1, 2, 3, and 4)
* **Left Ventricular (LV) Function:**
	+ **Regional and Global Systolic Function:** Normal (Document 1, 2, 3, and 4)
	+ **Visually Estimated LV Ejection Fraction (EF):** 65% (Document 1, 2, 3, and 4)
* **Additional Relevant Finding:**
	+ **Left Ventricular Outflow Tract (LVOT) Gradient:** No resting gradient (Document 1, 2, 3, and 4)
	+ **Filling Pressure (PCWP):** Increased (> 18 mmHg) (Document 3 and 4, **NOT MENTIONED** in Document 1 and 2)

**Observations:**
- Documents 1 and 2 are identical in both metadata and content.
- Documents 3 and 4 are also identical in both metadata and content, but differ from Documents 1 and 2 in content format and the additional information provided (e.g., Filling Pressure).
- Document 5 discusses valve and other heart structure findings but does not provide information on left ventricular function and structure as requested, so it is not included in the key findings for this specific question.","['* **Echocardiogram (TTE) Findings:**\n\t+ Left Atrial Volume Index: Normal\n\t+ Estimated Right Atrial Pressure: **[NOT PROVIDED]**\n\t+ Left Ventricular (LV) Characteristics:\n\t\t- Mild symmetric LV hypertro', '* **Echocardiogram (TTE) Findings:**\n\t+ Left Atrial Volume Index: Normal\n\t+ Estimated Right Atrial Pressure: **[NOT PROVIDED]**\n\t+ Left Ventricular (LV) Characteristics:\n\t\t- Mild symmetric LV hypertro', '* **Left Atrial Volume Index**: Normal\n* **Estimated Right Atrial Pressure**: [NOT PROVIDED]\n* **Left Ventricular (LV) Findings**:\n\t+ **Hypertrophy**: Mild, symmetric\n\t+ **Cavity Size**: Normal\n\t+ **S', '* **Left Atrial Volume Index**: Normal\n* **Estimated Right Atrial Pressure**: [NOT PROVIDED]\n* **Left Ventricular (LV) Findings**:\n\t+ **Hypertrophy**: Mild, symmetric\n\t+ **Cavity Size**: Normal\n\t+ **S', '+ **Mitral Valve Leaflets**: Mildly thickened, trivial regurgitation, no prolapse\n\t+ **Pulmonic Valve Leaflets**: Normal\n\t+ **Tricuspid Valve Leaflets**: Structurally normal, physiologic regurgitation']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What is the prescribed dosage and administration schedule for HydrALAZINE in the provided medical discharge instructions, and what are the primary and secondary diagnoses associated with its prescription?","['058d90f2-3d7b-4d29-bca6-e70e3cb19e4d\n\n4.  HydrALAZINE 100 mg PO TID \nRX *hydralazine 100 mg 1 tablet(s) by mouth three times daily \nDisp #*90 Tablet Refills:*0 \n5.  Glargine 30 Units Breakfast \n6.  Albuterol Inhaler 2 PUFF IH Q4H  \n7.  amLODIPine 10 mg PO DAILY  \n8.  Atorvastatin 80 mg PO QPM  \n9.  CloNIDine 0.2 mg PO BID  \n10.  Gabapentin 400 mg PO TID  \n11.  Levothyroxine Sodium 100 mcg PO DAILY  \n12.  MetFORMIN (Glucophage) 850 mg PO TID  \n13.  Vitamin D ___ UNIT PO WEEKLY  \n14. HELD- Lisinopril 40 mg PO DAILY  This medication was held. \nDo not restart Lisinopril until told to do so by your doctor\n15.Outpatient Lab Work\nChem-7 to be draw ___\nICD 10: I50.3: Diastolic (congestive) heart failure\nFax results to: ___ ATTN: ___\n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___', '5d1619ab-197a-416d-b0af-616eff82199c\n\n#*60 Tablet Refills:*0 \n12.  HydrALAZINE 100 mg PO TID \nRX *hydralazine 100 mg 1 tablet(s) by mouth three times a day \nDisp #*90 Tablet Refills:*0 \n13.  Levothyroxine Sodium 100 mcg PO DAILY \nRX *levothyroxine 100 mcg 1 tablet(s) by mouth once a day Disp \n#*30 Tablet Refills:*0 \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPRIMARY DIAGNOSIS\n==================\nAcute on chronic heart failure with preserved ejection fraction\nSECONDARY DIAGNOSES\n====================\nAcute kidney injury\nCoronary artery disease\nType 2 Diabetes Mellitus\nHyperkalemia']","According to the discharge instructions, HydrALAZINE is prescribed as follows: 100 mg PO (by mouth) TID (three times a day). This medication regimen is associated with the following diagnoses: **PRIMARY DIAGNOSIS** - Acute on chronic heart failure with preserved ejection fraction, and **SECONDARY DIAGNOSES** - Acute kidney injury, Coronary artery disease, Type 2 Diabetes Mellitus, and Hyperkalemia. The prescription details are consistent across both provided medical records (Disp #*90 Tablet Refills:*0 in one record and implied in the other with #*60 Tablet Refills:*0 for a different medication, suggesting a similar dispensing approach might be intended for HydrALAZINE despite the specific refill number not being directly mentioned in the second record for HydrALAZINE).",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Prescribed Dosage and Administration Schedule for HydrALAZINE:**
* **Dosage:** NOT PROVIDED
* **Administration Schedule:** NOT PROVIDED

**Reason:** HydrALAZINE is not mentioned in any of the provided medical discharge instruction documents (Document 1 through Document 5).

**Primary and Secondary Diagnoses Associated with HydrALAZINE Prescription:**
* **Primary Diagnosis:** NOT APPLICABLE (since HydrALAZINE is not prescribed)
* **Secondary Diagnosis:** NOT APPLICABLE (since HydrALAZINE is not prescribed)

**Additional Observations Based on the Provided Documents:**

* **Common Patient/Subject ID:** The same `Patient/Subject ID: 13180007` is mentioned across all documents (Document 1 through Document 5), indicating these documents pertain to the same patient.
* **Common Note ID and Admission ID:** The `Note ID: 13180007-DS-19` and `Admission ID: 20774429` are also consistent across all provided documents, suggesting these documents are part of the same medical encounter or admission.
* **Medications Listed:** While HydrALAZINE is not listed, the documents mention various other medications, including Torsemide, 70/30 Insulin, Albuterol Inhaler, Amlodipine, Aspirin, Atorvastatin, Carvedilol, Levothyroxine Sodium, Minoxidil, and a mention of ferric gluconate in Document 4.
* **Chronic Problems:** Document 5 highlights ""Hypothyroidism"" and ""History of CVA (Cerebrovascular Accident)"" as chronic problems, with associated medications.","['+ **Follow-up Appointments**: [NOT PROVIDED]\n* **Discharge Medications** (same as listed in the original document):\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (dosage and timing)\n\t3. Albuterol In', '+ **Follow-up Appointments**: [NOT PROVIDED]\n* **Discharge Medications** (same as listed in the original document):\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (dosage and timing)\n\t3. Albuterol In', '1. **Medications**:\n\t* List of discharge medications (13 items, see below)\n\t* **Note**: Take all medications as prescribed\n\t* **Discharge Medications List**:\n\t\t1. Torsemide 100 mg PO DAILY\n\t\t2. 70/30 ', '* **Additional Recommendations:**\n\t+ Consider completing the 4-day course of **ferric gluconate** (started during admission; received 2 doses of 250mg IV on **[NOT PROVIDED]**).\n\t+ One additional infu', 'Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What me worry bout wen patient hav small left pleural effusion, borderline cardiac silhouette, and chronic infarcts in brain CT, but no acute intracranial abnormality? Should i look into somethin else wit dis patient?","[""2b2ce4e1-1e51-4483-8a53-32a58ee918d2\n\nleft pleural effusion. Borderline size of the cardiac silhouette\nwithout pulmonary edema. No pneumonia, no pneumothorax.  The\nlateral radiograph shows mild flattening of the hemidiaphragms,\npotentially as a consequence of functional obstruction.\nHead CT: 1. No evidence of acute intracranial abnormality.\n2. Unchanged appearance of chronic infarcts within the right\nfrontal lobe and left occipital lobe.\n3. Chronic lacunar infarcts within the right basal ganglia.\n4. Redemonstration of few calcifications within the pons,\nfindings which are unchanged in appearance and likely sequela of\nprior ischemic or inflammatory process.\n___ 11:00AM BLOOD cTropnT-0.04*\n___ 09:00PM BLOOD cTropnT-0.02*\n___ 11:00AM BLOOD %HbA1c-14.4* eAG-367*\n___ 11:00AM BLOOD Lipase-73*\n___ 11:00AM BLOOD CK-MB-4 proBNP-754*\nIMAGING:\n___ CXR -\nComparison to ___.  On today's radiograph, a small \npleural\nleft-sided calcification is seen.  There also is a small left \npleural\neffusion.  Borderline size of the cardiac silhouette without"", 'a0523bf3-a15e-4abc-bd78-1c98b6c5dc7e\n\nedema.  No\nevidence of displaced fracture.\nCT head ___:\nThere is no evidence of infarction, hemorrhage, edema,or midline \nshift.  There\nis prominence of the ventricles and sulci suggestive of \ninvolutional changes.\n \nThere is no evidence of fracture.  Opacification of the mastoid \nair cells. \nThe visualized portion of the paranasal sinuses, mastoid air \ncells, and middle\near cavities are clear.  The visualized portion of the orbits \nare\nunremarkable.\nCT abd/pelvis ___:\n1. Bilateral lower lobe opacities, concerning for aspiration or \npneumonia.\n2. No acute finding in the abdomen or pelvis.\nCT C spine ___:\nNG tube and endotracheal tube are noted.  Alignment is normal. \nNo fractures\nare identified. There is no evidence of high-grade spinal canal']","Based on provided CT scans and blood work, key concerns for the patient include:      1. **Small left pleural effusion and borderline size of the cardiac silhouette** observed in the chest X-ray (CXR), suggesting potential cardiac or pulmonary issues, but **no pneumonia or pneumothorax**.     2. **Chronic infarcts** within the right frontal lobe, left occipital lobe, and right basal ganglia, as well as **calcifications in the pons**, indicating past ischemic or inflammatory processes, but **no evidence of acute intracranial abnormality** on the Head CT.     3. **Elevated %HbA1c (14.4)** and **eAG (367)**, indicating poorly controlled diabetes.     4. **proBNP of 754**, which may suggest heart failure or other cardiac conditions.     **Recommendation**: Further investigation into the patient's cardiac health (given the borderline cardiac silhouette and proBNP levels) and management of diabetes are warranted. Monitoring for any signs of neurological deterioration, despite the current lack of acute intracranial abnormalities, is also advisable.",custom_multi_hop_query_synthesizer,"**Response as a Medical Document Assistant**

**Addressing the Current Question:**

The provided documents (1-5) do not mention a ""small left pleural effusion,"" ""borderline cardiac silhouette,"" or ""chronic infarcts in brain CT"" with ""no acute intracranial abnormality."" These findings seem to be from an external source not included in the documents provided for analysis. However, I'll guide you on what to consider given these new findings:

1. **Small Left Pleural Effusion**:
	* **Concern**: May indicate fluid overload, infection, or malignancy. Given the patient's known **Small Pericardial Effusion** (Documents 1-4), monitoring for signs of fluid overload or cardiac decompensation is crucial.
	* **Action**: Review recent chest X-rays or CT scans to assess the effusion's size and potential impact on lung function. Consider echocardiography to evaluate cardiac function in the context of both effusions.

2. **Borderline Cardiac Silhouette**:
	* **Concern**: Could suggest cardiomegaly or pericardial disease. This, combined with the known **Stiff Left Ventricle** and **Small Pericardial Effusion**, warrants a detailed cardiac evaluation.
	* **Action**: Order or review recent echocardiograms to assess ventricular function and pericardial disease. Consider cardiac MRI for detailed myocardial and pericardial evaluation if not already done.

3. **Chronic Infarcts in Brain CT with No Acute Intracranial Abnormality**:
	* **Concern**: Indicates past cerebrovascular events. The absence of acute findings is reassuring but necessitates management of stroke risk factors.
	* **Action**: Ensure comprehensive stroke risk factor modification (e.g., hypertension, diabetes, lipid management, antiplatelet therapy as appropriate). Schedule a follow-up with Neurology for further management and potential carotid or vascular evaluation.

**Additional Recommendations Based on Provided Documents:**

- **Consistency in Findings**: Documents 1-4 show consistent impressions regarding image quality, stiff left ventricle, and small pericardial effusion, indicating a reliable diagnostic baseline.
- **Valvular and Pulmonary Assessment**: Document 5 provides a more detailed valvular and pulmonary assessment. Consider integrating these findings into the patient's cardiac evaluation plan.

**Metadata Observations:**

- **Patient/Subject ID**: Consistently **13180007** across all documents.
- **Note ID and Admission ID**: Also consistent (**13180007-DS-19** and **20774429**, respectively) across all documents, indicating these documents pertain to the same patient encounter.
- **Chart Time and Store Time**: Listed as **N/A** for all documents. If timelines are crucial for your analysis, consider obtaining this information through alternative means.

**IDs as per Metadata:**

- **Patient/Subject ID**: **13180007** (Consistent across Documents 1-5)
- **Note ID**: **13180007-DS-19** (Consistent across Documents 1-5)
- **Admission ID**: **20774429** (Consistent across Documents 1-5)","['**IMPRESSION**\n\n* **Image Quality**: Suboptimal\n* **Key Findings**: Stiff left ventricle, small pericardial effusion, no frank tamponade.', '**IMPRESSION**\n\n* **Image Quality**: Suboptimal\n* **Key Findings**: Stiff left ventricle, small pericardial effusion, no frank tamponade.', '* **Impression:** Suboptimal image quality, Stiff Left Ventricle, Small Pericardial Effusion, No frank tamponade.', '* **Impression:** Suboptimal image quality, Stiff Left Ventricle, Small Pericardial Effusion, No frank tamponade.', '- Mitral Valve: Mildly thickened leaflets, no prolapse, trivial regurgitation\n\t\t- Pulmonic Valve: Normal leaflets\n\t\t- Tricuspid Valve: Structurally normal, physiologic tricuspid regurgitation\n\t+ Estim']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What medikashuns shud patient wit Type 2 Diabetes Mellitus, heart failure, and acute kidney injury take when goin home from hospital, espeshally for diabetis?","['281ec1ee-1c32-43a3-8667-6c9eaa2f4734\n\nEKG:  SR, NL axis, NIs, TWIs laterally (c/w prior) \nLabs/studies notable for:  proBNP: 1140, Cr 1.9\nPatient was given:  IV Furosemide 10mg\nOn the floor...  \n---------------\nStates that he feels better than he did when he came to the\nhospital. No SOB, CP, or palpitations. Only complaint is the\nburning/itching in his lower extremities. \n \nPast Medical History:\n1. CARDIAC RISK FACTORS  \n- Type 2 Diabetes Mellitus\n- Hypertension  \n- Dyslipidemia  \n- Coronary artery disease\n2. CARDIAC HISTORY  \n- Secondum ASD\n- Mild AR\n3. OTHER PAST MEDICAL HISTORY  \n- Extensive intracranial atherosclerosis, worse in the right\nMCA territory.\n- Cerebrovascular disease, status post CVA in ___\n- Asthma\n- OSteoarthritis', '5d1619ab-197a-416d-b0af-616eff82199c\n\n#*60 Tablet Refills:*0 \n12.  HydrALAZINE 100 mg PO TID \nRX *hydralazine 100 mg 1 tablet(s) by mouth three times a day \nDisp #*90 Tablet Refills:*0 \n13.  Levothyroxine Sodium 100 mcg PO DAILY \nRX *levothyroxine 100 mcg 1 tablet(s) by mouth once a day Disp \n#*30 Tablet Refills:*0 \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPRIMARY DIAGNOSIS\n==================\nAcute on chronic heart failure with preserved ejection fraction\nSECONDARY DIAGNOSES\n====================\nAcute kidney injury\nCoronary artery disease\nType 2 Diabetes Mellitus\nHyperkalemia']","Based on provided context, for a patient with Type 2 Diabetes Mellitus discharged home, the specified medications do not directly target diabetes management at home. However, medications listed in the context that the patient was on or discharged with, which might be relevant or need monitoring in the context of their diabetes and other conditions, include:  - **HydrALAZINE 100 mg PO TID** (primarily for hypertension, a cardiac risk factor for diabetes patients) - **Levothyroxine Sodium 100 mcg PO DAILY** (for thyroid conditions, not directly related to diabetes but important for overall metabolic health) - **IV Furosemide 10mg** was administered in the hospital (for acute kidney injury and heart failure, not a home medication in this context but important for managing conditions that impact diabetes care).  **Direct Diabetes Management Medication:** Not specified in the discharge or hospital administration context provided. Typically, a patient with Type 2 Diabetes Mellitus would be on medications such as Metformin, Sulfonylureas, or other classes depending on their specific condition and health status, but these are not mentioned in the given context.",custom_multi_hop_query_synthesizer,"**Answering the Question with Provided Guidelines**

**Patient Identification (as per guideline 1 & 2):**
* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, and Document 5)
* **Admission ID:** 20774429 (consistent across all documents)
* **Note ID:** 13180007-DS-19 (consistent across all documents)

**Medications for Type 2 Diabetes Mellitus, Heart Failure, and Acute Kidney Injury upon Discharge (focusing on Diabetes as requested):**

Based on the provided documents, especially Document 5 which lists discharge medications, and cross-referencing with conditions mentioned in other documents:

* **For Type 2 Diabetes Mellitus (IDDM):**
	1. **70/30 Insulin** - Specific dosages mentioned: 30 Units at Breakfast, 10 Units at Lunch (Document 5)
	2. **Victoza (Liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) subcutaneous DAILY** (mentioned in Document 1 and Document 2, but **NOT** explicitly listed in the discharge medications in Document 5; **Clarification Needed** from healthcare provider regarding continuation)
* **For Heart Failure (specifically ""Acute on chronic diastolic heart failure exacerbation"" as per Document 3):**
	1. **Torsemide 100 mg PO DAILY** (Document 5) - Commonly used for managing fluid overload in heart failure.
	2. **Carvedilol 50 mg PO BID** (Document 1, Document 2, and Document 5) - A beta-blocker used in heart failure management.
* **For Acute Kidney Injury (as per Document 3):**
	- No specific medications are listed in the provided documents solely for the treatment of Acute Kidney Injury. Management might involve adjusting medications that impact renal function, such as:
		1. **Torsemide** (above) with careful monitoring.
		2. **Avoidance or adjustment of nephrotoxic medications** (not explicitly mentioned in the documents).

**Additional Medications Listed at Discharge (Document 5) that may be relevant under medical supervision:**

* **Amlodipine 10 mg PO DAILY** (for Hypertension, which can be comorbid with Heart Failure and Diabetes)
* **Aspirin 81 mg PO DAILY** (common for cardiovascular protection)
* **Atorvastatin 80 mg PO QPM** (for cholesterol management, relevant for cardiovascular health)
* **Albuterol Inhaler 2 PUFF IH Q8H:PRN** (for respiratory symptoms, if applicable)
* **Levothyroxine Sodium 100 mcg PO DAILY** (for thyroid hormone replacement, if applicable)

**Important Note:**
- The absence of **Victoza (Liraglutide)** in the discharge medications list (Document 5) but its presence in earlier documents (Document 1 and Document 2) for Diabetes management **requires clarification** from the healthcare provider to ensure continuity of care.
- Medication adjustments are common; these documents might not reflect the most current treatment plan if changes occurred after the last document's store time. Always verify with the healthcare provider for the most accurate and up-to-date information.","['1. **Hypertension**\n\t* Medications: \n\t\t+ Amlodipine 10 mg PO DAILY (continued from home)\n\t\t+ Carvedilol 50 mg PO BID (continued from home)\n\t\t+ Minoxidil 10 mg PO DAILY (continued from home)\n2. **Diabe', '1. **Hypertension**\n\t* Medications: \n\t\t+ Amlodipine 10 mg PO DAILY (continued from home)\n\t\t+ Carvedilol 50 mg PO BID (continued from home)\n\t\t+ Minoxidil 10 mg PO DAILY (continued from home)\n2. **Diabe', '* **Discharge Location**: Home With Service\n* **Facility**: [REDACTED]\n* **Discharge Diagnosis**:\n\t+ **Primary Diagnosis**: Acute on chronic diastolic heart failure exacerbation\n\t+ **Secondary Diagnos', '### 5. **Acute on Chronic Anemia**\n\n* **Presentation:** Hb 7.4 on admission\n* **Possible Causes:** Worsening renal function or dilutional iso heart failure\n* **Management:**\n\t+ Received 3 doses of Fer', '1. **Medications**:\n\t* List of discharge medications (13 items, see below)\n\t* **Note**: Take all medications as prescribed\n\t* **Discharge Medications List**:\n\t\t1. Torsemide 100 mg PO DAILY\n\t\t2. 70/30 ']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"Whats the deal with the Asprin perscription for a patient with a history of CAD and CKD stage III, shouldnt they be on somethin els?","['4b3d7a96-6534-434e-8295-b8356c5ca64d\n\nbasal/bolus four times daily regimen. However, this is not a \nsustainable regimen for patient on discharge. Discussed \npossibility of switching to 70/30 mix BID, however currently \npatient cannot be guaranteed to eat regular meal after each \ninsulin injection therefore currently not a tenable plan. In the \nfuture, if patient able to be placed in a day program, \npotentially could switch to this but for now will we continued \nhis prior home regimen (EXCEPT for Jardiance, which was \ndiscontinued due to contraindication with chronic kidney \ndisease) on discharge, with very close ___ follow-up and ___ \nservices to help increase compliance. With regards to his more \nsubacute mental status decompensation, would benefit from \nreferral for outpatient neurocognitive evaluation.\n# Hx of CAD: \n# Hx of ischemic CVA:\nStress test in ___ with area of inducible ischemia in LCx \ndistribution, in setting of multiple risk factors. Has been \nmedically optimized by prescribed medications, but as above it \nseems that pt has been taking these medications. TnT 0.04->0.02 \nin setting of CKD stage III-IV. Continued home aspirin, \natorvastatin, and carvedilol. Note that he was once on \nlisinopril (most recently filled in ___ for 2.5mg dose) \nhowever seems that this has since been discontinued.\n# CKD stage III:', 'cd30826d-ad9e-4a08-8b63-15e1e3bbfe0c\n\nYou were admitted to the hospital because:\n================================\n-You had worsening shortness of breath, with increased leg \nswelling and weight gain.\nDuring your stay:\n============\n-You had too much volume onboard so you were given IV diuretic \nmedications,. You improved significantly.\nAfter your discharge:\n================\n-Please continue taking all medications as prescribed (see \nbelow).\n-Please stop taking Lisinopril and metoprolol.\n-Please continue taking insulin according to the regimen you \nwere following before this admission.\n-New medications:\n  - Aspirin 81mg once daily\n  - Carvedilol 25mg twice daily\n  - Furosemide 40mg twice daily\n  - Hydralazine 100mg three times daily\n-Please attend any upcoming outpatient appointments you have \n(see below).\nWe wish you the very best!']","According to the patient's care plan, **Aspirin** is indeed continued at home, alongside **atorvastatin** and **carvedilol**, despite the patient's history of CAD (with a past stress test showing inducible ischemia in LCx distribution) and CKD stage III. This decision was made as part of medically optimizing the patient, with close follow-up planned. Specifically, the patient is to take **Aspirin 81mg once daily** as prescribed upon discharge, with no indication in the provided context to switch to an alternative due to these conditions.",custom_multi_hop_query_synthesizer,"**Response to Current Question**

**Patient Context:**
Based on the provided documents, here is the relevant patient context for addressing the question:

* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, 2, 3, 4, and 5)
* **Relevant Medical History from Documents:**
	+ Carotid Artery Disease (Document 1 and 2)
	+ Secundum ASD (Atrial Septal Defect) and Mild AR (Aortic Regurgitation) (Document 1 and 2), though not directly relevant to the CAD and CKD question
	+ Acute on Chronic Kidney Disease (CKD) (Document 3, 4, and 5)
	+ Chest Pain with mild troponin elevation, managed with ASA and Atorvastatin (Document 3 and 4), implying a history of Coronary Artery Disease (CAD)

**Addressing the Question:**
**Shouldn't a patient with a history of CAD and CKD Stage III be on something else instead of Aspirin (ASA)?**

1. **CAD and Aspirin Use:** Aspirin is commonly used for secondary prevention in patients with established CAD due to its antiplatelet effects, which help prevent further cardiovascular events. Unless contraindicated (e.g., due to bleeding risks), ASA is typically continued.

2. **CKD Stage III and Aspirin Use:** For patients with CKD, the use of aspirin for cardiovascular protection is more nuanced. Guidelines suggest considering aspirin for primary prevention in CKD patients with high cardiovascular risk, but the decision is individualized due to the increased risk of bleeding. For secondary prevention (as implied here with CAD history), aspirin is often continued, balancing cardiovascular benefits against bleeding risks, especially with close monitoring.

3. **Alternative Therapies Consideration:**
    - **P2Y12 Inhibitors:** Might be considered in addition to ASA for certain patients with CAD (e.g., post-stent placement), but not as a replacement for ASA in standard secondary prevention scenarios.
    - **Other Antiplatelets:** The choice of antiplatelet therapy is guided by clinical context (e.g., recent stent placement, history of stroke), and switching from ASA would depend on specific patient factors not detailed in the provided documents.
    - **Anticoagulants for AF or Venous Thromboembolism Prophylaxis:** Not indicated based on the information provided, which does not mention atrial fibrillation or venous thromboembolic events requiring anticoagulation.

**Conclusion:**
Given the provided information, continuing ASA for a patient with a history of CAD is standard practice for secondary prevention. The presence of CKD Stage III necessitates careful consideration of bleeding risks but does not inherently mandate an alternative to ASA for CAD management. The decision to modify or add to antiplatelet therapy should be based on a comprehensive assessment of the patient's risk profile, which may involve factors not detailed in the documents (e.g., bleeding history, other comorbidities).

**Recommendation for Further Action:**
- Review the patient's full medical record for comprehensive risk assessment.
- Consider consulting with a cardiologist or nephrologist for personalized management strategies balancing cardiovascular and renal health.

**Metadata Consistency Note:**
- **Patient/Subject ID:** Consistently reported as **13180007** across all documents.
- **Note ID, Admission ID, Chart Time, and Store Time:** Also consistent across documents, though **Chart Time** and **Store Time** are listed as **N/A**.","['6. **Carotid Artery Disease** (mentioned in Past Medical History, no specific medications listed in discharge medications)\n7. **Secundum ASD (Atrial Septal Defect)** (mentioned in Past Medical History', '6. **Carotid Artery Disease** (mentioned in Past Medical History, no specific medications listed in discharge medications)\n7. **Secundum ASD (Atrial Septal Defect)** (mentioned in Past Medical History', '### 2. **Chest Pain**\n\n* **Presentation:** Chest pain with mild troponin elevation (0.03)\n* **Interpretation:** Difficult due to CKD, levels similar to prior months\n* **Findings:**\n\t+ No evidence of d', '### 2. **Chest Pain**\n\n* **Presentation:** Chest pain with mild troponin elevation (0.03)\n* **Interpretation:** Difficult due to CKD, levels similar to prior months\n* **Findings:**\n\t+ No evidence of d', '* **Acute Problems Addressed**:\n\t1. **Acute on Chronic HFpEF**\n\t2. **Chest Pain** (mild troponin elevation, likely related to CKD)\n\t3. **CKD** (elevated Cr, possibly due to renal congestion)\n\t4. **Hyp']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
What is the prescribed administration schedule for Albuterol Inhaler upon hospital admission for a patient experiencing shortness of breath?,['8c579626-76a5-4cd0-9f53-1feadb6904be\n\nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath \n2. amLODIPine 10 mg PO DAILY \n3. Atorvastatin 80 mg PO QPM \n4. CARVedilol 50 mg PO BID \n5. Furosemide 80 mg PO DAILY \n6. 70/30 30 Units Breakfast\n70/30 10 Units Lunch\n7. Levothyroxine Sodium 100 mcg PO DAILY \n8. Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY \n9. Minoxidil 10 mg PO DAILY \n10. Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine \n11. sevelamer CARBONATE 800 mg PO TID W/MEALS \n12. Aspirin 81 mg PO DAILY \n13. Vitamin D 1000 UNIT PO DAILY \n \nDischarge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast'],"According to the preadmission medication list, Albuterol Inhaler is prescribed as 2 puffs, inhaled (IH) every 8 hours as needed (Q8H:PRN) specifically for shortness of breath.",custom_multi_hop_query_synthesizer,"Based on the provided documents, here is the answer to the question following the specified instructions:

**Question:** What is the prescribed administration schedule for Albuterol Inhaler upon hospital admission for a patient experiencing shortness of breath?

**Answer:**

* **Patient/Subject ID (for context, as per instruction 2):** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, Document 5)
* **Prescribed Administration Schedule for Albuterol Inhaler:**
	+ **Dose:** 2 PUFF
	+ **Frequency:** IH Q8H:PRN (every 8 hours as needed)
	+ **Indication:** For shortness of breath

**Source Documents for Answer:**
- **Primary Source:** Document 2 (matches the question's context of ""upon hospital admission"" more closely due to its detailed frequency and additional info format, though the content is largely consistent across relevant documents)
- **Secondary Confirmation:** Document 1 (initial listing), Document 3 (under **Asthma**), Document 4 (under **Discharge Medications**), and Document 5 (under **Medications to Take as Prescribed**) all confirm the dose and indication, but Document 2 most clearly outlines the administration schedule in the context of hospital admission protocols.","['1. **Albuterol Inhaler**\n\t* Dose: 2 PUFF IH Q8H\n\t* Indication: PRN shortness of breath\n2. **Amlodipine**\n\t* Dose: 10 mg PO DAILY\n3. **Atorvastatin**\n\t* Dose: 80 mg PO QPM\n4. **Carvedilol**\n\t* Dose: 50', '1. **Torsemide**\n\t* Dose: 100 mg\n\t* Frequency: PO DAILY\n\t* Additional Info: *torsemide 20 mg 5 tablet(s) by mouth once a day, Disp #*70, Tablet Refills:*0\n2. **70/30 Insulin**\n\t* Dose: \n\t\t+ 30 Units w', '3. **Chronic Kidney Disease (CKD)**\n\t* Medication: Sevelamer Carbonate 800 mg PO TID W/MEALS (continued from home)\n4. **Asthma**\n\t* Medication: Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath ', '+ **Follow-up Appointments**: [NOT PROVIDED]\n* **Discharge Medications** (same as listed in the original document):\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (dosage and timing)\n\t3. Albuterol In', '* **Medications to Take as Prescribed:**\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (30 Units Breakfast, 10 Units Lunch)\n\t3. Albuterol Inhaler 2 PUFF IH Q8H:PRN\n\t4. Amlodipine 10 mg PO DAILY\n\t5. ']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What adjustments were made to the patient's medication regimen for managing Type 2 Diabetes Mellitus (T2DM) and Hypertension, and what follow-up actions were recommended upon discharge?","['386e4975-89d1-411a-99a3-9d225138df6c\n\n[] Ensure that patient was able to adhere to a diabetic diet\nPCP:\n[] Had elevated SBP in 130s-150s. Increased minoxidil to 5mg and \ncarvedilol to 50 mg BID. Please follow-up on blood pressures. \n[] Follow up on diuretics and volume status. Please get \nfollow-up labs BUN/Cr at follow-up appointment.\nNew meds: 70-30 novolog (30 units in AM, 20 units at dinner)\nStopped meds: none\nChanged meds: Carvedilol 50 mg twice a day, increased minoxidil \n5 mg daily \nACUTE ISSUES: \n=============== \n# HHS\n# T2DM\nPatient has history of poorly-controlled DM w/ A1c ~14. Based on \nlabs, determined to be in HHS likely precipitated by med \nnon-adherence or difficulty understanding multi-step process. No \nclear infection was identified. Of note, he tends to have high \ninsulin requirements. Pt was continued on insulin basal/bolus \nwhile inpatient. There was significant efforts to have him bring \nin home Victoza but he only had a half dose so he was continued \non basal/bolus course and made a plan for close outpatient \nfollow up and home 2 injections (Victoza and pre-mixed insulin).']","Adjustments made to the patient's medication regimen include: increasing minoxidil to 5mg daily and carvedilol to 50mg twice a day (BID) to manage elevated Systolic Blood Pressure (SBP); continuation of basal/bolus insulin due to high insulin requirements and the patient's difficulty with multi-step medication processes. Specifically for T2DM, the patient was started on 70-30 novolog (30 units in the morning, 20 units at dinner). Upon discharge, recommended follow-up actions include: monitoring blood pressures, assessing diuretics and volume status, and obtaining follow-up labs for BUN/Cr at the next appointment. Additionally, plans were made for close outpatient follow-up and administering two injections at home (Victoza and pre-mixed insulin).",custom_multi_hop_query_synthesizer,"**Response to Current Question**

**Patient Identification:**
* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, and Document 5)
* **Note ID:** 13180007-DS-19 (consistent across all documents)
* **Admission ID:** 20774429 (consistent across all documents)

**Adjustments to Medication Regimen for T2DM and Hypertension:**

* **Type 2 Diabetes Mellitus (T2DM) Adjustments:**
	+ **Document 4** lists ""70/30 Insulin (dosage and timing)"" indicating that insulin dosage adjustments were made, but the specific adjustments are **NOT PROVIDED**.
	+ **Document 5** mentions ""70/30 Insulin (dosage varies, continued from home with adjustments)"" suggesting changes were made to the insulin regimen, but the exact nature of these adjustments is not specified.
	+ **Victoza (Liraglutide)** is mentioned in **Document 5** as continued from home, with no indicated changes.
* **Hypertension Adjustments:**
	+ **No explicit adjustments** are mentioned in any of the documents (Document 1 through Document 5) for the hypertension medications:
		- Amlodipine 10 mg PO DAILY
		- Carvedilol 50 mg PO BID
		- Minoxidil 10 mg PO DAILY
	All are noted as ""continued from home"" in **Document 5**, indicating no changes upon discharge.

**Follow-up Actions Recommended Upon Discharge:**

* **Follow-up Labs:** Scheduled date **NOT PROVIDED** in both **Document 1** and **Document 2**.
* **Creatinine (Cr) Monitoring:** Due to elevated levels at discharge (2.9), as noted in **Document 1**, **Document 2**, and **Document 3**, but no specific follow-up schedule is provided.
* **Follow-up Appointments:** **NOT PROVIDED** in **Document 4**.","['* **Discharge Status:**\n\t+ Symptoms associated with volume overload had subsided, but patient was still slightly volume up on exam.\n\t+ 1+ edema to ankles bilaterally.\n\t+ JVP of 12cm.\n* **Medications a', '* **Discharge Status:**\n\t+ Symptoms associated with volume overload had subsided, but patient was still slightly volume up on exam.\n\t+ 1+ edema to ankles bilaterally.\n\t+ JVP of 12cm.\n* **Medications a', '**Key Findings:**\n\n* Slightly improved Hemoglobin (Hgb) level from admission (7.4 to 7.6)\n* Elevated Creatinine (Cr) level at discharge (2.9), indicating persistent renal impairment\n* Abnormal glucose', '+ **Follow-up Appointments**: [NOT PROVIDED]\n* **Discharge Medications** (same as listed in the original document):\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (dosage and timing)\n\t3. Albuterol In', '1. **Hypertension**\n\t* Medications: \n\t\t+ Amlodipine 10 mg PO DAILY (continued from home)\n\t\t+ Carvedilol 50 mg PO BID (continued from home)\n\t\t+ Minoxidil 10 mg PO DAILY (continued from home)\n2. **Diabe']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What are the current management strategies for a patient with Coronary Artery Disease (CAD) presenting with inducible ischemia and a recent Non-ST Elevation Myocardial Infarction (NSTEMI), given the presence of chronic kidney disease (CKD)?","['2574c42a-a6ef-418e-ac90-a21855611d18\n\npulmonary edema. No pneumonia, no pneumothorax.  The lateral \nradiograph shows mild flattening of the hemidiaphragms, \npotentially as a consequence of functional obstruction.\n___ CT HEAD -\n1. No evidence of acute intracranial abnormality.\n2. Unchanged appearance of chronic infarcts within the right \nfrontal lobe and left occipital lobe.\n3. Chronic lacunar infarcts within the right basal ganglia.\n4. Re-demonstration of few calcifications within the pons, \nfindings which are unchanged in appearance and likely sequela of \nprior ischemic or inflammatory process.\nMICRO:\n___ 3:38 pm URINE\n                            **FINAL REPORT ___\n   URINE CULTURE (Final ___:    < 10,000 CFU/mL. \n \nBrief Hospital Course:\nMr. ___ is a ___ ___ speaking male with a \nPMH of prior CVA ___, residual emotional lability, \ndysarthria), HFpEF, uncontrolled DM2, HTN, CAD, CKD, \n?hypothyroidism, asthma, mild cognitive impairment who presented', '5afc91e0-6481-46b3-aa3c-473b2c2e6895\n\n#Community acquired pneumonia\nCough, worsened SOB, hypoxemia (although alternate explanation) \nbut no leukocytosis or fevers; influenza negative. Legionella \nand strep were negative. Patient was given a 5-day course of \nceftriaxone and azithromycin. \n#Hypertension\nGoal <130/80. As patient is on several anti-hypertensives with \nstill an elevated blood pressure, he underwent a secondary \nhypertension workup. His last renal ultrasound in ___ was \nwithin normal limits. He was placed on continuous O2 monitoring \novernight, and patient did not desaturate. His aldosterone to \nrenin ratio was 0.13, indicating no primary hyperaldosteronism. \n24 hour urine metanephrines and catecholamines were within \nnormal limits.\n#CAD w/ inducible ischemia\n#NSTEMI\nTroponin peaked at 0.02, thought to be type 2 due to volume \noverload. Continued aspirin, atorvastatin, carvedilol. The \ndecision was made to hold off on coronary angiogram due to \nkidney function and the suspicion that this was type 2.\n#H/o CVA\nPatient had an episode while in hospital with dysarthria,']","According to the provided context, for a patient with CAD, inducible ischemia, and recent NSTEMI (troponin peaked at 0.02, suspected as type 2 due to volume overload), the management includes:  - Continuation of aspirin, atorvastatin, and carvedilol.  - A decision was made to hold off on the coronary angiogram due to compromised kidney function and the suspicion of a type 2 myocardial infarction.  Additionally, the patient’s hypertension is being managed with multiple anti-hypertensives, aiming for <130/80, and a secondary hypertension workup was conducted, which included an aldosterone to renin ratio and 24-hour urine metanephrines and catecholamines, all within normal limits.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, I must point out that:

1. **The question does not match the provided documents' content**. The documents discuss various conditions (e.g., Acute on Chronic Kidney Disease (CKD), Hypertension, Acute on Chronic Anemia, Heart Failure with preserved Ejection Fraction (HFpEF), etc.) but do **not mention Coronary Artery Disease (CAD) or Non-ST Elevation Myocardial Infarction (NSTEMI)**.

2. **Given the mismatch**, it's impossible to directly answer the question based on the provided documents.

However, to adhere to the instructions and provide some relevant information based on the documents:

**Answering the question with the available, yet irrelevant, information:**

* **Patient/Subject ID** (as it appears in all documents, indicating they all pertain to the same patient): **13180007**
* **Note ID** (common across all documents, suggesting these are parts of the same note or discharge summary): **13180007-DS-19**
* **Admission ID** (also consistent across documents): **20774429**

**Regarding the question's subject matter (CAD, NSTEMI, and CKD management):**

* Since the documents do not mention CAD or NSTEMI, **no management strategies for these conditions can be inferred from the provided information**.
* **CKD is mentioned** across several documents, with management strategies including:
	+ Medication: Sevelamer Carbonate 800 mg PO TID W/MEALS (continued from home) [Document 3].
	+ Monitoring of renal function (implied through the tracking of Cr levels) [Documents 1 and 4].

**To answer the original question accurately, additional documents or information specifically addressing CAD, NSTEMI, and their management in the context of CKD would be required**. 

**Format Compliance:**
Given the question's mismatch with the documents, the standard answer format (e.g., step-by-step reasoning leading to a direct answer) cannot be fully applied. Instead, this response clarifies the discrepancy and extracts relevant, albeit non-applicable, information as per the instructions.","['### 3. **Acute on Chronic Kidney Disease (CKD)**\n\n* **Presentation:** Elevated Cr (2.6 from baseline 1.8-2.2)\n* **Concerns:** Renal congestion causing renal dysfunction\n* **Status at Discharge:** Cr 2', '* **Acute Problems Addressed**:\n\t1. **Acute on Chronic HFpEF**\n\t2. **Chest Pain** (mild troponin elevation, likely related to CKD)\n\t3. **CKD** (elevated Cr, possibly due to renal congestion)\n\t4. **Hyp', '3. **Chronic Kidney Disease (CKD)**\n\t* Medication: Sevelamer Carbonate 800 mg PO TID W/MEALS (continued from home)\n4. **Asthma**\n\t* Medication: Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath ', '* **Primary Diagnosis:**\n\t+ **Condition:** Acute on chronic diastolic heart failure exacerbation\n\t+ **Implication:** Heart failure with preserved ejection fraction (HFpEF) exacerbation, as noted in Hi', '* **Discharge Location**: Home With Service\n* **Facility**: [REDACTED]\n* **Discharge Diagnosis**:\n\t+ **Primary Diagnosis**: Acute on chronic diastolic heart failure exacerbation\n\t+ **Secondary Diagnos']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What is the prescribed dosage and administration schedule for sevelamer CARBONATE in the provided patient discharge information, and how might it relate to the patient's diagnosed conditions, particularly those affecting kidney function (e.g., CKD)?","['080dba33-29e9-4409-89cb-54a03af0e470\n\n8.  Levothyroxine Sodium 100 mcg PO DAILY  \n9.  Minoxidil 10 mg PO DAILY  \n10.  Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine  \n11.  sevelamer CARBONATE 800 mg PO TID W/MEALS  \n12.  Torsemide 100 mg PO DAILY  \n13.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n14.  Vitamin D 1000 UNIT PO DAILY  \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPRIMARY DIAGNSOIS:\n==================\nAcute Hypoxemic Respiratory Failure\nAcute on Chronic Diastolic Heart Failure\nHyperglycemia, Type 2 Diabetes \n___ on CKD \nSECONDARY DIAGNOSIS:', '784a4f17-941d-40ee-a5aa-7471e6a5f600\n\n70/30 10 Units Lunch \n3.  Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath  \n4.  amLODIPine 10 mg PO DAILY  \n5.  Aspirin 81 mg PO DAILY  \n6.  Atorvastatin 80 mg PO QPM  \n7.  CARVedilol 50 mg PO BID  \n8.  Levothyroxine Sodium 100 mcg PO DAILY  \n9.  Minoxidil 10 mg PO DAILY  \n10.  Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine  \n11.  sevelamer CARBONATE 800 mg PO TID W/MEALS  \n12.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n13.  Vitamin D 1000 UNIT PO DAILY  \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPrimary Diagnosis:\n-Acute on chronic diastolic heart failure exacerbation\nSecondary Diagnosis:']","According to the discharge medication lists (nodes: 080dba33-29e9-4409-89cb-54a03af0e470 and 784a4f17-941d-40ee-a5aa-7471e6a5f600), the prescribed dosage for sevelamer CARBONATE is 800 mg, administered orally three times a day (PO TID) with meals. Sevelamer carbonate is often used to treat high phosphate levels in patients with chronic kidney disease (CKD). Given the patient's secondary diagnosis includes '___ on CKD' in one discharge summary and no explicit mention in the other, but both indicating the presence of kidney issues through CKD, the sevelamer carbonate is likely prescribed to manage hyperphosphatemia associated with CKD, thereby supporting the patient's renal health alongside other treatments for diagnosed conditions like Acute on Chronic Diastolic Heart Failure and Type 2 Diabetes.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Prescribed Dosage and Administration Schedule for Sevelamer Carbonate:**

* **Dosage:** 800 mg
* **Administration Schedule:** PO (orally) TID (three times a day) W/MEALS (with meals)

**Source Document:**
This information is found in **Document 3**, under the medication list, specifically at point **11**.

**Relation to Diagnosed Conditions, Particularly Kidney Function (e.g., CKD):**

* **Condition Relevance:** Sevelamer Carbonate is prescribed for the management of **Chronic Kidney Disease (CKD)**, as indicated in **Document 2** (Section 3) and implied in **Document 1** (Section 3, **Acute on Chronic Kidney Disease (CKD)**).
* **CKD Management:** Sevelamer is used to control phosphorus levels in the blood, a common complication in CKD patients, thereby helping to manage the disease's progression and alleviate associated symptoms.

**Cross-Document Consistency for Patient and Admission IDs:**
All documents (**Document 1** through **Document 5**) share the same:
- **Patient/Subject ID:** **13180007**
- **Note ID:** **13180007-DS-19**
- **Admission ID:** **20774429**
This consistency confirms that the information across these documents pertains to the same patient and admission event.","['### 3. **Acute on Chronic Kidney Disease (CKD)**\n\n* **Presentation:** Elevated Cr (2.6 from baseline 1.8-2.2)\n* **Concerns:** Renal congestion causing renal dysfunction\n* **Status at Discharge:** Cr 2', '3. **Chronic Kidney Disease (CKD)**\n\t* Medication: Sevelamer Carbonate 800 mg PO TID W/MEALS (continued from home)\n4. **Asthma**\n\t* Medication: Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath ', '11. Sevelamer CARBONATE 800 mg PO TID W/MEALS\n\t12. Victoza (Liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) subcutaneous DAILY\n\t13. Vitamin D 1000 UNIT PO DAILY\n* **Follow-up Appointments:**\n\t+ **Lab Follow-u', '* **Discharge Status:**\n\t+ Symptoms associated with volume overload had subsided, but patient was still slightly volume up on exam.\n\t+ 1+ edema to ankles bilaterally.\n\t+ JVP of 12cm.\n* **Medications a', '3. **Discharge**: Symptoms improved, but still slightly volume up (JVP ~12, 1+ edema to ankles)\n* **Discharge Details**:\n\t+ **Weight**: 166.6lb\n\t+ **Creatinine (Cr)**: 2.9 (elevated from baseline 1.8-']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What is the significance of continuing ASA (Aspirin) in the patient's treatment plan, given their medical history and recent hospitalization?","[""a6e734ef-1c30-4cb6-ba6d-41227251d4d0\n\nWhen he came home to ___, he apparently thought that he was\nstill in ___, confused his wife for his daughter. On\n___ morning, he fell again. He was confused about the\nconfiguration of the bathroom (no tub in bathroom in PR), so he\ntripped and fell, called his daughter in tears (he often gets\nemotional since his CVA). She booked an appointment for same \nday,\nat which his FSBG>500, HbA1c (point of care, not in OMR) was\n15.0%. He declined to be transferred to the ED. Daughter ___\nwas on vacation from work, and so was able to check on him\nregularly. During these visits, she again established that he is\nnot taking prescribed medications. On the morning of\npresentation, pt's wife called daughter ___, concerned that \npt\nwas increasingly confused. FSBG was >500, and administered\nTresiba 50u at about 8 am. Pt called ___ about 15 minutes\nlater, at which time she again noted confusion and slurred\nspeech, which has intermittently been present since his CVA.\nDecision was made to bring him to the ED. \nOf note, during his last hospitalization ___, he had an\nepisode of dysarthria with confusion and mild expressive and\nreceptive aphasia for which code stroke was called. MRI/MRA \nbrain\nand EEG were unrevealing, with chronic changes and EEG slowing\nonly. He was continued on ASA and atorvastatin."", 'd2113a66-fe4f-4869-b3c0-73646862b32b\n\ngluconate (received 3 doses ___. Upon review of recent \noutpatient visit notes, it appears his volume exam is similar to \nbaseline, and patient was asymptomatic during hospital course. \nHe was diuresed effectively with IV Lasix 80. He was \ntransitioned to PO torsemide 100. His BP was well controlled \nwith regimen as described below.\n# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\nat or lower than levels earlier this year. He has denied chest\npain during admission. He does have risk factors for ischemia \nand\nhas not had stress since ___. However, findings and history \nto\ndate are not suggestive of ischemia and he has an ___. TTE did \nnot show evidence of focal wall motion abnormalities or other \nfindings suggestive of ischemia, so further workup was not \npursued. He was continued on ASA and atorvastatin.\n# ___ on CKD:\nCr elevated to 2.6 on admission from baseline of 1.8-2.2. Given\nevidence of congestion elsewhere, concerns for renal congestion\ncausing renal dysfunction. Cr remained stable and was 2.9 on day \nof discharge. He was continued on home sevelamer.']","The patient was continued on ASA (Aspirin) and atorvastatin, indicating that these medications are crucial for managing the patient's condition. Given the patient's history of CVA (Cerebrovascular Accident) with episodes of dysarthria, confusion, and aphasia, ASA is likely prescribed for its antiplatelet effects to prevent further cerebrovascular events. Additionally, the patient has risk factors for ischemia, although recent findings were not suggestive of ischemia. ASA's continuation suggests its importance in primary or secondary prevention of cardiovascular events, aligning with the patient's overall cardiovascular and cerebrovascular risk management.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Significance of Continuing ASA (Aspirin) in the Patient's Treatment Plan:**

Given the patient's medical history and recent hospitalization, continuing Aspirin (ASA) 81 mg PO DAILY is significant for the following reasons:

1. **History of CVA (Cerebrovascular Accident)**: Aspirin is commonly prescribed as an antiplatelet agent to prevent future strokes or CVAs in patients with a history of such events. Its continuation suggests an ongoing effort to reduce the risk of subsequent cerebrovascular accidents.

2. **Presence of Other Cardiovascular-Related Medications**: The co-prescription of Atorvastatin (a statin, used to lower cholesterol and prevent cardiovascular disease) alongside Aspirin, as seen in all documents (especially Document 1, under ""CHRONIC PROBLEMS"", and consistently across Documents 3, 4, and 5 in the discharge medications lists), indicates a comprehensive approach to managing the patient's cardiovascular health. Aspirin's role here is to prevent clot formation, complementing the plaque reduction efforts of Atorvastatin.

3. **Absence of Contradictory Information**: Across all provided documents (1 through 5), there is no mention of bleeding disorders, gastrointestinal issues, or other conditions that might contraindicate the use of Aspirin. This suggests that, based on the patient's current medical profile as presented, the benefits of continuing Aspirin outweigh the risks.

**Metadata Relevance to the Question:**
- **Patient/Subject ID**: Consistently listed as **13180007** across all documents, ensuring that the medical history and treatment plan analyzed pertain to the same individual.
- **Note ID and Admission ID**: The consistent **Note ID (13180007-DS-19)** and **Admission ID (20774429)** across documents indicate that the information provided (including the decision to continue Aspirin) is part of a cohesive treatment plan following a specific hospital admission.

**IDs as per Metadata (as instructed):**
- **Patient/Subject ID**: 13180007 (consistent across Documents 1 through 5)
- **Note ID**: 13180007-DS-19 (consistent across Documents 1 through 5)
- **Admission ID**: 20774429 (consistent across Documents 1 through 5)","['Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D', 'Here is the extracted and summarized information for the subheading ""* CHRONIC PROBLEMS"":\n\n**CHRONIC PROBLEMS**\n================\n\n1. **Hypothyroidism**\n\t* Medication: Levothyroxine Sodium 100 mcg PO D', '+ **Follow-up Appointments**: [NOT PROVIDED]\n* **Discharge Medications** (same as listed in the original document):\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (dosage and timing)\n\t3. Albuterol In', '* **Medications to Take as Prescribed:**\n\t1. Torsemide 100 mg PO DAILY\n\t2. 70/30 Insulin (30 Units Breakfast, 10 Units Lunch)\n\t3. Albuterol Inhaler 2 PUFF IH Q8H:PRN\n\t4. Amlodipine 10 mg PO DAILY\n\t5. ', '1. **Medications**:\n\t* List of discharge medications (13 items, see below)\n\t* **Note**: Take all medications as prescribed\n\t* **Discharge Medications List**:\n\t\t1. Torsemide 100 mg PO DAILY\n\t\t2. 70/30 ']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
